0001493152-18-008940.txt : 20180619 0001493152-18-008940.hdr.sgml : 20180619 20180619165319 ACCESSION NUMBER: 0001493152-18-008940 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180619 DATE AS OF CHANGE: 20180619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 18907718 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 10-Q 1 form10q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark one)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2018

 

OR

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______.

 

Commission File Number: 001-35141

 

RENNOVA HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   68-0370244

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

     

400 South Australian Ave., 8th Floor

West Palm Beach, FL

  33401
(Address of principal executive offices)   (Zip Code)

 

(561) 855-1626

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act: (Check one)

 

Large accelerated filer [  ] Accelerated filer [  ]
Non-accelerated filer [  ]    (Do not check if a smaller reporting company) Smaller reporting company [X]

 

  Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of June 18, 2018, the registrant had 1,110,232,133 shares of its Common Stock, $0.01 par value, outstanding.

 

 

 

 
 

 

RENNOVA HEALTH, INC.

FORM 10-Q

 

March 31, 2018

TABLE OF CONTENTS

 

  Page No.
PART I – FINANCIAL INFORMATION    
       
Item 1. Financial Statements   3
  Condensed Consolidated Balance Sheets as of March 31, 2018 (unaudited) and December 31, 2017   3
  Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017 (unaudited)   4
  Condensed Consolidated Statement of Changes in Stockholders’ Deficit for the three months ended March 31, 2018 (unaudited)   5
  Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017 (unaudited)   6
  Notes to Condensed Consolidated Financial Statements (unaudited)   7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   29
Item 3. Quantitative and Qualitative Disclosures About Market Risk   37
Item 4. Controls and Procedures   37
       
PART II – OTHER INFORMATION    
       
Item 1. Legal Proceedings   38
Item 1A. Risk Factors   38
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   38
Item 3. Defaults Upon Senior Securities   38
Item 4. Mine Safety Disclosures   38
Item 5. Other Information   38
Item 6. Exhibits   39
       
SIGNATURES   40

 

2
 

 

RENNOVA HEALTH, INC.

PART I-FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   March 31, 2018   December 31, 2017 
   (unaudited)     
ASSETS          
Current assets:          
Cash  $35,096   $- 
Accounts receivable, net   1,101,758    971,312 
Inventory   251,029    236,914 
Prepaid expenses and other current assets   35,350    9,842 
Income tax refunds receivable   1,915,343    1,940,845 
Current assets of AMSG and HTS classified as held for sale   222,051    226,732 
Total current assets   3,560,627    3,385,645 
           
Property and equipment, net   2,362,225    2,695,440 
Deposits   193,006    180,875 
Non-current assets of AMSG and HTS classified as held for sale   21,912    28,834 
           
Total assets  $6,137,770   $6,290,794 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable (includes related parties of $0.3 and $0.2 million, respectively)  $4,605,123   $4,188,678 
Accrued expenses (includes related parties of $0.1 and $0.1 million, respectively)   4,131,767    4,967,405 
Income taxes payable   1,968,750    1,971,592 
Current portion of notes payable   6,957,830    6,957,830 
Current portion of notes payable, related parties   1,068,500    1,128,500 
Current portion of capital lease obligations   1,715,727    2,079,137 
Current portion of debentures   3,445,841    1,615,693 
Current portion of derivative liabilities   152,423,375    12,435,250 
Current liabilities of AMSG and HTS classified as held for sale   2,062,992    1,972,854 
Total current liabilities   178,379,905    37,316,939 
           
Other liabilities:          
Debentures, net current portion   3,794,079    3,752,022 
           
Total liabilities   182,173,984    41,068,961 
           
Redeemable Preferred Stock I-1   5,835,294    5,835,294 
Redeemable Preferred Stock I-2   2,036,118    - 
Stockholders’ deficit:          
Series G preferred stock, $0.01 par value, 14,000 shares authorized, 215 shares issued and outstanding   2    2 
Series H preferred stock, $0.01 par value, 14,202 shares authorized, 60 shares issued and outstanding   -    - 
Series F preferred stock, $0.01 par value, 1,750,000 shares authorized, 1,750,000 shares issued and outstanding   17,500    17,500 
Common stock, $0.01 par value, 3,000,000,000 shares authorized, 499,992,133 and 19,750,844 shares issued and outstanding   4,999,922    197,508 
Additional paid-in-capital   126,619,959    128,351,954 
Accumulated deficit   (315,545,009)   (169,180,425)
Total stockholders’ deficit   (183,907,626)   (40,613,461)
Total liabilities and stockholders’ deficit  $6,137,770   $6,290,794 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3
 

 

RENNOVA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

 

   Three Months Ended 
   March 31, 
   2018   2017 
         
Net revenues  $1,601,661   $684,265 
           
Operating expenses:          
Direct costs of revenue   2,089,366    244,831 
General and administrative   2,892,019    3,316,448 
Sales and marketing expenses   (1,215)   252,314 
Depreciation and amortization   333,515    426,929 
Total operating expenses   5,313,685    4,240,522 
           
Loss from continuing operations before other income (expense) and income taxes   (3,712,024)   (3,556,257)
           
Other income (expense):          
Other income   11,969    - 
Change in fair value of derivative instruments   (139,779,232)   563,617 
Interest expense   (3,307,014)   (45,642,525)
Total other income (expense), net   (143,074,277)   (45,078,908)
           
Net loss from continuing operations before income taxes   (146,786,301)   (48,635,165)
           
Provision for income taxes   76    3,250 
           
Net loss from continuing operations   (146,786,377)   (48,638,415)
           
Net income (loss) from discontinued operations   421,793    (1,066,292)
           
Net loss   (146,364,584)   (49,704,707)
           
Net loss to common shareholders  $(146,364,584)  $(49,704,707)
           
Net loss per common share:          
Basic and diluted: continuing operations  $(0.66)  $(0.66)
           
Basic and diluted: discontinued operations   -    (0.01)
           
Total Basic and diluted  $(0.66)  $(0.67)
Weighted average number of common shares outstanding during the period:          
Basic and diluted   221,942,501    73,464,705 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4
 

 

RENNOVA HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2018 (unaudited)

 

   Preferred Stock   Common Stock   Additional
paid-in
   Accumulated   Total
Stockholders’
 
   Shares   Amount  

Shares

   Amount  

capital

  

Deficit

   Deficit 
Balance at December 31, 2017 -Post Split   1,750,275   $17,502    19,750,844   $197,508   $128,351,954   $(169,180,425)  $(40,613,461)
Common stock issued in cashless exercise of warrants   -    -    75,600,000    756,000    (756,000)   -    0 
Conversion of debentures into common stock   -    -    333,310,452    3,333,105    (276,431)   -    3,056,674 
Stock-based compensation   -    -    -    -    24,196    -    24,196 
Restricted stock issued to employees   -    -    71,333,331    713,333    (72,223)   -    641,110 
Shares returned to treasury   -    -    (2,494)   (25)   25    -    0 
Beneficial conversion feature of Series 1-2 preferred stock   -    -    -    -    (651,562)   -    (651,562)
Net loss   -    -    -    -    -    (146,364,584)   (146,364,584)
Balance at March 31, 2018   1,750,275   $17,502    499,992,133   $4,999,922   $126,619,959   $(315,545,009)  $(183,907,627)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5
 

 

RENNOVA HEALTH, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

    Three Months Ended March 31,  
    2018     2017  
             
Cash flows from operating activities:                
Net loss from continuing operations   $ (146,786,377 )   $ (48,638,415 )
Depreciation and amortization     333,515       426,929  
Non-cash gain on derivative instruments     -       (571,720 )
Stock-based compensation     665,307       35,215  
Non-cash interest expense     -       44,074,628  
Amortization of debt discount     4,522,329       943,160  
Non-cash settlement of debt     -       (50,000 )
Change in fair value of derivative instruments     139,779,232       8,102  
Income (loss) from discontinued operations     421,793       (1,066,292 )
Changes in operating assets and liabilities:                
Accounts receivable     (130,449 )     115,446  
Inventory     (14,115 )     -  
Prepaid expenses and other current assets     (25,508 )     21,964  
Security deposits     (12,128 )     14,594  
Accounts payable     416,445       146,969  
Accrued expenses     (835,638 )     (957,683 )
Income tax assets and liabilities     22,660       (241,997 )
Net cash used in operating activities of continuing operations     (1,642,934 )     (5,739,099 )
Net cash used in discontinued operations     (698,259 )     (212,365 )
Net cash used in operating activities     (2,341,193 )     (5,951,464 )
                 
Cash flows from investing activities:                
Purchase of property and equipment     (301 )     (1,090,922 )
Net cash used in investing activities of continuing operations     (301 )     (1,090,922 )
Net cash provided by (used in) investing activities of discontinued operations     800,000       -  
Net cash provided by (used in) investing activities     799,699       (1,090,922 )
                 
Cash flows from financing activities:                
Proceeds from issuance of related party notes payable and advances     -       3,395,000  
Proceeds from issuance of notes payable and debentures     2,000,000       9,892,500  
Payments on related party notes payable and advances     (60,000 )     (3,430,000 )
Payments on notes payable     -       (1,948,111 )
Payments on capital lease obligations     (363,410 )     (911,042 )
Net cash provided by financing activities of continuing operations     1,576,590       6,998,347  
Net cash provided by (used in) financing activities of discontinued operations     -       1,331,113  
Net cash provided by financing activities     1,576,590       8,329,460  
                 
Net increase in cash     35,096       1,287,074  
                 
Cash at beginning of period     -       77,979  
                 
Cash at end of period   $ 35,096     $ 1,365,053  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 1 – Organization and Basis of Presentation

 

Rennova Health, Inc. (“Rennova”), together with its subsidiaries (the “Company”, “we”, “us” or “our”), is a vertically integrated provider of healthcare related products and services. The Company’s principal lines of business are (i) clinical laboratory operations; and (ii) Hospital Operations. The Company presents its financial results based upon these two business segments.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the 2017 audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2018. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). All material intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) considered necessary for the fair presentation of the financial position and results of operations and cash flows for the interim periods reported herein. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

During the three months ended March 31, 2018 and 2017, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations. In addition, certain prior year balances have been reclassified to conform to the current presentation.

 

Based on new FASB rules for revenue recognition that became effective January 1, 2018, bad debts are now treated similar to contractual adjustments and directly reduce sales revenue. In an abundance of caution through the startup period of our Oneida hospital the Company has reserved a bad debt number of $591,323, which, when set against sales revenues of $2,191,983 means the Company is reporting net revenues for the first quarter of 2018 of $1.6 million. The Company will continue to review its provision for bad debt.

 

Reclassification

 

The Company has reclassified certain amounts in the 2017 condensed consolidated financial statements to be consistent with the 2018 presentation. These principally relate to classification of certain revenues, cost of revenues and related segment data, as well as balance sheet classifications to assets and liabilities held for sale. Reclassifications relating to the discontinued operations of AMSG and HTS are described further in Note 15. The reclassifications had no impact on operations or cash flows for the three months ended March 31, 2017. The Company also reclassified derivative liability previously reported in 2017 as long term to current liability.

 

Reverse Stock Splits

 

On February 7, 2017, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017 and on September 21, 2017, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-15 reverse stock split effective October 5, 2017 (the “Reverse Stock Splits”). The stockholders of the Company had approved these amendments to the Company’s Certificate of Incorporation on December 22, 2016 for the February 7, 2017 reverse stock split and on September 20, 2017 for the October 5, 2017 reverse stock split. In both cases, the Company’s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse splits within certain specified effective dates.

 

As a result of the Reverse Stock Splits, every 30 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on February 7, 2017 and every 15 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on October 5, 2017. In addition, the conversions and exercise prices of all of the Company’s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the 1:30 reverse split ratio and again at the 1:15 reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Splits, other than as a result of the rounding up of fractional shares in the February reverse split and the payment of cash in lieu of fractional shares in the October reverse split, as no fractional shares were issued in connection with the Reverse Stock Splits.

 

The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 3,000,000,000 shares of common stock and 5,000,000 shares of preferred stock were also unaffected by the Reverse Stock Splits. On May 9, 2018, the Company amended its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares (see note 17).

 

All share, per share and capital stock amounts for all periods presented have been restated to give effect to the Reverse Stock Splits.

 

7
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Adoption of ASU 2017-11

 

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.

 

Under current GAAP, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity’s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity’s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.

 

The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and embedded conversion options with down round features are no longer bifurcated.

 

For entities that present EPS in accordance with Topic 260, and when the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.

 

Those amendments in Part 1 of this Update are a cost savings relative to current GAAP. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basis of the existence of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic value of the feature only when the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.

 

The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.

 

For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 1 of this Update should be applied in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is effective; or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10.

 

8
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect.

 

The Company has determined that this amendment had a material impact on its consolidated financial statements and has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company’s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid in capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million. A $51 million deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature.

 

Going Concern

 

The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has recently accumulated significant losses and has negative cash flows from operations, and at March 31, 2018, had a working capital deficit of $174.8 million and a stockholders’ deficit of $183.9 million. In addition, the Company’s cash position as of the date of this report is critically deficient, critical payments, including capital lease obligations are not being made in the ordinary course of business and certain indebtedness, including accrued interest and extension fees, in the amount of $7.8 million matures on May 30, 2018, that the Company does not have the financial resources to satisfy. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report.

 

The Company continues to consider efficiencies and is currently using one laboratory for the majority of its toxicology diagnostics thereby reducing the number of employees and associated operating expenses, in order to reduce costs. In addition, the Company received approximately $2 million in cash from the issuances of debentures during the first quarter of 2018 (see Note 6).

 

In July 2017, the Company announced that it plans to spin off its Advanced Molecular Services Group (“AMSG”) and in the third quarter of 2017, the Company’s Board of Directors voted unanimously to spin off Health Technology Solutions, Inc., a wholly-owned subsidiary (“HTS”), as independent publicly traded companies by way of tax-free distributions to its shareholders. Completion of these spinoffs is expected to occur during the second half of 2018. Our Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead of two. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered into by the Company. The intent of the spinoffs of AMSG and HTS is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for “held for sale”, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 15.

 

The Company also announced that the Big South Fork Medical Center received CMS regional office licensure approval and opened on August 8, 2017. In addition, on January 31, 2018, the Company announced that it had entered into a definitive asset purchase agreement to acquire an acute care hospital in Jamestown, Tennessee known as Tennova Healthcare – Jamestown. The acquisition was completed on June 1, 2018. The Company may amend its current revenue recognition policy and percentage for the hospitals when payments are received to support amended revenue recognition methodologies. Therefore, the Company expects that these hospitals will continue to provide additional revenue and cash flow sources.

 

There can be no assurance that the Company will be able to achieve its business plan, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues and eventually regain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Recent Events

 

Asset Purchase Agreement to Acquire Acute Care Hospital

 

On January 31, 2018, the Company entered into an asset purchase agreement (the “Purchase Agreement”) to acquire certain assets related to an acute care hospital located in Jamestown, Tennessee. The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Center, Inc., and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services. The acquisition also included a separate physician practice which will now operate under Rennova as Mountain View Physician Practice, Inc.

 

9
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Net annual revenues in recent years have been approximately $15 million with government payers including Medicare and Medicaid accounting for in excess of 60% of the payor mix. Rennova does not expect this payer mix to change significantly in the near future. The hospital was acquired for approximately $635,000 from Community Health Systems, Inc. Diligence, legal and other costs associated with the acquisition are estimated to be approximately $500,000 meaning the total cost of acquisition to the Company is approximately $1,100,000.

 

Jamestown is located 38 miles from the Company’s existing hospital, the Big South Fork Medical Center, which is located in Oneida, Tennessee.

 

Proposals Submitted to Stockholders

 

On May 9, 2018, the Company held a Special Meeting of Stockholders to (1) approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares, (2) approve the Company’s new 2018 Incentive Award Plan, and (3) authorize an adjournment of the Special Meeting if necessary.

 

Proposal 1 was approved while proposal 2 was rejected. Proposal 3 was not voted on.

 

Accounts Receivable Financing

 

As previously announced, on March 31, 2016 the Company entered into an agreement to sell certain of its accounts receivable. The agreement was originally scheduled to mature on March 31, 2017, which date was extended to March 31, 2018 by an amendment on March 24, 2017. On April 2, 2018, the Company, the purchaser and Christopher Diamantis, a Director of the Company, as guarantor, entered into a second amendment to extend further the Company’s obligation to May 30, 2018. In connection with this further extension, the purchaser received a fee of $100,000. As of May 30, 2018, the Company has not made a payment under this agreement and the full balance is now payable.

 

Share Issuances

 

On March 6, 2018, the Board of Directors, based on the recommendation of the Compensation Committee, approved grants to employees and directors of an aggregate of 71,333,331 shares of common stock, including the following to the directors of the Company:

 

Seamus Lagan 26,666,667 shares
Dr. Kamran Ajami 3,333,333 shares
John Beach 3,333,333 shares
Gary L. Blum 3,333,333 shares
Christopher Diamantis 3,333,333 shares
Trevor Langley 3,333,333 shares

 

The shares were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), as a transaction by an issuer not involving a public offering.

 

On February 9, 2018, holders of the Company’s Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 exercised their right for the first time under exchange agreements (the “Exchange Agreements”) entered into with the Company by electing to exchange an aggregate of $1,384,556 principal amount of such Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Convertible Preferred Stock.

 

Such shares of Preferred Stock were issued in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.

 

NanoVibronix

 

On February 14, 2018, the Company entered into a Common Stock Purchase Agreement with two investors pursuant to which the Company agreed to sell an aggregate of 200,000 shares of common stock of NanoVibronix, Inc. owned by the Company at a purchase price of $4.00 per share. The Company had acquired the shares as a result of an investment originally made in 2011.

 

10
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

March 2018 Offering

 

On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.

 

The Debentures were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act and by Rule 506 of Registration D promulgated thereunder as a transaction by an issuer not involving a public offering.

 

Note 2 – Accounts Receivable

 

Accounts receivable at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

    March 31, 2018     December 31, 2017  
Accounts receivable - laboratory services   $ 1,302,579     $ 1,478,451  
Accounts receivable – hospital     11,783,802       8,593,747  
Total accounts receivable     13,086,381       10,072,198  
Less:                
Allowance for discounts - laboratory services     (1,150,800 )     (1,177,054 )
Allowance for discounts - hospital     (9,307,852 )     (6,936,429 )
Allowance for bad debts     (1,525,972 )     (987,403 )
Accounts receivable, net   $ 1,101,758     $ 971,312  

 

Note 3 – Property and Equipment

 

Property and equipment at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

   March 31, 2018   December 31, 2017 
Medical equipment  $713,799   $696,195 
Building   1,359,484    1,359,472 
Equipment   437,029    476,548 
Equipment under capital leases   4,686,736    4,686,736 
Furniture   232,495    222,824 
Leasehold improvements   1,303,131    1,303,131 
Vehicles   196,534    196,534 
Computer equipment   221,237    226,441 
Software   333,853    631,033 
    9,484,297    9,798,914 
Less accumulated depreciation   (7,122,072)   (7,103,474)
Property and equipment, net  $2,362,225   $2,695,440 

 

On January 13, 2017, the Company completed an asset purchase agreement to acquire certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the “Hospital Assets”). The Hospital Assets include a 52,000 square foot hospital building and 6,300 square foot professional building on approximately 4.3 acres. Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center, is classified as a Critical Access Hospital (rural). The Company acquired the Hospital Assets out of bankruptcy for a purchase price of $1.0 million, and the purchase price has been recorded as property and equipment in the Company’s condensed consolidated balance sheet. The Company opened the hospital on August 8, 2017.

 

11
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Depreciation expense on property and equipment was $0.3 million and $0.4 million for the three months ended March 31, 2018 and 2017, respectively. Management periodically reviews the valuation of long-lived assets, including property and equipment, for potential impairment. Management did not recognize any impairment of these assets during the three months ended March 31, 2018 and 2017

 

Note 4 – Accrued Expenses

 

Accrued expenses at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

   March 31, 2018   December 31, 2017 
Commissions payable  $13,345   $24,470 
Accrued payroll and related liabilities   1,419,779    897,088 
Accrued interest   1,402,498    2,636,057 
Other accrued expenses   1,296,146    1,409,790 
Total accrued expenses  $4,131,767   $4,967,405 

 

Note 5 – Notes Payable

 

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2018 (unaudited) and December 31, 2017, notes payable consisted of the following:

 

Notes Payable – Third Parties

 

   March 31, 2018   December 31, 2017 
Loan payable under prepaid forward purchase contract  $5,000,000   $5,000,000 
           
Loan payable to TCA Global Master Fund, LP (“TCA”) in the original principal amount of $3 million at 16% interest (the “TCA Debenture”). Principal and interest payments due in various installments through December 31, 2017.   1,616,218    1,616,218 
           
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the “Tegal Notes”). Prinicpal and interest payments are due annually from July 12, 2015 through July 12, 2017   341,612    341,612 
    6,957,830    6,957,830 
Less current portion   (6,957,830)   (6,957,830)
Notes payable - third parties, net of current portion  $-   $- 

 

On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract whereby the Company received consideration in the amount of $5.0 million. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to approximately $1.5 million on the Company’s balance sheet as of December 31, 2016 and $0 as of December 31, 2017. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference.

 

Christopher Diamantis, a director of the Company, guaranteed the Company’s obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company’s obligation to March 31, 2018. Also, what the counterparty is to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by 40%. In connection with this extension, the counterparty received a fee of $1,000,000. On April 2, 2018, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into a second amendment to extend further the Company’s obligation to May 30, 2018. In connection with this further extension, the counterparty received a fee of $100,000. To date, the Company has not recovered any payments against the accounts recievable.

 

The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million which was applied to accrued and unpaid interest and fees, including default interest, as of the date of payment. On March 21, 2017, the Company made a payment to TCA in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees in accordance with the terms of the TCA Debenture. Also on March 21, 2017, the Company entered into a letter agreement with TCA, which (i) waived any payment defaults through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after the effective date of the registration statement filed by the Company; which amount is reflected in accrued expenses in the accompanying condensed consolidated balance sheet at December 31, 2017. In addition, TCA entered into an inter-creditor agreement with the purchasers of the convertible debentures (see Note 6) which sets forth rights, preferences and priorities with respect to the security interests in the Company’s assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December 31,2017. The debt to TCA remains outstanding and the parties are currently working to amend the Note to extend the maturity.

 

12
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

On September 15, 2016, the Company entered into an agreement with two investors whereby the Company sold to the investors convertible notes in the aggregate principal amount of $0.4 million (the “September 2016 Notes”). The September 2016 Notes were convertible into shares of the Company’s common stock at a conversion price of $112.50 per share. In conjunction with the sale of the September 2016 Notes, the Company issued warrants to purchase an aggregate of 4,444 shares of the Company’s common stock at an exercise price of $180.00 per share. Based on the allocation of the net proceeds from the September 2016 Notes to the fair value of the warrants, and the resulting beneficial conversion features, the Company recognized a discount for the entire face value of the September 2016 Notes, which was accreted through the notes’ maturity date of March 15, 2017. On March 13, 2017, the September 2016 Notes, along with the accompanying warrants, were exchanged for 26,667 shares of the Company’s common stock.

 

The Company did not make the principal payments under the Tegal Notes that were due on July 12, 2016. On November 3, 2016, the Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal and accrued interest aggregating to $0.4 million. On December 7, 2016, the Company received a breach of contract complaint with a request for entry of a default judgment (see Note 12). To date, the Company has yet to repay this amount.

 

Notes Payable – Related Parties

 

   March 31, 2018   December 31, 2017 
Loan payable to Alcimede LLC, bearing interest at 6% per annum, with all principal and interest due on August 2, 2018  $168,500   $168,500 
           
Loan Payable to Christopher Diamantis   900,000    960,000 
    1,068,500    1,068,500 
Less current portion   (1,068,500)   (1,068,500)
Total notes payable - related parties, net of current portion  $0   $0 

 

On February 3, 2015, the Company borrowed $3.0 million from Alcimede LLC (“Alcimede”). Seamus Lagan, the Company’s President and Chief Executive Officer, is the sole manager of Alcimede. The note has an interest rate of 6% and was originally due on February 2, 2016. Alcimede later agreed to extend the maturity date of the loan to August 2, 2017. On June 29, 2015, Alcimede exercised options granted in October 2012 to purchase 66,667 shares of the Company’s common stock at an exercise price of $37.50 per share, and the loan outstanding was reduced in satisfaction of the aggregate exercise price of $2.5 million. In August of 2016, $0.3 million was repaid by the Company through the issuance of shares of common stock. In March of 2017, the Company and Mr. Lagan agreed that a payment made to Alcimede in the amount of $50,000 would be deducted from the outstanding balance of the note. On August 2, 2017, the Company and Alcimede agreed to further extend the maturity date of the loan to August 2, 2018. The remaining balance due on this loan as of March 31, 2018 was $168,500, including accrued interest.

 

Note 6 – Debentures

 

The carrying amount of all outstanding debentures as of March 31, 2018 (unaudited), and December 31, 2017 is as follows:

 

   March 31, 2018   December 31, 2017 
Debentures  $15,758,851   $17,720,082 
Discount on Debentures   (8,424,756)   (12,127,634)
Deferred financing fees   (94,175)   (224,733)
    7,239,921    5,367,715 
Less current portion   (3,445,841)   (1,615,693)
Debentures  $3,794,079   $3,752,022 

 

13
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Payment on all outstanding debentures as of March 31, 2018 are due as follows:

 

Period ended December 31,      
2018   $  5,647,271  
2019   $  10,111,580  
    $ 15,758,851  

 

February 2017 Offering

 

On February 2, 2017, the Company issued $1.6 million aggregate principal amount of Original Issue Discount Convertible Debentures due three months from the date of issuance (the “February Debentures”) and warrants to purchase an aggregate of 6,667 shares of common stock, which can be exercised at any time after August 17, 2017 at an exercise price of $38.70 per share (the “February Warrants”), to an accredited investor for a purchase price of $1.5 million. On March 21, 2017, the February Debentures were exchanged for $2.5 million of exchange debentures as more fully discussed below.

 

March 2017 Offerings

 

On March 21, 2017, the Company issued $10.85 million aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due March 21, 2019 (the “Convertible Debentures”). The Company received net proceeds from this transaction in the approximate amount of $8.4 million. The Company used $3.8 million of the net proceeds to repay the 2017 Diamantis Note (see Note 7) and $0.75 million of the net proceeds to make the partial repayment on the TCA Debenture. The remainder of the net proceeds were used for general corporate purposes. In conjunction with the issuance of the Convertible Debentures, the holder of the February Debentures exchanged these debentures for $2.5 million of new debentures (the “Exchange Debentures” and, collectively with the Convertible Debentures, the “March Debentures”) on the same terms as, and pari passu with, the Convertible Debentures and warrants. The Company recorded non-cash interest expense in the amount of $0.4 million as a result of this exchange. Additionally, the holders of an aggregate of $2.2 million stated value of the Company’s Series H Convertible Preferred Stock (the “Series H Preferred Stock”) exchanged such preferred stock into $2.7 million principal amount of Exchange Debentures and warrants. The March Debentures contain a 24% original issue discount, have no regularly scheduled interest payments except in the event of a default and have a maturity date of March 21, 2019.

 

In connection with the March Debentures the Company issued warrants to purchase shares of the Company’s common stock to several accredited investors. At March 31, 2018, these warrants were exercisable into an aggregate of 13,823,699,256 shares of common stock. The warrants were issued to the investors in three tranches, Series A Warrants, Series B Warrants and Series C Warrants (collectively, the “March Warrants”). At March 31, 2018, the Series A Warrants are exercisable for 4,949,270,368 shares of the Company’s common stock. They are immediately exercisable and have a term of exercise equal to five years. At March 31, 2018, the Series B Warrants are exercisable for 3,925,158,519 shares of the Company’s common stock and are exercisable for a period of 18 months commencing immediately. The Series C Warrants are exercisable for 4,949,270,368 shares of the Company’s common stock and have a term of five years provided such warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. At March 31, 2018, the Series A, Series B and Series C Warrants each have an exercise price of $0.0038 per share, which reflects adjustments pursuant to their terms. The Series A, Series B and Series C Warrants are subject to “full ratchet” and other customary anti-dilution protections.

 

The March Debentures are convertible into shares of the Company’s common stock, at a conversion price which has been adjusted pursuant to the terms of the March Debentures to $0.0038 per share as of March 31, 2018, due to prices at which the Company has subsequently issued shares of common stock. The Convertible Debentures began to amortize monthly commencing on the 90th day following the closing date. The Exchange Debentures began to amortize monthly on the closing date. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of the March Debentures in cash or, in lieu thereof, the conversion price of such debentures will thereafter be 85% of the volume weighted average price at the time of conversion. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount. The March Debentures contain customary affirmative and negative covenants. The conversion prices are subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then conversion price, as well as other customary anti-dilution protections as more fully described in the debentures.

 

14
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

On October 30, 2017, the Company agreed to amend the March Debentures and March Warrants to remove the floor in the anti-dilution provisions therein. The conversion price of the March Debentures and the exercise price of the March Warrants as of March 31, 2018 stated above reflect the amendment as well as other adjustments for dilutive issuances, which triggered the down round provisions in the March Debentures and March Warrants. The March Debentures are secured by all of the Company’s assets and are guaranteed by substantially all of the Company’s subsidiaries. Between March 22, 2017 and March 31, 2018, holders of the March Debentures converted an aggregate of $10,362,989 of these debentures into 359,281,017 shares of common stock.

 

The exercise prices of the March Warrants issued in connection with the March Debentures are subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then exercise price, as well as other customary anti-dilution protections. As a result of these provisions, both the March Debentures and the March Warrants were deemed to be not indexed to the Company’s common stock, and the Company recognized derivative liabilities for the embedded conversion feature of the March Debentures and the March Warrants in the original amount of $15.3 million and $41.3 million, respectively. The Company recognized a discount for 100% of the principal value of the March Debentures and non-cash interest expense in the amount of $43.7 million in connection with the recognition of these derivative liabilities. As a result of the adoption of ASU 2017-11 in the second quarter of 2017, the interest expense and derivative liability originally recognized were adjusted and extinguished during the three months ended June 30, 2017. See Note 1 for the adoption of ASU 2017-11 for the retrospective adjustments made to the Company’s condensed consolidated financial statements with respect to the derivative liabilities associated with these debentures and warrants.

 

June 2017 Offerings

 

In June 2017, the Company issued debentures due three months from the date of issuance in two issuances (collectively, the “June Debentures”) and warrants to purchase an aggregate of 100,000 shares of common stock (33,333 warrants in the June 2, 2017 transaction and 66,667 in the June 22, 2017 transaction), which can be exercised at any time after nine months at an exercise price of $5.85 per share for the June 2, 2017 warrants and $5.70 per share for the June 22, 2017 warrants (collectively the “June Warrants”), to accredited investors for a purchase price of $1,902,700 and proceeds to the Company of $1.5 million. The Company recorded a discount on the debentures of $107,700 which has been fully amortized. As more fully discussed below, on July 17, 2017, the June Debentures were exchanged.

 

July 2017 Offerings

 

On July 17, 2017, the Company closed an offering of $4,136,862 aggregate principal amount of Original Issue Discount Debentures due October 17, 2017 (the “July Debentures”) and warrants to purchase an aggregate of 141,333 shares of common stock (the “July Warrants”) for consideration of $2,000,000 in cash and the exchange of the full $1,902,700 aggregate principal amount of the June Debentures. Under the Purchase Agreement, the Company was required to hold a stockholders’ meeting to obtain stockholder approval for at least a 1-for-8 reverse split of the Company’s common stock on or before September 20, 2017. Accordingly, the Company’s stockholders approved a reverse stock split on September 20, 2017 and the Company effected a 1-for-15 reverse stock split of its common stock on October 5, 2017, as further discussed in Note 1. The July Debentures were guaranteed by substantially all of the subsidiaries of the Company pursuant to a Subsidiary Guarantee in favor of the holders of the July Debentures. As more fully discussed below, on September 19, 2017, the July Debentures were exchanged for $6.4 million of exchange debentures.

 

The July Warrants are exercisable into shares of the Company’s common stock at any time from and after six months from the closing date at an exercise price of $5.63 per common share (subject to adjustment). The July Warrants will terminate five years after they become exercisable.

 

September 2017 Offerings

 

On September 19, 2017, the Company closed an offering of $2,604,000 principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 (the “New Debentures”) and three series of warrants to purchase an aggregate of 34,677,585 shares of the Company’s common stock (the “Series A Warrants,” the “Series B Warrants,” and the “Series C Warrants,” and collectively, the “September Warrants”). The offering was pursuant to the terms of a Securities Purchase Agreement, dated as of August 31, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $2,100,000 from the offering.

 

Also on September 19, 2017, the Company closed exchanges by which the holders of the Company’s July Debentures exchanged $4,136,862 principal amount of such debentures for $6,412,136 principal amount of new debentures on the same items as, and pari passu with, the New Debentures (the “September Exchange Debentures” and, together with the New Debentures, the “September Debentures”). The Company recorded non-cash interest expense in the amount of $1.0 million as a result of this exchange. All issuance amounts of the September Debentures reflect a 24% original issue discount.

 

15
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The September Debentures contain customary affirmative and negative covenants. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the debentures. The September Debentures may be converted at any time into shares of the Company’s common stock. Originally, the September Debentures begin to amortize monthly commencing on October 1, 2017, and for the first three amortization dates, the amortization amount was $100,000. On October 19, 2017, the September Debentures were amended so that they began to amortize immediately. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of September Debentures in cash or, in lieu thereof, the conversion price of such September Debentures shall thereafter be 85% of the volume weighted average price at the time of conversion, but not less than the floor of $0.78 per share. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount. On October 30, 2017, the Company entered into exchange agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Convertible Preferred Stock of the Company (the “Series I-2 Preferred Stock”), which is more fully discussed in Note 9. On February 8, 2018, $1,384,556 of the September Debentures were exchanged for 1,730.1 shares of Series I-2 Preferred Stock as more fully discussed in Note 9.

 

At March 31, 2018, the Series A Warrants are exercisable for an aggregate of 11,559,195 shares of the Company’s common stock. They are immediately exercisable and have a term of exercise equal to five years. The Series B Warrants are exercisable for an aggregate of 11,559,195 shares of the Company’s common stock and are exercisable for a period of 18 months commencing immediately. At March 31, 2018, the Series C Warrants are exercisable for an aggregate of 11,559,195 shares of the Company’s common stock, and have a term of five years provided such Series C Warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. The September Warrants have a fixed exercise price, subject to a floor of $0.78 per share. At December 31, 2017, the exercise price was $0.78 per share, which reflects adjustments made pursuant to their terms due to the down round provisions in the September Warrants. The September Warrants are subject to “full ratchet” and other customary anti-dilution protections.

 

The Company’s obligations under the September Debentures are secured by a security interest in all of the Company’s and its subsidiaries’ assets, pursuant to the terms of the Security Agreement, dated as of March 20, 2017.

 

During the year ended December 31, 2017, the Company realized approximately $15.7 million in proceeds from the issuances of these debentures and warrants. At December 31, 2017, the unamortized discounts were $16.4 million. These discounts represent original issue discounts, the relative fair value of the warrants issued with the debentures and the relative fair value of the beneficial conversion features of the debentures. During the three and nine months ended December 31, 2017, the Company recorded approximately $4.8 million and approximately $14.7 million of non-cash interest and amortization of debt discount expense primarily in connection with the debentures and warrants. See Note 9 for summarized information related to warrants issued and the activity during the twelve months ended December 31, 2017

 

March 2018 Offering

 

On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.

 

See Note 10 for summarized information related to warrants issued and the activity during the three months ended March 31, 2018 and 2017.

 

See Note 10 for a discussion of the dilutive effect of the outstanding debentures and warrants as of March 31, 2018.

 

Note 7 – Related Party Transactions

 

In addition to the transactions discussed in Note 5, the Company had the following related party transactions during the three months ended March 31, 2018 and 2017:

 

In January and February of 2017, the Company received advances aggregating $3.6 million from Christopher Diamantis, a director of the Company. The advances, along with $0.5 million of previously accrued but unpaid interest, were due on demand, bearing interest at 10% per annum. The Company used the advances to pay the purchase price for the Hospital Assets and for general corporate purposes. On March 7, 2017, the Company issued a promissory note to Mr. Diamantis in the amount of $0.5 million (the “2017 Diamantis Note”) in connection with these advances received in 2017, plus accrued and unpaid interest of $0.5 million. In conjunction with the issuance of the 2017 Diamantis Note, the Company also issued to Mr. Diamantis warrants to purchase 27,667 shares of the Company’s common stock, exercisable at $15.00. the 2017 Diamantis Note was repaid on March 21, 2017 with the proceeds received from the issuance of the Convertible Debentures (see Note 6).

 

Alcimede billed the Company $0.1 million for consulting fees pursuant to a consulting agreement for each of the three months ended March 31, 2018 and 2017, respectively.

 

16
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Monarch Capital, LLC (“Monarch”) billed the Company for consulting fees pursuant to a consulting agreement in the amount of $0.1 million for the three months ended March 31, 2017. The agreement expired on August 31, 2017. Michael Goldberg, a director of the Company up until his resignation effective April 24, 2017, is the Managing Director of Monarch.

 

Note 8 – Capital Lease Obligations

 

The Company leases various assets under capital leases expiring through 2020 as follows. At March 31, 2018 (unaudited) and December 31, 2017, capital lease obligations consisted of the following:

 

   March 31, 2018   December 31, 2017 
Medical equipment  $4,686,736   $4,686,736 
Less accumulated depreciation   (4,010,259)   (3,842,443)
           
Net  $676,477   $844,293 

 

During the fourth quarter of 2016, the Company did not meet its payment obligations under two of its capital lease agreements, which comprise substantially all of the Company’s aggregate capital lease obligations. In December 2016, the two counterparties to these lease agreements filed separate lawsuits against the Company and in January of 2017 default judgments were issued against the Company in the aggregate amount of $3.5 million, which includes default interest, late fees, penalties and other fees (see Note 12). As a result, the Company recognized additional interest expense of $0.6 million to recognize the additional obligations under these leases. As of March 31, 2018 the Company did not meet its obligations under these two capital leases, therefore, the aggregate future minimum rentals under capital leases are deemed to be current.

 

Note 9 – Redeemable Preferred Stock

 

The Company has 5,000,000 authorized shares of Preferred Stock at a par value of $0.01. Issuances of the Company’s Preferred Stock included as part of stockholders’ deficit are discussed in Note 10. The following is a summary of the issuances of the Company’s Redeemable Preferred Stock.

 

Series I-1 Convertible Preferred Stock

 

On October 30, 2017, the Company closed an offering of $4,960,000 stated value of its 4,960 shares of newly-authorized Series I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”). Each share of Series I-1 Preferred Stock has a stated value of $1,000. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $4.0 million from the offering. The Purchase Agreement gives the investors the right to participate in up to 50% of any offering of common stock or common stock equivalents by the Company. In the event of any such offering, the investors may also exchange all or some of their Series I-1 Preferred Stock for such new securities on an $0.80 stated value of Series I-1 Preferred Stock for $1.00 of new subscription amount basis. Each share of Series I-1 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-1 Preferred Stock. Upon the occurrence of certain Triggering Events, as defined in the Certificate of Designation of the Series I-1 Preferred Stock, the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-1 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

Series I-2 Convertible Preferred Stock

 

On October 30, 2017, the Company entered into exchange agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Preferred Stock. The exchange agreements permit the holders of the September Debentures to exchange specified principal amounts of the September Debentures on various closing dates starting on December 2, 2017. Any exchange is at the option of the holders. Each holder may reduce the principal amount of September Debentures exchanged on any particular closing date, or elect not to exchange any September Debentures at all on a closing date. If a holder does choose to exchange less principal amount of September Debentures, or no September Debentures at all, it can carry forward such lesser amount to a future closing date and then exchange more than the originally specified principal amount for that later closing date. For each $0.80 of principal amount of September Debenture surrendered to the Company at any closing date, the Company will issue the holder a share of Series I-2 Preferred Stock with a stated value of $1.00. Each share of Series I-2 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-2 Preferred Stock.

 

The Company’s board of directors has designated up to 11,271 shares of the 5,000,000 authorized shares of preferred stock as the Series I-2 Preferred Stock. Each share of Series I-2 Preferred Stock has a stated value of $1,000. Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-2 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-2 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

On February 9, 2018, the holders exercised their right to exchange a portion of the September Debentures for shares of the Series I-2 Preferred Stock for the first time. On that date, the holders elected to exchange an aggregate of $1,384,556 principal amount of September Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Preferred Stock.

 

17
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 10 – Stockholders’ Deficit

 

Preferred Stock

 

The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of March 31, 2018, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock, shares of Series I-2 Preferred Stock, 215 shares of its Series G Preferred Stock, 60 shares of its Series H Preferred Stock and 1,750,000 shares of its Series F Convertible Preferred Stock.

 

The rights of Preferred F, G, H, I-1 and I-2 shares are disclosed in the 2017 10K. There are no changes in these rights.

 

Common Stock

 

The Company had 499,992,133 and 19,750,844 shares of common stock issued and outstanding at March 31, 2018 and December 31, 2017, respectively. The Company issued 480,249,156 shares of its common stock during the three months ended March 31, 2018 as follows:

 

During the three months ended March 31, 2018, the Company issued an aggregate of 333,315,823 shares of its common stock upon conversion of $3.1 million of the principal amount of the March 2017 Debentures.

 

During the three months ended March 31, 2018, the Company issued 75,600,000 shares of common stock upon exercise of 119,746,776 March 2017 Series B Warrants, on a cashless basis.

 

During the three months ended March 31, 2018 the Company issued an aggregate of 71,333,333 shares of restricted stock as described below.

 

Restricted Stock

 

On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 181,933 shares of restricted common stock of the Company. The grants fully vest on the first anniversary of the date of grant, subject to the grantee’s continued status as an employee or director, as the case may be, on the vesting date. During the three months ended March 31, 2018, 2,493 shares of the restricted stock were forfeited by their terms and returned to treasury.

 

On March 6, 2018, the Company issued an aggregate of 71,333,333 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board. The grants fully vested immediately. The Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $.0067 per share.

 

Stock Options

 

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2018:

 

   Number of
options
   Weighted-
average
exercise
price
   Weighted-
average contractual
term (Yrs.)
 
Outstanding at December 31, 2017   38,478   $2,072.75    8.33 
Granted   -    -      
Expired   -    -      
Forfeit        -      
Exercised   -    -      
Outstanding at March 31, 2018   38,478   $2,072.75    8.33 
Exercisable at March 31, 2018   32,922   $2,373.16      

 

As of March 31, 2018, the Company had approximately $0.1 million of unrecognized compensation cost related to stock options granted under the Company’s 2007 Equity Plan, which is expected to be recognized over a weighted-average period of 0.94 years.

 

Warrants

 

The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock. The following summarizes the information related to warrants issued and the activity during the three months ended March 31, 2018:

 

   Number of warrants   Weighted
average
exercise price
 
Balance at December 31, 2017   2,176,403,218   $0.0444 
Warrants issued during the period   -   $- 
Increases due to dilution   13,411,976,939   $- 
Warrants exercised during the period   (119,746,776)  $0.0038 
Warrants expired during the period   -   $- 
Balance at March 31, 2018   15,468,633,381   $0.0062 

 

18
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Basic and Diluted Loss per Share

 

Basic loss per share excludes dilution and is computed by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. For the three months ended March 31, 2018 and 2017, basic loss per share is the same as diluted loss per share.

 

Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2018 and 2017, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

 

   As of March 31, 
   2018   2017 
Warrants   15,468,633,381    30,595,665 
Convertible preferred stock   893,098,291    595,556 
Convertible debt   781,485,502    10,007,141 
Stock options   38,478    709,025 
    17,143,255,652    41,907,387 

 

Note 11 – Supplemental Disclosure of Cash Flow Information

 

The supplemental cash flow information for the three months ended March 31, 2018 and 2017 (unaudited) is as follows:

 

   Three Months Ended March 31, 
   2018   2017 
Cash paid for interest  $24,791   $881,457 
Cash paid for income taxes  $-   $296,313 
           
Non-cash investing and financing activities:          
Exchange of I-2 preferred stock for convertible debentures  $1,384,556   $2,695,760 
Exchange of convertible debentures for convertible debentures and warrants  $-   $2,464,500 
Note payable and warrants settled through issuance of common stock  $-   $440,000 
Debentures converted into common stock  $3,056,675   $486,032 
Conversions of preferred stock into common stock  $-   $6,280,000 
Common stock issued in cashless excercise of warrants  $756,000   $- 

 

Note 12 – Commitments and Contingencies

 

Legal Matters

 

From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.

 

Biohealth Medical Laboratory, Inc, and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans.

 

19
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The Company’s Epinex Diagnostics Laboratories, Inc. subsidiary was sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys’ fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs’ motion for payment of attorneys’ fees in the amount of $0.3 million, and the Company has accrued this amount in its condensed consolidated financial statements. Additionally, the Company is seeking indemnification for these amounts from Epinex Diagnostics, Inc. (“EDI”), the seller of Epinex Diagnostic Laboratories, Inc. (“EDL”), pursuant to a Stock Purchase Agreement entered into by and among the parties.

 

In February 2016, the Company received notice that the Internal Revenue Service (the “IRS”) placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. The Company paid $0.1 million toward its 2014 tax liability on March 2016. The Company filed its 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and on September of 2016 the Company received a refund from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of the Company’s 2015 Federal tax return. The Company is currently unable to predict the outcome of the audit or any liability to the Company that may result from the audit.

 

On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. On January 25, 2017, the Company paid the DOR $250,000 as partial payment on this liability, and in February 2017 the Company entered into a Stipulation Agreement with the DOR which allows the Company to make monthly installment payments of $35,000 until February 2018 and negotiate a new payment agreement then, if the balance of $0.3 million cannot be satisfied in a lump sum. If at any time during the Stipulation period the Company fails to timely file any required tax returns with the DOR or does not meet the payment obligations under the Stipulation Agreement, the entire amount due will be accelerated. The Company has managed to pay some but not all of the required payments and $0.5 million remains outstanding to the DOR at March 31, 2018.

 

In December of 2016, TCS-Florida, L.P. (“Tetra”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with Tetra (see Note 8). On January 3, 2017, Tetra received a Default Judgment against the Company in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. In January and February of 2017, the Company made payments to Tetra in connection with this judgment aggregating to $0.7 million, and on February 15, 2017, the Company entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due will be paid in 24 equal monthly installments. Payments commenced on May 1, 2017 and a total of $1.1 million remains outstanding to Tetra at March 31, 2018. The Company and Tetra have agreed to dispose of certain equipment and proceeds from the sale of surplus equipment have been applied to the outstanding balance.

 

In December of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 8). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due will be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company and DeLage have now disposed of certain equipment and reduced the balance owed to DeLage. The reduced balance remains outstanding at March 31, 2018.

 

On December 7, 2016, the holders of the Tegal Notes (see Note 5) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of $0.4 million, including accrued interest. A request for entry of default judgment was filed on January 24, 2017. A judgment was entered against the Company on April 23, 2018. These amounts remain outstanding at March 31, 2018.

 

In November 2017 a former shareholder of Genomas filed suit against the Company for payment of a $200,000 Note payable by the subsidiary Genomas. This Note is recorded in the financial statements of the subsidiary and is not payable directly from the Company. Other claims were included in the suit which the Company believes to be frivolous and without merit. The Company has filed a motion to dismiss certain of the claims. The Company has made a $100,000 payment and agreed to a schedule of payments to discharge the remaining balance of the Note. The parties have agreed to dismiss the legal action.

 

The Company and subsidiaries have been party to suits filed by landlords for late payment of rent and have either settled these claims or are in process of agreeing to settlement. The Company does not deem these actions to be material.

 

20
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 13 – Segment Information

 

Operating segments are defined under U.S. GAAP as components of an enterprise for which discrete financial information is available and are evaluated regularly by the enterprise’s chief operating decision maker in determining how to allocate resources and assess performance. The Company operates in two reportable business segments:

 

  Clinical Laboratory Operations, which specializes in providing urine and blood toxicology and pain medication testing to physicians, clinics and rehabilitation facilities in the United States.
     
  Hospital Operations, which reflects the purchase of the Hospital Assets (see Note 3) and the operations of Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center.

 

The Company’s Corporate expenses reflect consolidated company wide support services such as finance, legal counsel, human resources, and payroll.

 

The Company’s Decision Support and Informatics segment and its Supportive Software Solutions segment are now included in discontinued operations as they have been classified as held for sale as of March 31, 2018. The accounting policies of the reportable segments are the same as those described in Note 1. Selected financial information for the Company’s operating segments is as follows:

 

21
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

    Three Months Ended March 31,  
    2018     2017  
Net revenues – External                
Clinical Laboratory Operations   $ 45,586     $ 684,265  
Hospital Operations     1,556,075       -  
    $ 1,601,661     $ 684,265  
                 
(Loss) income from operations                
Clinical Laboratory Operations   $ (756,083 )   $ (1,292,275 )
Hospital Operations     (1,472,600 )     (467,316 )
Corporate     (1,483,341 )     (1,804,517 )
Eliminations     -       7,851  
    $ (3,712,024 )   $ (3,556,257 )
Depreciation and amortization                
Clinical Laboratory Operations   $ 295,474     $ 434,468  
Hospital Operations     37,728       -  
Corporate     314       312  
Eliminations     -       (7,851 )
    $ 333,515     $ 426,929  
Capital expenditures                
Clinical Laboratory Operations   $ -     $ (100,382 )
Hospital Operations     -       1,090,922  
    $ -     $ 990,540  

 

***` Intersegment revenues are eliminated in consolidation.

 

 

   March 31, 2018   December 31, 2017 
Total assets          
Clinical Laboratory Operations  $1,019,946   $1,503,520 
Hospital Operations   2,788,059    2,549,504 
Corporate   3,510,297    3,436,773 
Assets of AMSG and HTS classified as held for sale   243,963    255,566 
Eliminations   (1,424,496)   (1,454,570)
   $6,137,769   $6,290,794 

 

22
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Note 14 – Recently Issued Accounting Standards

 

The following table provides a brief description of recently issued accounting standards:

 

Title and reference   Prescribed
Effective Date
  Commentary
ASU No. 2015-11, “Inventory” (Topic 330): Simplifying the Measurement of Inventory.   Fiscal years beginning after December 15, 2016 and for interim periods therein.   In July 2015, the FASB issued ASU No. 2015-11, “Inventory” (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”). ASU 2015-11 simplifies the measurement of inventory by requiring certain inventory to be subsequently measured at the lower of cost and net realizable value. The amendments in this guidance are effective for fiscal years beginning after December 15, 2016 and for interim periods therein and did not have a significant impact on the Company’s consolidated financial statements upon adoption.
         
ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”   Fiscal years beginning after December 15, 2017 and for interim periods therein.   In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most recent current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also specifies the accounting for certain incremental costs of obtaining a contract and costs to fulfill a contract with a customer. Entities have the option of applying either a full retrospective approach to all periods presented or a modified approach that reflects differences prior to the date of adoption as an adjustment to equity. The Company has adopted this guidance for this financial statement.
         
ASU No. 2014-15, “Presentation of Financial Statements - Going Concern” (Subtopic 205-40): Disclosure of Uncertainty about an Entity’s Ability to Continue as a Going Concern.   Fiscal years, and interim periods within those years, beginning on or after December 15, 2016, with early adoption permitted.   In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern” (Subtopic 205-40): Disclosure of Uncertainty about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 provides guidance that establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and setting rules for how this information should be disclosed in the financial statements. Adoption of this new standard did not have a significant impact on the Company’s consolidated financial statements. See Note 1 regarding management’s current disclosures regarding the Company’s ability to continue as a going concern.

 

23
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes”   Fiscal years beginning on or after December 15, 2016, with early adoption permitted.   In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). Topic 740, Income Taxes, requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. Deferred tax liabilities and assets that are not related to an asset or liability for financial reporting are classified according to the expected reversal date of the temporary difference. To simplify the presentation of deferred income taxes, the amendments in ASU 2015-17 require that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Adoption of ASU 2015-17 did not have a material impact on the Company’s consolidated financial statements.
         
Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842)”    Annual and interim periods within the annual period beginning after December 15, 2018.  

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The amendments in this update create Topic 842, Leases, and supersede the leases requirements in Topic 840, Leases. Topic 842 specifies the accounting for leases. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. The main difference between Topic 842 and Topic 840 is the recognition of lease assets and lease liabilities for those leases classified as operating leases under Topic 840. Topic 842 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years for public business entities. Early application of the amendments in ASU 2016-02 is permitted. The Company has not yet determined the impact that adoption of ASU 2016-02 will have on its consolidated financial statements.

         
ASU No. 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)” (“ASU 2017-11”)   Fiscal years beginning on or after December 15, 2018, with early adoption permitted.   The Company adopted this amendment as of its period ended June 30, 2017 (see Note 1)

 

24
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

ASU No. 2017-12, “Derivatives and Hedging (Topic 815)” (“ASU 2017-12”)   For public business entities, the amendments in this ASU 2017-12 are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption permitted in any interim period after issuance of this ASU.   The amendments in ASU 2017-12 (“Update”) provide recognition and presentation guidance for qualifying hedges. The amendments in this Update more closely align the results of cash flow and fair value hedge accounting with risk management activities through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results in the financial statements. The amendments address specific limitations in current U.S. GAAP by expanding hedge accounting for both nonfinancial and financial risk components and by refining the measurement of hedge results to better reflect an entity’s hedging strategies. Thus, the amendments will enable an entity to report more faithfully the economic results of hedging activities for certain fair value and cash flow hedges and will avoid mismatches in earnings by allowing for greater precision when measuring change in fair value of the hedged item for certain fair value hedges. Additionally, by aligning the timing of recognition of hedge results with the earnings effect of the hedged item for cash flow and net investment hedges, and by including the earnings effect of the hedging instrument in the same income statement line item in which the earnings effect of the hedged item is presented, the results of an entity’s hedging program and the cost of executing that program will be more visible to users of financial statements. Additionally, the amendments in this Update should ease the operational burden of applying hedge accounting by allowing more time to prepare hedge documentation and allowing effectiveness assessments to be performed on a qualitative basis after hedge inception. The Company has not yet determined the impact that adoption of ASU 2017-12 will have on its consolidated financial statements.

 

Note 15 – Discontinued Operations

 

On July 12, 2017, the Company announced plans to spin off its Advanced Molecular Services Group (“AMSG”) and in the third quarter of 2017 the Company’s Board of Directors voted unanimously to spin off the Company’s wholly-owned subsidiary, Health Technology Solutions, Inc. (“HTS”), as independent publicly traded companies by way of tax-free distributions to the Company’s stockholders. Completion of these spinoffs is expected to occur in the second half of 2018. The Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead off two. The spinoffs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spinoffs should be approximately 30 to 60 days prior to the dates of the spinoffs. The strategic goal of the spinoffs is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In addition, after the spinoffs, each company will provide a distinct and targeted investment opportunity.

 

The Company has reflected the amounts relating to AMSG and HTS as disposal groups classified as held for sale and included in discontinued operations in the Company’s accompanying consolidated financial statements. Prior to being classified as held for sale, AMSG had been included in the Decision Support and Informatics division, except for the Company’s subsidiary, Alethea Laboratories, Inc., which had been included in the Clinical Laboratories division and HTS had been included in the Company’s Supportive Software Solutions division. The segment disclosures included in our results of operations no longer include amounts relating to AMSG and HTS following the reclassification to discontinued operations except that the inter-company debt from HTS to the Company of $14,461,338 and from AMSG of $7,181,685 has not been separated. The Company hopes to complete the spin off(s) in a manner to permit it to recognize these amounts as investment in the divisions.

 

Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:

 

AMSG Assets and Liabilities:

 

    March 31, 2018     December 31, 2017  
    (unaudited)     (unaudited)  
Cash   $ 5,314     $ 9,273  
Accounts receivable, net     576       19,022  
Prepaid expenses and other current assets     25,477       25,477  
Current assets classified as held for sale   $ 31,367     $ 53,772  
                 
Property and equipment, net   $ -     $ -  
Deposits     -       -  
Non-current assets classified as held for sale   $ -     $ -  
                 
Accounts payable (includes related parties)   $ 674,425     $ 671,561  
Accrued expenses     388,666       375,165  
Current portion of notes payable     228,421       249,589  
Current liabilities classified as held for sale   $ 1,291,512     $ 1,296,315  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

25
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

HTS Assets and Liabilities:

 

   March 31, 2018   December 31, 2017 
   (unaudited)   (unaudited) 
Cash  $1,727   $8,281 
Accounts receivable, net   166,774    160,715 
Prepaid expenses and other current assets   22,183    3,964 
Current assets classified as held for sale  $190,684   $172,960 
           
Property and equipment, net  $15,883   $21,078 
Deposits   6,029    7,756 
Non-current assets classified as held for sale  $21,912   $28,834 
           
Accounts payable (includes related parties)  $500,235   $407,404 
Accrued expenses   271,245    269,135 
Current liabilities classified as held for sale  $771,480   $676,539 
           
Non-current liabilities classified as held for sale  $-   $- 

 

Consolidated Discontinued Operations Assets and Liabilities:

 

   March 31, 2018   December 31, 2017 
   (unaudited)   (unaudited) 
Cash  $7,041   $17,554 
Accounts receivable, net   167,350    179,737 
Prepaid expenses and other current assets   47,660    29,441 
Current assets classified as held for sale  $222,051   $226,732 
           
Property and equipment, net  $15,883   $21,078 
Deposits   6,029    7,756 
Non-current assets classified as held for sale  $21,912   $28,834 
           
Accounts payable (includes related parties)  $1,174,660   $1,078,965 
Accrued expenses   659,911    644,300 
Current portion of notes payable   228,421    249,589 
Current liabilities classified as held for sale  $2,062,992   $1,972,854 
           
Non-current liabilities classified as held for sale  $-   $- 

 

26
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

Major line items constituting loss from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2018 and 2017 consisted of the following:

 

AMSG Income (Loss) from Discontinued Operations:

 

   Three Months Ended March 31, 
   2018   2017 
   (unaudited)   (unaudited) 
Revenue from services  $33,685   $176,578 
Cost of services   16,138    769 
Gross profit   17,547    175,809 
Operating expenses   176,202    526,533 
Other income/expenses   (800,197)   (2,978)
Income/(Loss) from discontinued operations  $641,542   $(347,746)

 

HTS Income (Loss) from Discontinued Operations:

 

   Three Months Ended March 31, 
   2018   2017 
   (unaudited)   (unaudited) 
Revenue from services  $355,147   $315,270 
Cost of services   34,218    46,704 
Gross profit   320,929    268,566 
Operating expenses   538,199    987,111 
Other income/expenses   2,478    - 
Income/(Loss) from discontinued operations  $(219,748)  $(718,545)

 

Consolidated Income/(Loss) from Discontinued Operations:

 

   Three Months Ended March 31, 
   2018   2017 
   (unaudited)   (unaudited) 
Revenue from services  $388,832   $491,848 
Cost of services   50,356    47,473 
Gross profit   338,476    444,375 
Operating expenses   714,402    1,513,645 
Other income (expenses)   (797,719)   (2,978)
Income/(Loss) from discontinued operations  $421,793   $(1,066,292)

 

Note 16 – Derivative Financial Instruments and Fair Value

 

In accordance with ASC 820, “Fair Value Measurements and Disclosures,” the Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

  Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date.
     
  Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets).
     
  Level 3 applies to assets or liabilities for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including our own assumptions.

 

27
 

 

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The estimated fair value of financial instruments is determined by the Company using available market information and valuation methodologies considered to be appropriate. At March 31, 2018 and December 31, 2017, the carrying value of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to their short-term nature.

 

The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and March 31, 2018:

 

   Level 1   Level 2   Level 3   Total 
As of December 31, 2017:                    
Embedded conversion options  $-   $-   $1,577,025   $1,577,025 
Common stock warrants   -    -    10,858,225    10,858,225 
Total  $-   $-   $12,435,250   $12,435,250 
                     
As of March 31, 2018:                    
Embedded conversion options  $-   $-   $1,005,188   $1,005,188 
Common stock warrants   -    -    151,418,187    151,418,187 
Total  $-   $-   $152,423,375   $152,423,375 

 

For the three months ended March 31, 2018, total loss realized on instruments valued using Level 3 valuations was $140.0 million.

 

The Company utilized the following methods to value its derivative liabilities for the three months ended March 31, 2018: (i) for embedded conversion options valued at $1.0 million, the Company determined the fair value by comparing the discounted conversion price per share (85% of market price) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company’s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability; (ii) for warrants valued at $151.4 million, the Company determined the fair value by using a binomial model and monte carlo simulations; and (iii) for warrants valued at $0.1 million and embedded conversion options valued at $0.2 million, the Company determined the fair value using the Black-Scholes option pricing model. All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.

 

The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2018:

 

Balance at December 31, 2017  $12,435,250 
Loss on change in fair value included in net loss   139,779,232 
Issuance of convertible debt   208,893 
Balance at March 31, 2018  $152,423,375 

 

The increase in the fair value of the derivative liabilities is primarily due to the increase in the Company’s quoted trading price from $0.003 on December 31, 2017 to $0.009 on March 31, 2018.   Because the exercise price of a significant portion of the Company’s outstanding warrants are currently exercisable at $0.0038 per share, and subject to further reduction in their exercise price in the event of further issuances at lower than $0.0038 per share, the fair value of the warrants increased significantly during the three months ended March 31, 2018.

 

Note 17 – Subsequent Events

 

Common Stock

 

Outstanding shares as of June 18, 2018: 1,110,232,133

 

Since the period ended March 31, 2018, the Company has issued 610,240,000 shares of common stock through June 18, 2018 as follows:

 

The Company has issued 324,000,000 shares of its common stock upon conversion of $1,643,175 of the principal amount of the March 2017 Debentures.

 

The Company issued 286,240,000 shares of common stock to the holders of 381,405,434 March 2017 Series B warrants that were exercised on a cashless basis.

 

On May 9, 2018, the Company held a Special Meeting of Stockholders, in part, to approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares. The proposal was approved and on May 9, 2018 the Company filed an amendment to its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares.

 

28
 

 

RENNOVA HEALTH, INC.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS

 

Certain statements made in this Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving its continued business operations. Assumptions related to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate and, therefore, there can be no assurance the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

 

The forward-looking statements included in this Form 10-Q and referred to elsewhere are related to future events or our strategies or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “believe,” “anticipate,” “future,” “potential,” “estimate,” “expect,” “intend,” “plan,” or the negative of such terms or comparable terminology. All forward-looking statements included in this Form 10-Q are based on information available to us as of the filing date of this report, and the Company assumes no obligation to update any such forward-looking statements, except as required by law. Our actual results could differ materially from the forward-looking statements.

 

Important factors that might cause our actual results to differ materially from the results contemplated by the forward-looking statements are contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the “2017 Form 10-K”) and in our subsequent filings with the Securities and Exchange Commission. The following discussion of our results of operations should be read in conjunction with the audited financial statements contained within the 2017 Form 10-K and with our unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this report.

 

COMPANY OVERVIEW

 

We are a healthcare enterprise that delivers products and services to healthcare providers, their patients and individuals. We operate in two synergistic divisions: 1) Clinical diagnostics services through our clinical laboratories; and 2) Hospital operations. We aspire to create a more sustainable relationship with our customers by offering needed and interoperable solutions to capture multiple revenue streams from medical providers.

 

Our Services

 

Our principal line of business historically was clinical laboratory blood and urine testing services, with a particular emphasis on the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States, Testing services to rehabilitation facilities represented approximately 5% and 95% of our revenues for the three months ended March 31, 2018 and 2017 respectively, the change caused by the percentage increase in the revenue from hospital operations. Since the opening of our hospital in Oneida, Tennessee in August 2018, our principal line of business has been our hospital operations.

 

29
 

 

RENNOVA HEALTH, INC.

 

On January 13, 2017, we closed on an asset purchase agreement to acquire certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the “Hospital Assets”). The Hospital Assets include a 52,000 square foot hospital building and 6,300 square foot professional building on approximately 4.3 acres. Scott County Community Hospital is classified as a Critical Access Hospital (rural) with 25 beds, a 24/7 emergency department, operating rooms and a laboratory that provides a range of diagnostic services. Scott County Community Hospital closed in July 2016 in connection with the bankruptcy filing of its parent company, Pioneer Health Services, Inc. We acquired the Hospital Assets out of bankruptcy for a purchase price of $1.0 million. The hospital, which has been renamed Big South Fork Medical Center, became operational on August 8, 2017. We believe that the hospital will provide us with a stable revenue base, as well as the potential for significant synergistic opportunities with our Clinical Laboratory Operations business segment.

 

On January 31, 2018, the Company entered into an asset purchase agreement (the “Purchase Agreement”) to acquire certain assets related to an acute care hospital located in Jamestown, Tennessee. The purchase was completed on June 1, 2018. The hospital was acquired by a newly-formed subsidiary, Jamestown TN Medical Center, Inc., and is an 85 bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services. The acquisition also included a separate Physician Practice which will now operate under Rennova as Mountain View Physician Practice, Inc.

 

Net annual revenues for the hospital in Jamestown in recent years have been approximately $15 million with government payers including Medicare and Medicaid accounting for in excess of 60% of the payor mix. Rennova does not expect this payor mix to change significantly in the near future. The hospital was acquired for approximately $635,000 from Community Health Systems, Inc. Diligence, legal and other costs associated with the acquisition are estimated to be approximately $500,000 meaning the total cost of acquisition to the Company is approximately $1,100,000. Jamestown is located 38 miles from the Company’s existing hospital, the Big South Fork Medical Center, which is located in Oneida, Tennessee.

 

RESULTS OF OPERATIONS

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

 

We have identified the policies and significant estimation processes discussed below as critical to our business and to the understanding of our results of operations. For a detailed application of these and other accounting policies, see Notes 1 and 2 to the audited consolidated financial statements as of and for the year ended December 31, 2017 included in the 2017 Form 10-K.

 

Revenue Recognition

 

Service revenues are generated from laboratory testing services and hospital revenues.

 

Laboratory testing services include chemical diagnostic tests such as blood analysis and urine analysis. Laboratory service revenues are recognized at the time the testing services are performed and billed and are reported at their estimated net realizable amounts. Net service revenues are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the U.S. have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses; the majority of services provided by us are to patients covered under a third-party payer contract. In most cases, the Company is provided the third-party billing information and seeks payment from the third party in accordance with the terms and conditions of the third-party payer for health service providers like us. Each of these third-party payers may differ not only in terms of rates, but also with respect to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payer methods and trends. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings, including the patient responsibility portion of the billing for patients covered by third party payers. The Company currently does not have any capitated agreements.

 

30
 

 

RENNOVA HEALTH, INC.

 

For hospital goods and or services, net revenues are determined utilizing gross revenues net of contractual adjustments and discounts and are recognized when the goods and services are delivered. Even though it is the responsibility of the patient to pay for goods and services rendered, most individuals have an agreement with a third-party payer such as a commercial insurance provider, Medicaid or Medicare to pay all or a portion of their healthcare expenses.

 

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” The standard, including subsequently issued amendments, will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. There is a five-step approach outlined in the standard. Entities are permitted to apply the new standard under the full retrospective method, subject to certain practical expedients, or the modified retrospective method that requires the application of the guidance only to contracts that are uncompleted on the date of initial application.

 

In determining revenue, we first identify the contract according to the scope of ASC 606 with the following criteria:

 

 

The parties have approved the contract either in writing through the acknowledgement or consent of the patient responsibility or consent form; orally by acknowledgement or by scheduled appointment; or implicitly, based on the hospital’s customary business practices (outpatient services, inpatient, emergency room visits, for example).

  Each party’s rights and the contract’s payment terms are identified.
  The contract has commercial substance.
  Collection is probable.

 

The hospital ensures that it is probable and will collect substantially all of the consideration to which it is entitled. The hospital has established the transaction price for providing goods or services to a patient through historical cash collection and current data from each identified payer class. This may include the effects of variable consideration such as discounts and price concessions and may be less than the stated contract price, whether applied on a contract-by-contract basis or by using a portfolio approach. The ultimate transaction price reflects explicit price concessions. The hospital has an obligation to provide medically necessary or emergency services regardless of a patient’s intent or ability to pay. In determining collectability, the evaluation is based on experience or the contract portfolio approach with either a specific patient or a class of similar patients.

 

The Hospital practices the full retrospective approach of all the reporting periods presented under the new standard and discloses any adjustment to prior-period information.

 

This includes but is not limited to Disaggregated revenue information, Contract asset and liability information, including significant changes from prior year, and Judgements, and changes in judgement, that significantly affect the determination of the amount of revenue and timing.

 

We review our calculations for the realizability of gross service revenues on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payer groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions. This calculation is routinely analyzed by us on the basis of actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed.

 

Contractual Allowances and Doubtful Accounts

 

Accounts receivable are reported at realizable value, net of allowances for credits and doubtful accounts, which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimating and reviewing the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the collectability of these receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to provision for bad debts.

 

Impairment or Disposal of Long-Lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant and Equipment (“ASC 360”). ASC 360 clarifies the accounting for the impairment of long-lived assets and for long-lived assets to be disposed of, including the disposal of business segments and major lines of business. Long-lived assets are reviewed when facts and circumstances indicate that the carrying value of the asset may not be recoverable. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.

 

31
 

 

RENNOVA HEALTH, INC.

 

At December 31, 2016, we determined that a portion of our laboratory service equipment was impaired and we recorded an impairment charge of $0.8 million, and we also recorded an impairment charge for our equity investment in Genomas, Inc. (“Genomas”) in the amount of $0.2 million. At December 31, 2017, we recorded a goodwill impairment charge of $1.0 million related to the Genomas acquisition. Genomas is part of AMSG and is included in our discontinued operations.

 

Derivative Financial Instruments and Fair Value

 

In accordance with ASC 820, “Fair Value Measurements and Disclosures,” the Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

  ●  Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date.
     
  Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets).
     
  Level 3 applies to assets or liabilities for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including our own assumptions.

 

The estimated fair value of financial instruments is determined by the Company using available market information and valuation methodologies considered to be appropriate. At March 31, 2018 and December 31, 2017, the carrying value of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to their short-term nature.

 

The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and March 31, 2018:

 

   Level 1   Level 2   Level 3   Total 
As of December 31, 2017:                
Embedded conversion options  $-   $-   $1,577,025   $1,577,025 
Common stock warrants   -    -    10,858,225    10,858,225 
Total  $-   $-   $12,435,250   $12,435,250 
                     
As of March 31, 2018:                    
Embedded conversion options  $-   $-   $1,005,188   $1,005,188 
Common stock warrants   -    -    151,418,187    151,418,187 
Total  $-   $-   $152,423,375   $152,423,375 

 

For the three months ended March 31, 2018, total loss realized on instruments valued using Level 3 valuations was $140.0 million.

 

The Company utilized the following methods to value its derivative liabilities for the three months ended March 31, 2018: (i) for embedded conversion options valued at $1.0 million, the Company determined the fair value by comparing the discounted conversion price per share (85% of market price) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company’s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability; (ii) for warrants valued at $151.4 million, the Company determined the fair value by using a binomial model and monte carlo simulations; and (iii) for warrants valued at $0.1 million and embedded conversion options valued at 0.2 million, the Company determined the fair value using the Black-Scholes option pricing model. All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.

 

The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2018:

 

Balance at December 31, 2017  $12,435,250 
Loss on change in fair value included in net loss   139,779,232 
Issuance of convertible debt   208,893 
Balance at March 31, 2018  $152,423,375 

 

The increase in the fair value of the derivative liabilities is primarily due to the increase in the Company’s quoted trading price from $0.003 on December 31, 2017 to $0.009 on March 31, 2018. Because the exercise price of a significant portion of the Company’s outstanding warrants are currently exercisable at $0.0038 per share, and subject to further reduction in their exercise price in the event of further issuances at lower than $0.0038 per share, the fair value of the warrants increased significantly during the three months ended March 31, 2018.

 

32
 

 

RENNOVA HEALTH, INC.

 

Stock Based Compensation

 

We account for Stock-Based Compensation under ASC 718 “Compensation – Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

 

The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees. Under ASC 505-50, the Company determines the fair value of the options, warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Any stock options or warrants issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity (deficit) over the applicable service periods using variable accounting through the vesting dates based on the fair value of the options or warrants at the end of each period.

 

Three months ended March 31, 2018 compared to three months ended March 31, 2017

 

The following table summarizes the results of our consolidated continuing operations for the three months ended March 31, 2018 and 2017 (unaudited):

 

  

Three Months Ended March 31,

 
   2018    2017 
   $   %   $   % 
Net revenues  $1,601,661    100.0%  $684,265    100.0%
Operating expenses:                    
Direct costs of revenue   2,089,366    130.4%   244,831    35.8%
General and administrative expenses   2,892,019    180.6%   3,316,448    484.7%
Sales and marketing expenses   (1,215)   -0.1%   252,314    36.9%
Depreciation and amortization   333,515    20.8%   426,929    62.4%
Loss from operations   (3,712,024)   -169.3%   (3,556,257)   -519.7%
Interest expense   (3,307,014)   -206.5%   (45,642,525)   -6670.3%
Change in fair value of derivative instruments   139,779,232    8727.1%   563,617    82.4%
Other income, net   11,969    0.7%   -    0.0%
Income tax expense   76    0.0%   3,250    0.5%
Net loss  $(146,786,377)   437.5%  $(48,638,415)   -7108.1%

 

Net Revenues

 

Consolidated net revenues were $1.6 million for the three months ended March 31, 2018, as compared to $0.7 million for the three months ended March 31, 2017, an increase of $0.9 million. The increase is mainly due to the opening of the Oneida Hospital which resulted in net revenues of $1.6 million for the three months ended March 31, 2018. The increase in Hospital revenue was offset by a $0.6 million decrease in Lab revenue for the three months ended March 31, 2018 compared to the same period in 2017.

 

Direct Cost of Revenue

 

Direct costs of revenue increased by $1.8 million compared to the three months ended March 31, 2017.

 

General and Administrative Expenses

 

General and administrative expenses decreased by $0.4 million, or 13%, compared to the same period a year ago.

 

Sales and Marketing Expenses

 

There was a decline in sales and marketing expenses of $0.2 million, or 100%, for the three months ended March 31, 2018 as compared to the three months ended March 31, 2017.

 

Bad Debt Expense

 

Bad debt expense for the three months ended March 31, 2018 was $0.6 million, as compared to zero for the three months ended March 31, 2017. The increase is related to allowance for doubtful accounts and allowance billing adjustments by insurance companies.

 

Depreciation and Amortization Expenses

 

Depreciation and amortization expense was $0.3 million for the three months ended March 31, 2018 as compared to $0.4 million for the same period a year ago.

 

Loss from Operations

 

Our operating loss decreased by $0.2 million for the three months ended March 31, 2018 as compared to same period a year ago.

 

Interest Expense

 

Interest expense for the three months ended March 31, 2018 was $2.5 million, as compared to $45.6 million for the three months ended March 31, 2017.

 

33
 

 

RENNOVA HEALTH, INC.

 

Other income (expense)

 

Other income decreased by $0.6 million for the three months ended March 31, 2018 as compared to same period a year ago.

 

Net Loss

 

Our net loss increased by $98.1 million, to $146.7 million for the three months ended March 31, 2018, as compared to $48.6 million for the three months ended March 31, 2017. The decrease is due primarily to the revaluation of our derivative liability.

 

The following table presents key financial and operating metrics for our Clinical Laboratory Operations segment:

 

   Three Months Ended March 31,         
Clinical Laboratory Operations  2018   2017   Change   % 
                 
Net revenues  $45,586   $684,265   $(638,679)   -93.3%
Operating expenses:                    
Direct costs of revenue   20,412    230,459    (210,047)   -91.1%
Bad debt expense        -    -    0.0%
General and administrative expenses   486,998    1,061,914    (574,917)   -54.1%
Sales and marketing expenses   (1,215)   249,699    (250,914)   -100.5%
Depreciation and amortization   295,474    434,468    (138,994)   -32.0%
                     
Loss from operations  $(756,083)  $(1,292,275)  $536,192    41.5%
                     
Key Operating Measures - Revenues:                    
Insured tests performed   705    5,116    (4,411)   -86.2%
Net revenue per insured test  $64.66   $133.75   $(69.09)   51.7%
Revenue recognition percent of gross billings   13%   13%   0.0%     
                     
Key Operating Measures - Direct Costs:                    
Total samples processed   1,935    6,525    (4,590)   -70.3%
Direct costs per sample  $10.55   $35.32   $(24.77)   -70.1%

 

The following table presents key financial metrics for our Hospital segment:

 

   Three Months Ended March 31,         
Hospital  2018   2017   Change   % 
                 
Net revenues  $1,556,075   $-   $1,556,075    NM 
Operating expenses:                    
Direct costs of revenue   2,068,954    -    2,068,954    NM 
General and administrative expenses   921,993    467,316    454,677    NM 
Depreciation and amortization   37,728    -    37,728    NM 
                     
Loss from operations  $(1,472,600)  $(467,316)  $(1,005,284)   NM 
                     
                     
Number of Patients Served   2,598    NM    NM     
                     
Key Operating Measures - Net Revenues per patient:  $598.95    NM    NM     
                     
Key Operating Measures - Direct Costs of revenue per patient:  $

796.36

    NM    NM     
                     
Our hospital operations began on August 8, 2017.                

 

34
 

 

RENNOVA HEALTH, INC.

 

The following table presents key financial metrics for our Corporate group:

 

   Three Months Ended March 31,         
Corporate  2018   2017   Change   % 
                 
Operating expenses:                    
General and administrative expenses  $1,483,027   $1,787,218   $(304,191)   -17.0%
Direct costs of revenue   -    14,372    (14,372)   - 
Sales and marketing expenses   -    2,615    (2,615)   - 
Depreciation and amortization   314    312    2    0.6%
                     
Loss from operations  $(1,483,341)  $(1,804,517)  $321,176    -17.8%

 

LIQUIDITY AND CAPITAL RESOURCES

 

For the quarters ended March 31, 2018 and 2017, we have financed our operations primarily from the sale of our equity securities, the issuance of debentures, short-term advances from related parties, and the proceeds we received from pledging certain of our accounts receivable. Future cash needs for working capital, capital expenditures and potential acquisitions will require management to seek additional equity or obtain additional credit facilities. The sale of additional equity will result in additional dilution to our stockholders. A portion of our cash may be used to acquire or invest in complementary businesses or products or to obtain the right to use complementary technologies. From time to time, in the ordinary course of business, we evaluate potential acquisitions of such businesses, products or technologies.

 

At March 31, 2018, we had $35 thousand in cash on hand from continuing operations, a working capital deficit of $174.8 million and a stockholders’ deficit of $183.9 million. In addition, we incurred a loss from continuing operations of $3.7 million for the quarter ended March 31, 2018. As of the date of this report, our cash position is critically deficient and payments critical to our ability to operate are not being made in the ordinary course. Our fixed operating expenses, including payroll, rent, capital lease payments and other fixed expenses, including the costs required to operate Big South Fork Medical Center, which began operations on August 8, 2017, are approximately $1.5-$2.0 million per month.

 

On February 9, 2018, the holders exercised their right to exchange a portion of the September Debentures for shares of the Series I-2 Preferred Stock for the first time. On that date, the holders elected to exchange an aggregate of $1,384,556 principal amount of September Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Preferred Stock.

 

On March 6, 2018, the Company issued 71,333,333 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board.

 

During the three months ended March 31, 2018, the Company issued 333,315,823 shares of its common stock upon conversion of $3.1 million of the principal amount of the March 2017 Debentures.

 

During the three months ended March 31, 2018, the Company issued 75,600,000 shares of common stock to the holders of 119,746,776 March 2017 Series B warrants, that were exercised on a cashless basis.

 

On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.

 

The Debentures were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act and by Rule 506 of Registration D promulgated thereunder as a transaction by an issuer not involving a public offering.

 

35
 

 

RENNOVA HEALTH, INC.

 

The following table presents our capital resources as of March 31, 2018 and December 31, 2017:

 

   March 31, 2018   December 31, 2017   Change 
             
Cash  $35,096   $-   $35,096 
Working capital   (174,819,277)   (21,496,044)   (153,323,233)
Total debt, excluding discounts and deferred financing fees   182,173,983    41,068,961    141,105,022 
Capital lease obligations   1,715,727    2,079,137    (363,410)
Stockholders' deficit   (183,907,627)   (40,613,461)   (143,294,166)

 

The following table presents the major sources and uses of cash for the three months ended March 31, 2018 and 2017:

 

    Three Months Ended March 31,        
    2018     2017     Change  
                   
Cash used in operations   $ (2,341,193 )   $ (5,951,464 )   $ 3,610,271  
Cash provided by (used in) investing activities     799,699       (1,090,922 )     1,890,621  
Cash provided by financing activities     1,576,590       8,329,460       (6,752,870 )
                         
Net change in cash   $ 35,096     $ 1,287,074     $ (1,251,978 )

 

The decrease in cash used in operations for the three months ended March 31, 2018 and 2017 is presented in the following table:

 

   Three Months Ended March 31,     
   2018   2017   Change 
             
Net loss  $(146,786,377)  $(48,638,415)  $(98,147,962)
Accounts receivable   (720,769)   115,446    (836,215)
Accounts payable and accrued expenses   (419,193)   (810,714)   391,521 
Loss from discontinued operations   421,793    (1,066,292)   1,488,085 
Other   145,861,612    44,660,876    101,200,736 
Net cash used in operating activities   (1,642,934)   (5,739,099)   4,096,165 
Cash used in discontinued operations   (698,259)   (212,365)   (485,894)
Cash used in operations  $(2,341,193)  $(5,951,464)  $3,610,271 

 

Cash provided by investing activities for the three months ended March 31, 2018 consist of the $800,000 received from the February 14, 201 Common Stock Purchase Agreement with two investors pursuant to which the Company agreed to sell an aggregate of 200,000 shares of common stock of NanoVibronix, Inc. owned by the Company at a purchase price of $4.00 per share. The Company had acquired the shares as a result of an investment originally made in 2011.

 

Cash provided by financing activities for the three months ended March 31, 2018 consists of the $2.0 million received from the debenture issuance, partially offset by the $60,000 of related party payments, net of advances, and repayment of capital lease obligations in the amount of $0.4 million.

 

36
 

 

RENNOVA HEALTH, INC.

 

OTHER MATTERS

 

Inflation

 

We do not believe inflation has a significant effect on the Company’s operations at this time.

 

Off Balance Sheet Arrangements

 

Under SEC regulations, we are required to disclose the Company’s off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources that are material to investors. Off-balance sheet arrangements consist of transactions, agreements or contractual arrangements to which any entity that is not consolidated with us is a party, under which we have:

 

    Any obligation under certain guarantee contracts.
     
  Any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets.
     
  Any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to the Company’s stock and classified in stockholder’s equity in the Company’s statement of financial position.
     
  Any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us.

 

As of March 31, 2018, the Company had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable

 

Item 4. Controls and Procedures.

 

  (a) Evaluation of Disclosure Controls and Procedures

 

In connection with the preparation of this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of our chief executive officer and interim chief financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”)) as of March 31, 2018. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the chief executive officer, to allow timely decisions regarding required disclosures.

 

Based on that evaluation, our management concluded, as of the end of the period covered by this report, that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective. In connection with such evaluation, management concluded that the material weakness in internal control over financial reporting identified in our Form 10-K for the year ended December 31, 2017 continued to exist, and as such our disclosure controls and procedures were not effective as of March 31, 2018. Insufficient staffing, accounting processes and procedures led to a lack of contemporaneous documentation supporting the accounting for certain transactions and the approval of certain cash disbursements. The Company is in the process of taking the following steps to remediate these material weaknesses: (i) increasing the staffing of its internal accounting department, including the addition of a full time Chief Financial Officer; (ii) beginning the process of converting to a new integrated accounting system to enhance controls and procedures for recording accounting transactions; and (iii) implementing enhanced documentation procedures to be followed by the internal accounting department, including independent review of material cash disbursements.

 

Notwithstanding such material weakness, management believes that the condensed consolidated financial statements included in this Form 10-Q fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods and dates presented.

 

  (b) Changes in Internal Control over Financial Reporting

 

During the three months ended March 31, 2018, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

37
 

 

RENNOVA HEALTH, INC.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims, which are presented in Note 12 to the accompanying unaudited condensed consolidated financial statements.

 

Item 1A. Risk Factors.

 

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A of the 2017 Form 10-K which could materially affect our business, financial condition, or future results. There have been no material changes to the risk factors previously disclosed in our 2017 Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

During the three-months ended March 31, 2018, the Company had no issuances of unregistered sales of equity securities.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

38
 

 

RENNOVA HEALTH, INC.

 

Item 6. Exhibits

 

10.155 Asset Purchase Agreement, dated as of January 31, 2018, by and among HMA Fentress County Hospital, LLC, Jamestown HMA Physician Management, LLC, Jamestown TN Medical Center, Inc., CHS Community Health Systems, Inc. and Rennova Health, Inc. (incorporated by reference to Exhibit 10.162 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2018).
10.156 Common Stock Purchase Agreement, dated as of February 14, 2018, by and among Rennova Heath, Inc. and the purchasers named on the signature pages hereto (incorporated by reference to Exhibit 10.163 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 15, 2018).
10.157 Form of Additional Issuance Agreement, dated as of March 5, 2018 (incorporated by reference to Exhibit 10.164 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2018).
10.158 Amendment to Prepaid Forward Purchase Agreement, dated as of March 24, 2017, between Racine FundingCo, LLC, on the one hand, and Rennova Health, Inc., Biohealth Medical Laboratory, Inc. and PB Laboratories, LLC, on the other hand, and Christopher Diamantis, as Guarantor (incorporated by reference to Exhibit 10.165 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2018).
10.159 Second Amendment to Prepaid Forward Purchase Agreement, dated as of March 30, 2018, between Racine FundingCo, LLC, on the one hand, and Rennova Health, Inc., Biohealth Medical Laboratory, Inc. and PB Laboratories, LLC, on the other hand, and Christopher Diamantis, as Guarantor (incorporated by reference to Exhibit 10.166 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2018).
31.1 Rule 13a-14(a) Certification by the Principal Executive Officer and Interim Principal Financial Officer.
32.1 Certification by the Principal Executive Officer and Interim Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS XBRL Instance Document
   
101.SCH XBRL Schema Document
   
101.CAL XBRL Calculation Link base Document
   
101.DEF XBRL Definition Link base Document
   
101.LAB XBRL Label Link base Document
   
101.PRE XBRL Presentation Link base Document

 

 

*Furnished herewith

 

39
 

 

RENNOVA HEALTH, INC.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  RENNOVA HEALTH, INC.
     
Date: June 19, 2018 By: /s/ Seamus Lagan
    Seamus Lagan
   

Chief Executive Officer and Interim Chief Financial Officer

(Principal Executive Officer and Interim Principal Financial Officer)

 

40
 

EX-31.1 2 ex31-1.htm

 

RENNOVA HEALTH, INC.

 

EXHIBIT 31.1

 

CERTIFICATION OF

PRINICPAL EXECUTIVE OFFICER AND INTERIM PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Seamus Lagan, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q of Rennova Health, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s), if any, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s), if any, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  /s/ Seamus Lagan
  Seamus Lagan
  Chief Executive Officer and Interim Chief Financial Officer
  (Principal Executive Officer and Interim Principal Financial Officer)
   
Dated: June 19, 2018  

 

 
 

 

EX-32.1 3 ex32-1.htm

 

RENNOVA HEALTH, INC.

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Rennova Health, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission (the “Report”), I, Seamus Lagan, Chief Executive Officer and Interim Chief Financial Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to the best of my knowledge:

 

  1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Seamus Lagan
Seamus Lagan
Chief Executive Officer and Interim Chief Financial Officer 
Dated: June 19, 2018

 

 
 

EX-101.INS 4 rnva-20180331.xml XBRL INSTANCE FILE 0000931059 2018-01-01 2018-03-31 0000931059 us-gaap:SeriesGPreferredStockMember 2017-12-31 0000931059 us-gaap:SeriesHPreferredStockMember 2017-12-31 0000931059 2017-12-31 0000931059 us-gaap:SeriesGPreferredStockMember 2018-03-31 0000931059 us-gaap:SeriesHPreferredStockMember 2018-03-31 0000931059 2018-03-31 0000931059 us-gaap:CorporateMember 2017-01-01 2017-03-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2017-01-01 2017-03-31 0000931059 us-gaap:CorporateMember 2017-12-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2017-12-31 0000931059 RNVA:NotesPayableRelatedPartiesOneMember 2017-01-01 2017-12-31 0000931059 us-gaap:PreferredStockMember 2017-12-31 0000931059 us-gaap:CommonStockMember 2017-12-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000931059 us-gaap:RetainedEarningsMember 2017-12-31 0000931059 2017-02-06 2017-02-07 0000931059 2017-02-07 0000931059 2017-01-01 2017-03-31 0000931059 RNVA:LaboratoryServiceMember 2017-12-31 0000931059 RNVA:HospitalAssetMember 2018-01-01 2018-03-31 0000931059 RNVA:MedicalEquipmentMember 2017-12-31 0000931059 us-gaap:BuildingMember 2017-12-31 0000931059 us-gaap:EquipmentMember 2017-12-31 0000931059 us-gaap:AssetsHeldUnderCapitalLeasesMember 2017-12-31 0000931059 us-gaap:FurnitureAndFixturesMember 2017-12-31 0000931059 us-gaap:LeaseholdImprovementsMember 2017-12-31 0000931059 us-gaap:VehiclesMember 2017-12-31 0000931059 us-gaap:ComputerEquipmentMember 2017-12-31 0000931059 us-gaap:SoftwareDevelopmentMember 2017-12-31 0000931059 2016-03-30 2016-03-31 0000931059 RNVA:TCADebentureMember 2017-02-01 2017-02-02 0000931059 RNVA:TCADebentureMember 2017-03-20 2017-03-21 0000931059 RNVA:TCADebentureMember RNVA:AprilTwoThousandSeventeenThroughSeptemberTwoThousandSeventeenMember 2017-03-20 2017-03-21 0000931059 RNVA:TCADebentureMember 2017-03-21 0000931059 RNVA:TwoInvestorMember RNVA:SeptemberTwoThousandSixteenMember 2016-09-15 0000931059 RNVA:SeptemberTwoThousandSixteenMember 2016-09-15 0000931059 2016-11-02 2016-11-03 0000931059 RNVA:AlcimedeLLCMember 2015-02-03 0000931059 RNVA:AlcimedeLLCMember 2015-02-01 2015-02-03 0000931059 RNVA:AlcimedeLLCMember 2015-06-29 0000931059 RNVA:AlcimedeLLCMember 2015-06-28 2015-06-29 0000931059 RNVA:MrLaganMember 2017-03-01 2017-03-31 0000931059 RNVA:NotesPayableThirdPartiesOneMember 2017-12-31 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2017-12-31 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2017-12-31 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2017-01-01 2017-12-31 0000931059 RNVA:NotesPayableRelatedPartiesOneMember 2017-12-31 0000931059 RNVA:NotesPayableRelatedPartiesMember 2017-12-31 0000931059 RNVA:FebruaryTwoThousandAndSeventeenOfferingMember 2017-02-02 0000931059 RNVA:FebruaryTwoThousandAndSeventeenOfferingMember 2017-02-01 2017-02-02 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember 2017-03-21 0000931059 RNVA:FebruaryTwoThousandAndSeventeenOfferingMember 2017-03-20 2017-03-21 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:TwoThousandSeventeenDiamantisNoteMember 2017-03-19 2017-03-21 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember 2017-03-21 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember 2017-03-20 2017-03-21 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchWarrantsAndExchangeWarrantsMember 2018-01-01 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:DebentureWarrantMember 2018-01-01 2018-03-31 0000931059 RNVA:JuneWarrantsMember RNVA:AccreditedInvestorMember 2018-01-01 2018-03-31 0000931059 RNVA:SettlementAgreementMember RNVA:EpinexDiagnosticsLaboratoriesIncMember 2016-07-29 0000931059 RNVA:EpinexDiagnosticsLaboratoriesIncMember 2017-03-24 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-02-01 2016-02-29 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-09-30 0000931059 RNVA:FloridaDepartmentOfRevenueMember 2016-09-27 0000931059 RNVA:FloridaDepartmentOfRevenueMember 2017-01-23 2017-01-25 0000931059 RNVA:TCSFloridaLPMember 2017-01-02 2017-01-03 0000931059 RNVA:TCSFloridaLPMember 2017-01-01 2017-02-28 0000931059 RNVA:TCSFloridaLPMember RNVA:ForbearanceAgreementMember 2017-02-14 2017-02-15 0000931059 RNVA:DeLageLandenFinancialServicesIncMember 2017-01-23 2017-01-24 0000931059 RNVA:DeLageLandenFinancialServicesIncMember 2017-02-06 2017-02-08 0000931059 2016-12-07 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2018-01-01 2018-03-31 0000931059 RNVA:HospitaOperationsMember 2018-01-01 2018-03-31 0000931059 us-gaap:CorporateMember 2018-01-01 2018-03-31 0000931059 RNVA:HospitaOperationsMember 2017-01-01 2017-03-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2018-03-31 0000931059 RNVA:HospitaOperationsMember 2018-03-31 0000931059 us-gaap:CorporateMember 2018-03-31 0000931059 RNVA:AssetsOfAMSGandHTSClassifiedHeldForSaleMember 2018-03-31 0000931059 RNVA:EliminationsMember 2018-03-31 0000931059 RNVA:HospitaOperationsMember 2017-12-31 0000931059 RNVA:AssetsOfAMSGandHTSClassifiedHeldForSaleMember 2017-12-31 0000931059 us-gaap:SeriesFPreferredStockMember 2017-12-31 0000931059 us-gaap:SeriesFPreferredStockMember 2018-03-31 0000931059 2017-09-20 2017-09-21 0000931059 2017-03-31 0000931059 RNVA:HospitalMember 2017-12-31 0000931059 RNVA:SeptemberTwoThousandSixteenMember 2016-09-14 2016-09-15 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:SeriesHConvertiblePreferredStockMember 2017-03-20 2017-03-21 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember RNVA:SeriesAWarrantMember 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember RNVA:SeriesBWarrantMember 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember RNVA:SeriesCWarrantMember 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember RNVA:SeriesAWarrantMember 2018-01-01 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember RNVA:SeriesBWarrantMember 2018-01-01 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember RNVA:SeriesCWarrantMember 2018-01-01 2018-03-31 0000931059 RNVA:JulyTwoThousandAndSeventeenOfferingsMember 2017-07-17 0000931059 RNVA:JulyOfferingsMember 2017-07-16 2017-07-17 0000931059 RNVA:JulyTwoThousandAndSeventeenOfferingsMember 2018-03-31 0000931059 RNVA:JulyTwoThousandAndSeventeenOfferingsMember 2017-10-04 2017-10-05 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember 2017-09-19 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesAWarrantMember 2017-09-19 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesBWarrantMember 2017-09-19 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesCWarrantMember 2017-09-19 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember 2017-09-18 2017-09-19 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember 2018-01-01 2018-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember 2018-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesAWarrantMember 2018-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesAWarrantMember 2018-01-01 2018-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesBWarrantMember 2018-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesBWarrantMember 2018-01-01 2018-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesCWarrantMember 2018-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeriesCWarrantMember 2018-01-01 2018-03-31 0000931059 RNVA:EmployeesAndDirectorsMember 2017-08-13 2017-08-14 0000931059 us-gaap:WarrantMember 2017-12-31 0000931059 RNVA:EpinexDiagnosticsLaboratoriesIncMember 2016-10-31 0000931059 RNVA:SeptemberTwoThousandSixteenMember 2017-03-12 2017-03-13 0000931059 RNVA:JulyDebenturesMember 2017-09-18 2017-09-19 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember 2017-03-20 2017-03-21 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember 2018-01-01 2018-03-31 0000931059 RNVA:SeptemberDebentureMember 2017-09-18 2017-09-19 0000931059 2017-10-04 2017-10-05 0000931059 2017-10-05 0000931059 us-gaap:FairValueInputsLevel3Member 2017-12-31 0000931059 RNVA:AlcimedeLLCMember 2016-08-01 2016-08-31 0000931059 RNVA:AlcimedeLLCMember 2017-08-01 2017-08-02 0000931059 RNVA:AlcimedeLLCMember 2018-03-31 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2017-01-01 2017-12-31 0000931059 RNVA:NotesPayableRelatedPartiesTwoMember 2017-12-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember RNVA:MarchWarrantsMember 2018-03-31 0000931059 RNVA:JuneTwoThousandAndSeventeenOfferingsMember RNVA:JuneDebenturesMember 2017-06-30 0000931059 RNVA:JuneTwoThousandAndSeventeenOfferingsMember 2017-06-02 0000931059 RNVA:JuneTwoThousandAndSeventeenOfferingsMember 2017-06-22 0000931059 RNVA:SeptemberDebentureMember 2018-02-04 2018-02-08 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeptemberWarrantsMember 2018-03-31 0000931059 2017-01-01 2017-01-31 0000931059 RNVA:SeriesIOnePreferredStockMember 2017-10-29 2017-10-30 0000931059 RNVA:SeriesIOnePreferredStockMember 2017-10-30 0000931059 RNVA:SeriesIOnePreferredStockMember RNVA:PurchaseAgreementMember 2017-10-29 2017-10-30 0000931059 RNVA:SeriesIOnePreferredStockMember us-gaap:InvestorMember 2017-10-30 0000931059 us-gaap:InternalRevenueServiceIRSMember RNVA:MedytoxSolutionsIncMember 2016-03-31 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2017-12-31 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2018-03-31 0000931059 RNVA:HealthTechnologySolutionsIncMember 2017-12-31 0000931059 RNVA:HealthTechnologySolutionsIncMember 2018-03-31 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2017-01-01 2017-03-31 0000931059 RNVA:AdvancedMolecularServicesGroupMember 2018-01-01 2018-03-31 0000931059 RNVA:HealthTechnologySolutionsIncMember 2018-01-01 2018-03-31 0000931059 RNVA:HealthTechnologySolutionsIncMember 2017-01-01 2017-03-31 0000931059 2017-02-21 2017-02-22 0000931059 RNVA:FloridaDepartmentOfRevenueMember 2018-03-31 0000931059 RNVA:TCSFloridaLPMember 2017-04-29 2017-05-01 0000931059 RNVA:RedeemablePreferredStockIOneMember 2018-03-31 0000931059 RNVA:RedeemablePreferredStockIOneMember 2017-12-31 0000931059 RNVA:RedeemablePreferredStockITwoMember 2018-03-31 0000931059 RNVA:RedeemablePreferredStockITwoMember 2017-12-31 0000931059 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0000931059 us-gaap:PreferredStockMember 2018-03-31 0000931059 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000931059 us-gaap:CommonStockMember 2018-03-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000931059 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000931059 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000931059 us-gaap:RetainedEarningsMember 2018-03-31 0000931059 2016-12-31 0000931059 RNVA:MayThirtyTwoThousandAndEighteenMember 2018-03-31 0000931059 RNVA:MayNineTwoThousandEighteenMember srt:MinimumMember 2018-03-31 0000931059 RNVA:MayNineTwoThousandEighteenMember srt:MaximumMember 2018-03-31 0000931059 RNVA:EmployeesAndDirectorsMember 2018-03-04 2018-03-06 0000931059 RNVA:SeamusLaganMember 2018-03-04 2018-03-06 0000931059 RNVA:DrKamranAjamiMember 2018-03-04 2018-03-06 0000931059 RNVA:JohnBeachMember 2018-03-04 2018-03-06 0000931059 RNVA:GaryLBlumMember 2018-03-04 2018-03-06 0000931059 RNVA:ChristopherDiamantisMember 2018-03-04 2018-03-06 0000931059 RNVA:TrevorLangleyMember 2018-03-04 2018-03-06 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember 2018-02-09 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember 2018-02-04 2018-02-09 0000931059 RNVA:NanoVibronixIncMember 2018-02-13 2018-02-14 0000931059 RNVA:NanoVibronixIncMember 2018-02-14 0000931059 RNVA:MarchTwoThousandEighteenOfferingMember 2018-03-05 0000931059 RNVA:LaboratoryServiceMember 2018-03-31 0000931059 RNVA:HospitalMember 2018-03-31 0000931059 RNVA:MedicalEquipmentMember 2018-03-31 0000931059 us-gaap:BuildingMember 2018-03-31 0000931059 us-gaap:EquipmentMember 2018-03-31 0000931059 us-gaap:AssetsHeldUnderCapitalLeasesMember 2018-03-31 0000931059 us-gaap:FurnitureAndFixturesMember 2018-03-31 0000931059 us-gaap:LeaseholdImprovementsMember 2018-03-31 0000931059 us-gaap:VehiclesMember 2018-03-31 0000931059 us-gaap:ComputerEquipmentMember 2018-03-31 0000931059 us-gaap:SoftwareDevelopmentMember 2018-03-31 0000931059 RNVA:NotesPayableThirdPartiesOneMember 2018-03-31 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2018-03-31 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2018-03-31 0000931059 RNVA:NotesPayableThirdPartiesTwoMember 2018-01-01 2018-03-31 0000931059 RNVA:NotesPayableThirdPartiesThreeMember 2018-01-01 2018-03-31 0000931059 RNVA:NotesPayableRelatedPartiesOneMember 2018-03-31 0000931059 RNVA:NotesPayableRelatedPartiesTwoMember 2018-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember 2018-03-31 0000931059 2017-01-01 2017-12-31 0000931059 RNVA:MarchTwoThousandAndEighteenOfferingMember 2018-03-05 0000931059 RNVA:MarchTwoThousandAndEighteenOfferingMember 2018-03-04 2018-03-05 0000931059 RNVA:EliminationsMember 2018-01-01 2018-03-31 0000931059 RNVA:EliminationsMember 2017-01-01 2017-03-31 0000931059 RNVA:EliminationsMember 2017-12-31 0000931059 us-gaap:SubsequentEventMember srt:MaximumMember 2018-05-09 0000931059 us-gaap:SubsequentEventMember srt:MinimumMember 2018-05-09 0000931059 RNVA:MarchTwoThousandAndSeventeenDebenturesMember 2018-01-01 2018-03-31 0000931059 us-gaap:CommonStockMember RNVA:JuneEighteenTwoThousandAndEighteenMember 2018-01-01 2018-03-31 0000931059 RNVA:FloridaDepartmentOfRevenueMember RNVA:StipulationAgreementMember 2018-01-01 2018-03-31 0000931059 RNVA:GenomasIncMember 2017-11-01 2017-11-30 0000931059 RNVA:AlcimedeMember 2018-01-01 2018-03-31 0000931059 RNVA:AlcimedeMember 2017-01-01 2017-03-31 0000931059 RNVA:MonarchCapitalLLCMember 2018-01-01 2018-03-31 0000931059 us-gaap:CommonStockMember 2018-03-31 0000931059 RNVA:EmployeesAndDirectorsMember 2018-03-03 2018-03-06 0000931059 RNVA:EmployeesAndDirectorsMember 2018-03-06 0000931059 RNVA:TwoThousandSevenEquityPlanMember 2018-03-31 0000931059 RNVA:TwoThousandSevenEquityPlanMember 2018-01-01 2018-03-31 0000931059 us-gaap:WarrantMember 2018-01-01 2018-03-31 0000931059 us-gaap:WarrantMember 2018-03-31 0000931059 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-03-31 0000931059 us-gaap:ConvertibleDebtMember 2018-01-01 2018-03-31 0000931059 us-gaap:StockOptionMember 2018-01-01 2018-03-31 0000931059 us-gaap:ConvertiblePreferredStockMember 2017-01-01 2017-03-31 0000931059 us-gaap:ConvertibleDebtMember 2017-01-01 2017-03-31 0000931059 us-gaap:StockOptionMember 2017-01-01 2017-03-31 0000931059 RNVA:MarchTwoThousandEighteenOfferingMember 2018-03-04 2018-03-05 0000931059 2017-01-12 2017-01-13 0000931059 RNVA:NotesPayableRelatedPartiesOneMember 2018-01-01 2018-03-31 0000931059 RNVA:WarrantsMember 2018-01-01 2018-03-31 0000931059 RNVA:WarrantsMember 2017-01-01 2017-03-31 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember 2017-10-30 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember 2018-03-31 0000931059 RNVA:SeriesITwoConvertiblePreferredStockMember 2018-02-03 2018-02-09 0000931059 RNVA:MarchTwoThousandAndSeventeenSeriesBWarrantsMember 2018-03-31 0000931059 RNVA:AssetPurchaseAgreementMember 2018-01-30 2018-01-31 0000931059 2016-03-31 0000931059 RNVA:SeptemberTwoThousandAndSeventeenOfferingsMember RNVA:SeptemberWarrantsMember 2017-12-31 0000931059 RNVA:MonarchCapitalLLCMember 2017-01-01 2017-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenSeriesBWarrantsMember 2018-03-31 0000931059 RNVA:MayNineTwoThousandAndEighteenMember 2018-03-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel3Member 2018-03-31 0000931059 us-gaap:FairValueInputsLevel3Member 2018-01-01 2018-03-31 0000931059 us-gaap:ValuationTechniqueOptionPricingModelMember 2018-01-01 2018-03-31 0000931059 us-gaap:ValuationTechniqueOptionPricingModelMember 2018-03-31 0000931059 srt:MaximumMember 2018-03-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0000931059 us-gaap:FairValueInputsLevel1Member 2017-12-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel2Member 2018-03-31 0000931059 us-gaap:FairValueInputsLevel2Member 2017-12-31 0000931059 RNVA:CommonStockWarrantsMember us-gaap:FairValueInputsLevel1Member 2018-03-31 0000931059 RNVA:CommonStockWarrantsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0000931059 RNVA:CommonStockWarrantsMember us-gaap:FairValueInputsLevel2Member 2018-03-31 0000931059 RNVA:CommonStockWarrantsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0000931059 RNVA:EmbeddedConversionOptionsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000931059 RNVA:CommonStockWarrantsMember us-gaap:FairValueInputsLevel3Member 2018-03-31 0000931059 RNVA:CommonStockWarrantsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0000931059 us-gaap:FairValueInputsLevel1Member 2018-03-31 0000931059 us-gaap:FairValueInputsLevel2Member 2018-03-31 0000931059 us-gaap:FairValueInputsLevel3Member 2018-03-31 0000931059 RNVA:EmbeddedConversionOptionsMember 2018-03-31 0000931059 RNVA:CommonStockWarrantsMember 2018-03-31 0000931059 RNVA:EmbeddedConversionOptionsMember 2017-12-31 0000931059 RNVA:CommonStockWarrantsMember 2017-12-31 0000931059 2018-06-18 0000931059 us-gaap:SubsequentEventMember 2018-06-18 0000931059 us-gaap:IndividualMember RNVA:ChristopherDiamantisMember 2018-03-31 0000931059 us-gaap:IndividualMember 2018-03-31 0000931059 RNVA:ChristopherDiamantisMember 2017-01-01 2017-01-31 0000931059 RNVA:ChristopherDiamantisMember 2017-02-01 2017-02-28 0000931059 RNVA:ChristopherDiamantisMember 2017-02-28 0000931059 RNVA:ChristopherDiamantisMember 2017-01-31 0000931059 RNVA:ChristopherDiamantisMember 2017-03-06 2017-03-07 0000931059 RNVA:ChristopherDiamantisMember 2017-03-07 0000931059 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0000931059 RNVA:MarchTwoThousandAndSeventeenOfferingsMember RNVA:MarchDebenturesAndExchangeDebentureMember 2017-03-22 2018-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure RNVA:Segment Rennova Health, Inc. 0000931059 10-Q 2018-03-31 false --12-31 Q1 6290794 6137770 3436773 1503520 1019946 2788059 3510297 243963 -1424496 2549504 255566 -1454570 1128500 1068500 -1068500 -1068500 2 2 17500 17500 -40613461 -183907626 17502 197508 128351954 -169180425 17502 4999922 126619959 -315545009 14000 14202 5000000 14000 14202 5000000 5000000 1750000 1750000 4960 5000000 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 1000 0.80 1.00 1000 215 60 215 60 1750000 1750000 215 60 215 60 1750000 1750000 0.01 0.01 0.01 0.01 3000000000 3000000000 500000000 500000000 3000000000 3000000000 500000000 3000000000 19750844 499992133 480249156 19750844 499992133 1110232133 Smaller Reporting Company 1601661 684265 684265 45586 1556075 333515 312 434468 426929 295474 37728 314 -7851 -3712024 -1804517 -1292275 -3556257 -756083 -1472600 -1483341 -467316 7851 44074628 1000000 400000 -146364584 -49704707 -146364584 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Selected financial information for the Company&#8217;s operating segments is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net revenues&#160;&#8211;&#160;External</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,586</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">684,265</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,556,075</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,601,661</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">684,265</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Loss) income from operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(756,083</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,292,275</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,472,600</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(467,316</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Corporate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,483,341</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,804,517</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Eliminations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,851</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(3,712,024</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(3,556,257</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation and amortization</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">295,474</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">434,468</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">37,728</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Corporate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">314</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">312</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Eliminations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,851</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">333,515</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">426,929</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Capital expenditures</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(100,382</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,090,922</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">990,540</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.9in"><b>***`&#160;</b>Intersegment revenues are eliminated in consolidation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,019,946</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,503,520</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,788,059</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,549,504</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Corporate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,510,297</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,436,773</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Assets of AMSG and HTS classified as held for sale</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">243,963</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">255,566</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Eliminations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,424,496</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,454,570</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,137,769</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,290,794</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 301 1090922 1750275 19750844 1750275 499992133 RNVA 35096 1365053 77979 24196 24196 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>AMSG Assets and Liabilities:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,314</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,273</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">576</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">19,022</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,477</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,477</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>31,367</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>53,772</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deposits</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable (includes related parties)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">674,425</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">671,561</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">388,666</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">375,165</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion of notes payable</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">228,421</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">249,589</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,291,512</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,296,315</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>HTS Assets and Liabilities:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,727</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8,281</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">166,774</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">160,715</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,183</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,964</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>190,684</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>172,960</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,883</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,078</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deposits</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,756</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>21,912</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>28,834</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable (includes related parties)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,235</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">407,404</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">271,245</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">269,135</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>771,480</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>676,539</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Consolidated Discontinued Operations Assets and Liabilities:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,041</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,554</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">167,350</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">179,737</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">47,660</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">29,441</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>222,051</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>226,732</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,883</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,078</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deposits</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,756</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>21,912</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>28,834</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable (includes related parties)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,174,660</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,078,965</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">659,911</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">644,300</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion of notes payable</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">228,421</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">249,589</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2,062,992</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,972,854</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Major line items constituting loss from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2018 and 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>AMSG Income (Loss) from Discontinued Operations:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">33,685</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">176,578</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of services</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">16,138</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">769</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Gross profit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,547</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">175,809</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">176,202</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">526,533</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income/expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(800,197</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,978</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Income/(Loss) from discontinued operations</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>641,542</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(347,746</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>HTS&#160;Income (Loss) from Discontinued Operations:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">355,147</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">315,270</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of services</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34,218</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">46,704</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Gross profit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">320,929</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">268,566</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">538,199</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">987,111</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income/expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,478</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Income/(Loss)&#160;from discontinued operations</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(219,748</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(718,545</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Consolidated Income/(Loss)&#160;from Discontinued Operations:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">388,832</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">491,848</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of services</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,356</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">47,473</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Gross profit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">338,476</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">444,375</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">714,402</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,513,645</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income (expenses)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(797,719</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,978</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Income/(Loss)&#160;from discontinued operations</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>421,793</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(1,066,292</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td></tr> </table> <p style="margin: 0pt"></p> 286240000 75600000 1731 200000 610240000 71333333 333315823 333310452 3056674 3333105 -276431 3100000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 &#8211; Accounts Receivable</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable - laboratory services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,302,579</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,478,451</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable&#160;&#8211;&#160;hospital</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,783,802</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8,593,747</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total accounts receivable</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,086,381</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,072,198</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for discounts - laboratory services</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,150,800</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,177,054</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for discounts - hospital</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(9,307,852</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(6,936,429</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for bad debts</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,525,972</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(987,403</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,101,758</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>971,312</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 &#8211; Property and Equipment</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Medical equipment</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">713,799</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">696,195</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Building</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,359,484</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,359,472</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">437,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">476,548</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Equipment under capital leases</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">232,495</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">222,824</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,303,131</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,303,131</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Vehicles</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">196,534</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">196,534</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">221,237</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">226,441</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Software</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">333,853</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">631,033</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,484,297</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,798,914</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less accumulated depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,122,072</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,103,474</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Property and equipment, net</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2,362,225</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2,695,440</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 13, 2017, the Company completed an asset purchase agreement to acquire certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the &#8220;Hospital Assets&#8221;). The Hospital Assets include a 52,000 square foot hospital building and 6,300 square foot professional building on approximately 4.3 acres. Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center, is classified as a Critical Access Hospital (rural). The Company acquired the Hospital Assets out of bankruptcy for a purchase price of $1.0 million, and the purchase price has been recorded as property and equipment in the Company&#8217;s condensed consolidated balance sheet. The Company opened the hospital on August 8, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense on property and equipment was $0.3 million and $0.4 million for the three months ended March 31, 2018 and 2017,&#160;respectively. Management periodically reviews the valuation of long-lived assets, including property and equipment, for potential impairment. Management did not recognize any impairment of these assets during the three months ended March 31, 2018 and 2017</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 &#8211; Notes Payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2018 (unaudited) and December 31, 2017, notes payable consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Notes Payable &#8211; Third Parties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Loan payable under prepaid forward purchase contract</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Loan payable to TCA Global Master Fund, LP (&#8220;TCA&#8221;) in the original principal amount of $3 million at 16% interest (the &#8220;TCA Debenture&#8221;). Principal and interest payments due in various installments through December 31, 2017.</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,616,218</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,616,218</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the &#8220;Tegal Notes&#8221;). Prinicpal and interest payments are due annually from July 12, 2015 through July 12, 2017</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">341,612</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">341,612</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,957,830</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,957,830</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(6,957,830</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(6,957,830</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt"><b>Notes payable - third parties, net of current portion</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract whereby the Company received consideration in the amount of $5.0 million. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to approximately $1.5 million on the Company&#8217;s balance sheet as of December 31, 2016 and $0 as of December 31, 2017. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Christopher Diamantis, a director of the Company, guaranteed the Company&#8217;s obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company&#8217;s obligation to March 31, 2018. Also, what the counterparty is to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by 40%. In connection with this extension, the counterparty received a fee of $1,000,000. On April 2, 2018, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into a second amendment to extend further the Company&#8217;s obligation to May 30, 2018. In connection with this further extension, the counterparty received a fee of $100,000. To date, the Company has not recovered any payments against the accounts recievable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million which was applied to accrued and unpaid interest and fees, including default interest, as of the date of payment. On March 21, 2017, the Company made a payment to TCA in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees in accordance with the terms of the TCA Debenture. Also on March 21, 2017, the Company entered into a letter agreement with TCA, which (i) waived any payment defaults through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after the effective date of the registration statement filed by the Company; which amount is reflected in accrued expenses in the accompanying condensed consolidated balance sheet at December 31, 2017. In addition, TCA entered into an inter-creditor agreement with the purchasers of the convertible debentures (see Note 6) which sets forth rights, preferences and priorities with respect to the security interests in the Company&#8217;s assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December 31,2017. The debt to TCA remains outstanding and the parties are currently working to amend the Note to extend the maturity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 15, 2016, the Company entered into an agreement with two investors whereby the Company sold to the investors convertible notes in the aggregate principal amount of $0.4 million (the &#8220;September 2016 Notes&#8221;). The September 2016 Notes were convertible into shares of the Company&#8217;s common stock at a conversion price of $112.50 per share. In conjunction with the sale of the September 2016 Notes, the Company issued warrants to purchase an aggregate of 4,444 shares of the Company&#8217;s common stock at an exercise price of $180.00 per share. Based on the allocation of the net proceeds from the September 2016 Notes to the fair value of the warrants, and the resulting beneficial conversion features, the Company recognized a discount for the entire face value of the September 2016 Notes, which was accreted through the notes&#8217; maturity date of March 15, 2017. On March 13, 2017, the September 2016 Notes, along with the accompanying warrants, were exchanged for 26,667 shares of the Company&#8217;s common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not make the principal payments under the Tegal Notes that were due on July 12, 2016. On November 3, 2016, the Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal and accrued interest aggregating to $0.4 million. On December 7, 2016, the Company received a breach of contract complaint with a request for entry of a default judgment (see Note 12). To date, the Company has yet to repay this amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notes Payable &#8211; Related Parties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Loan payable to Alcimede LLC, bearing interest at 6% per annum, with all principal and interest due on August 2, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">168,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">168,500</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Loan Payable to Christopher Diamantis</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">900,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">960,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,068,500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,068,500</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,068,500</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,068,500</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total notes payable - related parties, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2015, the Company borrowed $3.0 million from Alcimede LLC (&#8220;Alcimede&#8221;). Seamus Lagan, the Company&#8217;s President and Chief Executive Officer, is the sole manager of Alcimede. The note has an interest rate of 6% and was originally due on February 2, 2016. Alcimede later agreed to extend the maturity date of the loan to August 2, 2017. On June 29, 2015, Alcimede exercised options granted in October 2012 to purchase 66,667 shares of the Company&#8217;s common stock at an exercise price of $37.50 per share, and the loan outstanding was reduced in satisfaction of the aggregate exercise price of $2.5 million. In August of 2016, $0.3 million was repaid by the Company through the issuance of shares of common stock. In March of 2017, the Company and Mr. Lagan agreed that a payment made to Alcimede in the amount of $50,000 would be deducted from the outstanding balance of the note. On August 2, 2017, the Company and Alcimede agreed to further extend the maturity date of the loan to August 2, 2018. The remaining balance due on this loan as of March 31, 2018 was $168,500, including accrued interest.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 &#8211; Debentures</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amount of all outstanding debentures as of March 31, 2018 (unaudited), and December 31, 2017 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%"><font style="font-size: 10pt">Debentures</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 22%; text-align: right"><font style="font-size: 10pt">15,758,851</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 22%; text-align: right"><font style="font-size: 10pt">17,720,082</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Discount on Debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(8,424,756</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(12,127,634</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred financing fees</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(94,175</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(224,733</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,239,921</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,367,715</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,445,841</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,615,693</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Debentures</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>3,794,079</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>3,752,022</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment on all outstanding debentures as of March 31, 2018 are due as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt"><b><u>Period ended December 31,</u></b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2018</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$&#160;</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,647,271</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 71%; padding-bottom: 1.5pt"><font style="font-size: 10pt">2019</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$&#160;</font></td> <td style="width: 26%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10,111,580</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>15,758,851</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>February 2017 Offering</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 2, 2017, the Company issued $1.6 million aggregate principal amount of Original Issue Discount Convertible Debentures due three months from the date of issuance (the &#8220;February Debentures&#8221;) and warrants to purchase an aggregate of 6,667 shares of common stock, which can be exercised at any time after August 17, 2017 at an exercise price of $38.70 per share (the &#8220;February Warrants&#8221;), to an accredited investor for a purchase price of $1.5 million. On March 21, 2017, the February Debentures were exchanged for $2.5 million of exchange debentures as more fully discussed below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>March 2017 Offerings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 21, 2017, the Company issued $10.85 million aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due March 21, 2019 (the &#8220;Convertible Debentures&#8221;). The Company received net proceeds from this transaction in the approximate amount of $8.4 million. The Company used $3.8 million of the net proceeds to repay the 2017 Diamantis Note (see Note 7) and $0.75 million of the net proceeds to make the partial repayment on the TCA Debenture. The remainder of the net proceeds were used for general corporate purposes. In conjunction with the issuance of the Convertible Debentures, the holder of the February Debentures exchanged these debentures for $2.5 million of new debentures (the &#8220;Exchange Debentures&#8221; and, collectively with the Convertible Debentures, the &#8220;March Debentures&#8221;) on the same terms as, and pari passu with, the Convertible Debentures and warrants. The Company recorded non-cash interest expense in the amount of $0.4 million as a result of this exchange. Additionally, the holders of an aggregate of $2.2 million stated value of the Company&#8217;s Series H Convertible Preferred Stock (the &#8220;Series H Preferred Stock&#8221;) exchanged such preferred stock into $2.7 million principal amount of Exchange Debentures and warrants. The March Debentures contain a 24% original issue discount, have no regularly scheduled interest payments except in the event of a default and have a maturity date of March 21, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the March Debentures the Company issued warrants to purchase shares of the Company&#8217;s common stock to several accredited investors. At March 31, 2018, these warrants were exercisable into an aggregate of 13,823,699,256 shares of common stock. The warrants were issued to the investors in three tranches, Series A Warrants, Series B Warrants and Series C Warrants (collectively, the &#8220;March Warrants&#8221;). At March 31, 2018, the Series A Warrants are exercisable for 4,949,270,368 shares of the Company&#8217;s common stock. They are immediately exercisable and have a term of exercise equal to five years. At March 31, 2018, the Series B Warrants are exercisable for 3,925,158,519 shares of the Company&#8217;s common stock and are exercisable for a period of 18 months commencing immediately. The Series C Warrants are exercisable for 4,949,270,368 shares of the Company&#8217;s common stock and have a term of five years provided such warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. At March 31, 2018, the Series A, Series B and Series C Warrants each have an exercise price of $0.0038 per share, which reflects adjustments pursuant to their terms. The Series A, Series B and Series C Warrants are subject to &#8220;full ratchet&#8221; and other customary anti-dilution protections.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The March Debentures are convertible into shares of the Company&#8217;s common stock, at a conversion price which has been adjusted pursuant to the terms of the March Debentures to $0.0038 per share as of March 31, 2018, due to prices at which the Company has subsequently issued shares of common stock. The Convertible Debentures began to amortize monthly commencing on the 90th day following the closing date. The Exchange Debentures began to amortize monthly on the closing date. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of the March Debentures in cash or, in lieu thereof, the conversion price of such debentures will thereafter be 85% of the volume weighted average price at the time of conversion. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount. The March Debentures contain customary affirmative and negative covenants. The conversion prices are subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then conversion price, as well as other customary anti-dilution protections as more fully described in the debentures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2017, the Company agreed to amend the March Debentures and March Warrants to remove the floor in the anti-dilution provisions therein. The conversion price of the March Debentures and the exercise price of the March Warrants as of March 31, 2018 stated above reflect the amendment as well as other adjustments for dilutive issuances, which triggered the down round provisions in the March Debentures and March Warrants. The March Debentures are secured by all of the Company&#8217;s assets and are guaranteed by substantially all of the Company&#8217;s subsidiaries. Between March 22, 2017 and March 31, 2018, holders of the March Debentures converted an aggregate of $10,362,989 of these debentures into 359,281,017 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise prices of the March Warrants issued in connection with the March Debentures are subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then exercise price, as well as other customary anti-dilution protections. As a result of these provisions, both the March Debentures and the March Warrants were deemed to be not indexed to the Company&#8217;s common stock, and the Company recognized derivative liabilities for the embedded conversion feature of the March Debentures and the March Warrants in the original amount of $15.3 million and $41.3 million, respectively. The Company recognized a discount for 100% of the principal value of the March Debentures and non-cash interest expense in the amount of $43.7 million in connection with the recognition of these derivative liabilities. As a result of the adoption of ASU 2017-11 in the second quarter of 2017, the interest expense and derivative liability originally recognized were adjusted and extinguished during the three months ended June 30, 2017. See Note 1 for the adoption of ASU 2017-11 for the retrospective adjustments made to the Company&#8217;s condensed consolidated financial statements with respect to the derivative liabilities associated with these debentures and warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>June 2017 Offerings </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2017, the Company issued debentures due three months from the date of issuance in two issuances (collectively, the &#8220;June Debentures&#8221;) and warrants to purchase an aggregate of 100,000 shares of common stock (33,333 warrants in the June 2, 2017 transaction and 66,667 in the June 22, 2017 transaction), which can be exercised at any time after nine months at an exercise price of $5.85 per share for the June 2, 2017 warrants and $5.70 per share for the June 22, 2017 warrants (collectively the &#8220;June Warrants&#8221;), to accredited investors for a purchase price of $1,902,700 and proceeds to the Company of $1.5 million. The Company recorded a discount on the debentures of $107,700 which has been fully amortized. As more fully discussed below, on July 17, 2017, the June Debentures were exchanged.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>July 2017 Offerings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 17, 2017, the Company closed an offering of $4,136,862 aggregate principal amount of Original Issue Discount Debentures due October 17, 2017 (the &#8220;July Debentures&#8221;) and warrants to purchase an aggregate of 141,333 shares of common stock (the &#8220;July Warrants&#8221;) for consideration of $2,000,000 in cash and the exchange of the full $1,902,700 aggregate principal amount of the June Debentures. Under the Purchase Agreement, the Company was required to hold a stockholders&#8217; meeting to obtain stockholder approval for at least a 1-for-8 reverse split of the Company&#8217;s common stock on or before September 20, 2017. Accordingly, the Company&#8217;s stockholders approved a reverse stock split on September 20, 2017 and the Company effected a 1-for-15 reverse stock split of its common stock on October 5, 2017, as further discussed in Note 1. The July Debentures were guaranteed by substantially all of the subsidiaries of the Company pursuant to a Subsidiary Guarantee in favor of the holders of the July Debentures. As more fully discussed below, on September 19, 2017, the July Debentures were exchanged for $6.4 million of exchange debentures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The July Warrants are exercisable into shares of the Company&#8217;s common stock at any time from and after six months from the closing date at an exercise price of $5.63 per common share (subject to adjustment). The July Warrants will terminate five years after they become exercisable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>September 2017 Offerings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 19, 2017, the Company closed an offering of $2,604,000 principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 (the &#8220;New Debentures&#8221;) and three series of warrants to purchase an aggregate of 34,677,585 shares of the Company&#8217;s common stock (the &#8220;Series A Warrants,&#8221; the &#8220;Series B Warrants,&#8221; and the &#8220;Series C Warrants,&#8221; and collectively, the &#8220;September Warrants&#8221;). The offering was pursuant to the terms of a Securities Purchase Agreement, dated as of August 31, 2017 (the &#8220;Purchase Agreement&#8221;), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $2,100,000 from the offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also on September 19, 2017, the Company closed exchanges by which the holders of the Company&#8217;s July Debentures exchanged $4,136,862 principal amount of such debentures for $6,412,136 principal amount of new debentures on the same items as, and pari passu with, the New Debentures (the &#8220;September Exchange Debentures&#8221; and, together with the New Debentures, the &#8220;September Debentures&#8221;). The Company recorded non-cash interest expense in the amount of $1.0 million as a result of this exchange. All issuance amounts of the September Debentures reflect a 24% original issue discount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The September Debentures contain customary affirmative and negative covenants. The conversion price is subject to &#8220;full ratchet&#8221; and other customary anti-dilution protections as more fully described in the debentures. The September Debentures may be converted at any time into shares of the Company&#8217;s common stock. Originally, the September Debentures begin to amortize monthly commencing on October 1, 2017, and for the first three amortization dates, the amortization amount was $100,000. On October 19, 2017, the September Debentures were amended so that they began to amortize immediately. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of September Debentures in cash or, in lieu thereof, the conversion price of such September Debentures shall thereafter be 85% of the volume weighted average price at the time of conversion, but not less than the floor of $0.78 per share. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount. On October 30, 2017, the Company entered into exchange agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Convertible Preferred Stock of the Company (the &#8220;Series I-2 Preferred Stock&#8221;), which is more fully discussed in Note 9. On February 8, 2018, $1,384,556 of the September Debentures were exchanged for 1,730.1 shares of Series I-2 Preferred Stock as more fully discussed in Note 9.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2018, the Series A Warrants are exercisable for an aggregate of 11,559,195 shares of the Company&#8217;s common stock. They are immediately exercisable and have a term of exercise equal to five years. The Series B Warrants are exercisable for an aggregate of 11,559,195 shares of the Company&#8217;s common stock and are exercisable for a period of 18 months commencing immediately. At March 31, 2018, the Series C Warrants are exercisable for an aggregate of 11,559,195 shares of the Company&#8217;s common stock, and have a term of five years provided such Series C Warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. The September Warrants have a fixed exercise price, subject to a floor of $0.78 per share. At December 31, 2017, the exercise price was $0.78 per share, which reflects adjustments made pursuant to their terms due to the down round provisions in the September Warrants. The September Warrants are subject to &#8220;full ratchet&#8221; and other customary anti-dilution protections.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s obligations under the September Debentures are secured by a security interest in all of the Company&#8217;s and its subsidiaries&#8217; assets, pursuant to the terms of the Security Agreement, dated as of March 20, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2017, the Company realized approximately $15.7 million in proceeds from the issuances of these debentures and warrants. At December 31, 2017, the unamortized discounts were $16.4 million. These discounts represent original issue discounts, the relative fair value of the warrants issued with the debentures and the relative fair value of the beneficial conversion features of the debentures. During the three and nine months ended December 31, 2017, the Company recorded approximately $4.8 million and approximately $14.7 million of non-cash interest and amortization of debt discount expense primarily in connection with the debentures and warrants. See Note 9 for summarized information related to warrants issued and the activity during the twelve months ended December 31, 2017</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>March 2018 Offering</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company&#8217;s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 10 for summarized information related to warrants issued and the activity during the three months ended March 31, 2018 and 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See Note 10 for a discussion of the dilutive effect of the outstanding debentures and warrants as of March 31, 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7 &#8211; Related Party Transactions</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the transactions discussed in&#160;Note&#160;5, the&#160;Company had the following related party transactions during the three months ended March 31, 2018 and 2017:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January and February of 2017, the Company received advances aggregating $3.6 million from Christopher Diamantis, a director of the Company. The advances, along with $0.5 million of previously accrued but unpaid interest, were due on demand, bearing interest at 10% per annum. The Company used the advances to pay the purchase price for the Hospital Assets and for general corporate purposes. On March 7, 2017, the Company issued a promissory note to Mr. Diamantis in the amount of $0.5 million (the &#8220;2017 Diamantis Note&#8221;) in connection with these advances received in 2017, plus accrued and unpaid interest of $0.5 million. In conjunction with the issuance of the 2017 Diamantis Note, the Company also issued to Mr. Diamantis warrants to purchase 27,667 shares of the Company&#8217;s common stock, exercisable at $15.00. the 2017 Diamantis Note was repaid on March 21, 2017 with the proceeds received from the issuance of the Convertible Debentures (see Note 6).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Alcimede billed the Company $0.1 million for consulting fees pursuant to a consulting agreement for each of the three months ended March 31, 2018 and 2017, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Monarch Capital, LLC (&#8220;Monarch&#8221;) billed the Company for consulting fees pursuant to a consulting agreement in the amount of $0.1 million for the three months ended March 31, 2017. The agreement expired on August 31, 2017. Michael Goldberg, a director of the Company up until his resignation effective April 24, 2017, is the Managing Director of Monarch.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 &#8211; Capital Lease Obligations</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases various assets under capital leases expiring through 2020 as follows. At March 31, 2018 (unaudited) and December 31, 2017, capital lease obligations consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Medical equipment</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less accumulated depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(4,010,259</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(3,842,443</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>676,477</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>844,293</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fourth quarter of 2016, the Company did not meet its payment obligations under two of its capital lease agreements, which comprise substantially all of the Company&#8217;s aggregate capital lease obligations. In December 2016, the two counterparties to these lease agreements filed separate lawsuits against the Company and in January of 2017 default judgments were issued against the Company in the aggregate amount of $3.5 million, which includes default interest, late fees, penalties and other fees (see Note 12). As a result, the Company recognized additional interest expense of $0.6 million to recognize the additional obligations under these leases. As of March 31, 2018 the Company did not meet its obligations under these two capital leases, therefore, the aggregate future minimum rentals under capital leases are deemed to be current.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note&#160;10&#160;&#8211; Stockholders&#8217; Deficit</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of March 31, 2018, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock, shares of Series I-2&#160;Preferred Stock, 215 shares of its Series G Preferred Stock, 60 shares of its Series H Preferred Stock and 1,750,000 shares of its Series F Convertible Preferred Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The&#160;rights of Preferred F, G, H, I-1 and I-2&#160;shares are disclosed in the&#160;2017&#160;10K. There are no changes in these rights.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company had 499,992,133 and 19,750,844 shares of common stock issued and outstanding at March 31, 2018 and December 31, 2017, respectively. The Company issued 480,249,156 shares of its common stock during the three months ended March 31, 2018 as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2018, the Company issued an aggregate of 333,315,823 shares of its common stock upon conversion of $3.1 million of the principal amount of the March 2017 Debentures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2018, the Company&#160;issued&#160;75,600,000 shares of common stock upon exercise of&#160;119,746,776&#160;March 2017 Series B&#160;Warrants, on a cashless basis.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2018 the Company issued an aggregate of 71,333,333 shares of restricted stock as described below.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Restricted Stock</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 181,933 shares of restricted common stock of the Company. The grants fully vest on the first anniversary of the date of grant, subject to the grantee&#8217;s continued status as an employee or director, as the case may be, on the vesting date. During the three months ended March 31, 2018, 2,493 shares of the restricted stock were forfeited by their terms and returned to treasury.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On March 6, 2018, the Company issued an aggregate of 71,333,333 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board. The grants fully vested immediately. The Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $.0067 per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock Options</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table summarizes the Company&#8217;s stock option activity for the three months ended March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>options</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>average&#160;</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>exercise&#160;</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>price</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>average contractual</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>term (Yrs.)</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,478</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,072.75</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8.33</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,478</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,072.75</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8.33</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">32,922</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,373.16</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2018, the Company had approximately $0.1 million of unrecognized compensation cost related to stock options granted under the Company&#8217;s 2007 Equity Plan, which is expected to be recognized over a weighted-average period of 0.94 years.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Warrants</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company&#8217;s common stock. The following summarizes the information related to warrants issued and the activity during the three months ended March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of warrants</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>average&#160;</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>exercise price</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,176,403,218</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.0444</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Increases due to&#160;dilution</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,411,976,939</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercised during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(119,746,776</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.0038</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants expired during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,468,633,381</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.0062</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basic and Diluted Loss per Share</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share excludes dilution and is computed by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. For the three months ended March 31, 2018 and 2017, basic loss per share is the same as diluted loss per share.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2018 and 2017, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,468,633,381</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,595,665</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible preferred stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">893,098,291</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">595,556</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible debt</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">781,485,502</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,007,141</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock options</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,478</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">709,025</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,143,255,652</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">41,907,387</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note&#160;11&#160;&#8211; Supplemental Disclosure of Cash Flow Information</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The supplemental cash flow information for the three months ended March 31, 2018 and 2017 (unaudited) is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for interest</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,791</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">881,457</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for income taxes</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">296,313</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-cash investing and financing activities:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exchange of I-2 preferred stock for convertible debentures</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,384,556</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,695,760</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exchange of convertible debentures for convertible debentures and warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,464,500</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Note payable and warrants settled through issuance of common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">440,000</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Debentures converted into common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,056,675</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">486,032</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Conversions of preferred stock into common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,280,000</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock issued in cashless excercise of warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">756,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note&#160;12&#160;&#8211; Commitments and Contingencies</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Matters</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company&#8217;s financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Biohealth Medical Laboratory, Inc, and PB Laboratories, LLC (the &#8220;Companies&#8221;) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies&#8217; claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court&#8217;s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Epinex Diagnostics Laboratories, Inc. subsidiary was sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys&#8217; fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs&#8217; motion for payment of attorneys&#8217; fees in the amount of $0.3 million, and the Company has accrued this amount in its condensed consolidated financial statements. Additionally, the Company is seeking indemnification for these amounts from Epinex Diagnostics, Inc. (&#8220;EDI&#8221;), the seller of Epinex Diagnostic Laboratories, Inc. (&#8220;EDL&#8221;), pursuant to a Stock Purchase Agreement entered into by and among the parties.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the Company received notice that the Internal Revenue Service (the &#8220;IRS&#8221;) placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. The Company paid $0.1 million toward its 2014 tax liability on March 2016. The Company filed its 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and on September of 2016 the Company received a refund from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of the Company&#8217;s 2015 Federal tax return. The Company is currently unable to predict the outcome of the audit or any liability to the Company that may result from the audit.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the &#8220;DOR&#8221;) for unpaid 2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. On January 25, 2017, the Company paid the DOR $250,000 as partial payment on this liability, and in February 2017 the Company entered into a Stipulation Agreement with the DOR which allows the Company to make monthly installment payments of $35,000 until February 2018 and negotiate a new payment agreement then, if the balance of $0.3 million cannot be satisfied in a lump sum. If at any time during the Stipulation period the Company fails to timely file any required tax returns with the DOR or does not meet the payment obligations under the Stipulation Agreement, the entire amount due will be accelerated. The Company has managed to pay some but not all of the required payments and&#160;$0.5 million remains outstanding to the DOR at March 31, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December of 2016, TCS-Florida, L.P. (&#8220;Tetra&#8221;), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with Tetra (see Note 8). On January 3, 2017, Tetra received a Default Judgment against the Company in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. In January and February of 2017, the Company made payments to Tetra in connection with this judgment aggregating to $0.7 million, and on February 15, 2017, the Company entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due will be paid in 24 equal monthly installments. Payments commenced on May 1, 2017 and&#160;a&#160;total of $1.1 million remains outstanding to Tetra at March 31, 2018. The Company and Tetra have agreed to dispose of certain equipment and proceeds from the sale of surplus equipment have been applied to the outstanding balance.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December of 2016, DeLage Landen Financial Services, Inc. (&#8220;DeLage&#8221;), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 8). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due will be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company and&#160;DeLage&#160;have now disposed of certain equipment and reduced the balance owed to DeLage. The reduced balance remains outstanding at March 31, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 7, 2016, the holders of the Tegal Notes (see Note&#160;5) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of $0.4 million, including accrued interest. A request for entry of default judgment was filed on January 24, 2017. A judgment was entered against the Company on April 23, 2018. These amounts remain outstanding at March 31, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2017 a former shareholder of Genomas filed suit against the Company for payment of a $200,000 Note payable by the subsidiary Genomas. This Note is recorded in the financial statements of the subsidiary and is not payable directly from the Company. Other claims were included in the suit which the Company believes to be frivolous and without merit. The Company has filed a motion to dismiss certain of the claims. The Company has made a $100,000 payment and agreed&#160;to&#160;a schedule of payments to discharge the remaining balance of the Note. The parties have agreed to dismiss the legal action.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and subsidiaries have been party to suits filed by landlords for late payment of rent and have either settled these claims or are in process of agreeing to settlement. The Company does not deem these actions to be material.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note&#160;13&#160;&#8211; Segment Information</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating segments are defined under U.S. GAAP as components of an enterprise for which discrete financial information is available and are evaluated regularly by the enterprise&#8217;s chief operating decision maker in determining how to allocate resources and assess performance. The Company operates in two reportable business segments:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; line-height: 107%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Clinical Laboratory Operations</b>, which specializes in providing urine and blood toxicology and pain medication testing to physicians, clinics and rehabilitation facilities in the United States.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Hospital Operations</b>, which reflects the purchase of the Hospital Assets (see Note 3) and the operations of Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Corporate expenses reflect consolidated company wide support services such as finance, legal counsel, human resources, and payroll.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Decision Support and Informatics segment and its Supportive Software Solutions segment are now included in discontinued operations as they have been classified as held for sale as of March 31, 2018. The accounting policies of the reportable segments are the same as those described in Note 1. Selected financial information for the Company&#8217;s operating segments is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net revenues&#160;&#8211;&#160;External</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,586</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">684,265</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,556,075</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,601,661</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">684,265</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(Loss) income from operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(756,083</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,292,275</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,472,600</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(467,316</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Corporate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,483,341</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,804,517</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Eliminations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,851</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(3,712,024</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(3,556,257</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation and amortization</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">295,474</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">434,468</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">37,728</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Corporate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">314</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">312</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Eliminations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,851</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">333,515</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">426,929</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Capital expenditures</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(100,382</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,090,922</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">990,540</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.9in"><b>***`&#160;</b>Intersegment revenues are eliminated in consolidation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 58%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Clinical Laboratory Operations</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,019,946</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 19%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,503,520</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Hospital Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,788,059</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,549,504</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Corporate</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,510,297</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,436,773</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Assets of AMSG and HTS classified as held for sale</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">243,963</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">255,566</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Eliminations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,424,496</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,454,570</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,137,769</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,290,794</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note&#160;15 &#8211;&#160;Discontinued Operations</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 12, 2017, the Company announced plans to spin off its Advanced Molecular Services Group (&#8220;AMSG&#8221;) and in the third quarter of 2017 the Company&#8217;s Board of Directors voted unanimously to spin off the Company&#8217;s wholly-owned subsidiary, Health Technology Solutions, Inc. (&#8220;HTS&#8221;), as independent publicly traded companies by way of tax-free distributions to the Company&#8217;s stockholders. Completion of these spinoffs is expected to occur in the&#160;second half&#160;of 2018. The Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead off two. The spinoffs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spinoffs should be approximately 30 to 60 days prior to the dates of the spinoffs. The strategic goal of the spinoffs is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In addition, after the spinoffs, each company will provide a distinct and targeted investment opportunity.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reflected the amounts relating to AMSG and HTS as disposal groups classified as held for sale and included in discontinued operations in the Company&#8217;s accompanying consolidated financial statements. Prior to being classified as held for sale, AMSG had been included in the Decision Support and Informatics division, except for the Company&#8217;s subsidiary, Alethea Laboratories, Inc., which had been included in the Clinical Laboratories division and HTS had been included in the Company&#8217;s Supportive Software Solutions division. The segment disclosures included in our results of operations no longer include amounts relating to AMSG and HTS following the reclassification to discontinued operations except that the inter-company&#160;debt from HTS to the Company of $14,461,338&#160;and from AMSG of $7,181,685&#160;has not been separated. The Company hopes to complete the spin off(s) in a manner to permit it to recognize these amounts as investment in the divisions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>AMSG Assets and Liabilities:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,314</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,273</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">576</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">19,022</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,477</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,477</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>31,367</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>53,772</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deposits</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable (includes related parties)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">674,425</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">671,561</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">388,666</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">375,165</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion of notes payable</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">228,421</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">249,589</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,291,512</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,296,315</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>HTS Assets and Liabilities:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,727</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8,281</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">166,774</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">160,715</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,183</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,964</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>190,684</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>172,960</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,883</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,078</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deposits</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,756</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>21,912</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>28,834</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable (includes related parties)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">500,235</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">407,404</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">271,245</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">269,135</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>771,480</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>676,539</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Consolidated Discontinued Operations Assets and Liabilities:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,041</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,554</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">167,350</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">179,737</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">47,660</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">29,441</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>222,051</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>226,732</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,883</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,078</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Deposits</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,756</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current assets classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>21,912</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>28,834</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable (includes related parties)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,174,660</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,078,965</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">659,911</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">644,300</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Current portion of notes payable</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">228,421</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">249,589</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2,062,992</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,972,854</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-current liabilities classified as held for sale</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Major line items constituting loss from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2018 and 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>AMSG Income (Loss) from Discontinued Operations:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">33,685</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">176,578</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of services</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">16,138</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">769</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Gross profit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,547</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">175,809</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">176,202</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">526,533</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income/expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(800,197</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,978</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Income/(Loss) from discontinued operations</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>641,542</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(347,746</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>HTS&#160;Income (Loss) from Discontinued Operations:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">355,147</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">315,270</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of services</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">34,218</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">46,704</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Gross profit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">320,929</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">268,566</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">538,199</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">987,111</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income/expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,478</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Income/(Loss)&#160;from discontinued operations</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(219,748</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(718,545</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Consolidated Income/(Loss)&#160;from Discontinued Operations:</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(unaudited)</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Revenue from services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">388,832</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">491,848</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of services</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,356</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">47,473</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Gross profit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">338,476</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">444,375</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Operating expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">714,402</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,513,645</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other income (expenses)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(797,719</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(2,978</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Income/(Loss)&#160;from discontinued operations</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>421,793</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(1,066,292</b></font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>)</b></font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note&#160;17&#160;&#8211; Subsequent Events</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Outstanding shares as of June&#160;18, 2018:&#160;1,110,232,133</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the period ended&#160;March 31, 2018, the&#160;Company has issued 610,240,000 shares of common stock through June 18, 2018 as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The&#160;Company has issued 324,000,000 shares of its common stock upon conversion of $1,643,175 of the principal amount of the March 2017 Debentures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The&#160;Company issued&#160;286,240,000 shares of common stock to the holders of 381,405,434 March 2017 Series B warrants that were exercised on a cashless basis.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2018, the Company held a Special Meeting of Stockholders, in part, to approve an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares. The proposal was approved and on May 9, 2018 the Company filed an amendment to its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000&#160;shares.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable - laboratory services</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,302,579</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,478,451</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable&#160;&#8211;&#160;hospital</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,783,802</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8,593,747</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total accounts receivable</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,086,381</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,072,198</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less:</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for discounts - laboratory services</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,150,800</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,177,054</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for discounts - hospital</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(9,307,852</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(6,936,429</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for bad debts</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,525,972</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(987,403</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable, net</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>1,101,758</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>971,312</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Medical equipment</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">713,799</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">696,195</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Building</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,359,484</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,359,472</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">437,029</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">476,548</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Equipment under capital leases</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">232,495</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">222,824</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,303,131</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,303,131</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Vehicles</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">196,534</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">196,534</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Computer equipment</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">221,237</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">226,441</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Software</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">333,853</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">631,033</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,484,297</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,798,914</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less accumulated depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,122,072</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(7,103,474</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Property and equipment, net</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2,362,225</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2,695,440</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notes Payable &#8211; Related Parties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Loan payable to Alcimede LLC, bearing interest at 6% per annum, with all principal and interest due on August 2, 2018</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">168,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">168,500</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Loan Payable to Christopher Diamantis</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">900,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">960,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,068,500</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,068,500</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,068,500</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,068,500</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Total notes payable - related parties, net of current portion</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The supplemental cash flow information for the three months ended March 31, 2018 and 2017 (unaudited) is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="6" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months Ended March 31,</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for interest</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,791</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">881,457</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cash paid for income taxes</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">296,313</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Non-cash investing and financing activities:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exchange of I-2 preferred stock for convertible debentures</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,384,556</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,695,760</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exchange of convertible debentures for convertible debentures and warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,464,500</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Note payable and warrants settled through issuance of common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">440,000</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Debentures converted into common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,056,675</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">486,032</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Conversions of preferred stock into common stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,280,000</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock issued in cashless excercise of warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">756,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 200000 300000 221942501 73464705 -0.66 -0.67 -0.01 -0.66 -0.66 -146364584 -49704707 421793 -1066292 -146786377 -48638415 76 3250 -146786301 -48635165 -143074277 -45078908 3307014 45642525 11969 5313685 4240522 -1215 252314 2892019 3316448 2089366 244831 641110 713333 -72223 181933 71333331 71333333 0 -25 25 -2494 665307 35215 477933 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 &#8211; Accrued Expenses</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Commissions&#160;payable</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,345</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,470</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued payroll and related liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,419,779</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">897,088</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued interest</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,402,498</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,636,057</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,296,146</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,409,790</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,131,767</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,967,405</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Commissions&#160;payable</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,345</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">24,470</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued payroll and related liabilities</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,419,779</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">897,088</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued interest</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,402,498</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,636,057</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,296,146</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,409,790</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total accrued expenses</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,131,767</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,967,405</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 971312 1101758 236914 251029 9842 35350 1940845 1915343 226732 222051 53772 31367 172960 190684 3385645 3560627 2695440 2362225 180875 193006 28834 21912 4188678 4605123 4967405 4131767 1971592 1968750 6957830 6957830 2079137 1715727 1972854 2062992 37316939 178379905 41068961 182173984 197508 4999922 128351954 126619959 -169180425 -315545009 6290794 6137770 1615693 3445841 7181685 14461338 5835294 5835294 2036118 100000 100000 -651562 -651562 571720 4522329 943160 107700 100000 14700000 -50000 130449 -115446 25508 -21964 14115 -12128 14594 416445 146969 -835638 -957683 22660 -241997 -1642934 -5739099 -698259 -212365 -2341193 -5951464 -301 -1090922 800000 799699 -1090922 363410 911042 1576590 6998347 1331113 1576590 8329460 35096 1287074 3395000 2000000 9892500 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note&#160;14&#160;&#8211; Recently Issued Accounting Standards</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides a brief description of recently issued accounting standards:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: bottom; width: 24%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Title and reference</b></font></td> <td style="vertical-align: top; width: 2%; line-height: 107%">&#160;</td> <td style="vertical-align: top; width: 24%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Prescribed&#160;</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Effective Date</b></font></td> <td style="vertical-align: top; width: 2%; line-height: 107%">&#160;</td> <td style="vertical-align: bottom; width: 48%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Commentary</b></font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ASU No. 2015-11, &#8220;Inventory&#8221; (Topic 330): Simplifying the Measurement of Inventory.</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal years beginning after December 15, 2016 and for interim periods therein.</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">In July 2015, the FASB issued ASU No. 2015-11, &#8220;Inventory&#8221; (Topic 330): Simplifying the Measurement of Inventory (&#8220;ASU 2015-11&#8221;). ASU 2015-11 simplifies the measurement of inventory by requiring certain inventory to be subsequently measured at the lower of cost and net realizable value. The amendments in this guidance are effective for fiscal years beginning after December 15, 2016 and for interim periods therein and did not have a significant impact on the Company&#8217;s consolidated financial statements upon adoption.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ASU No. 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606)&#8221;</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal years beginning after December 15, 2017 and for interim periods therein.</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most recent current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also specifies the accounting for certain incremental costs of obtaining a contract and costs to fulfill a contract with a customer. Entities have the option of applying either a full retrospective approach to all periods presented or a modified approach that reflects differences prior to the date of adoption as an adjustment to equity. The Company has adopted this guidance for this financial statement.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ASU No. 2014-15, &#8220;Presentation of Financial Statements - Going Concern&#8221; (Subtopic 205-40): Disclosure of Uncertainty about an Entity&#8217;s Ability to Continue as a Going Concern.</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal years, and interim periods within those years, beginning on or after December 15, 2016, with early adoption permitted.</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">In August 2014, the FASB issued ASU No. 2014-15, &#8220;Presentation of Financial Statements - Going Concern&#8221; (Subtopic 205-40): Disclosure of Uncertainty about an Entity&#8217;s Ability to Continue as a Going Concern (&#8220;ASU 2014-15&#8221;). ASU 2014-15 provides guidance that establishes management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and setting rules for how this information should be disclosed in the financial statements. Adoption of this new standard did not have a significant impact on the Company&#8217;s consolidated financial statements. See Note 1 regarding management&#8217;s current disclosures regarding the Company&#8217;s ability to continue as a going concern.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ASU No. 2015-17, &#8220;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes&#8221;</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 24%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal years beginning on or after December 15, 2016, with early adoption permitted.</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 48%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">In November 2015, the FASB issued ASU No. 2015-17, &#8220;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes&#8221; (&#8220;ASU 2015-17&#8221;). Topic 740, Income Taxes, requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. Deferred tax liabilities and assets that are not related to an asset or liability for financial reporting are classified according to the expected reversal date of the temporary difference. To simplify the presentation of deferred income taxes, the amendments in ASU 2015-17 require that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Adoption of ASU 2015-17 did not have a material impact on the Company&#8217;s consolidated financial statements.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, &#8220;Leases (Topic 842)&#8221;</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;Annual and interim periods within the annual period beginning after December 15, 2018.</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). The amendments in this update create Topic 842, Leases, and supersede the leases requirements in Topic 840, Leases. Topic 842 specifies the accounting for leases. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. The main difference between Topic 842 and Topic 840 is the recognition of lease assets and lease liabilities for those leases classified as operating leases under Topic 840. Topic 842 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years for public business entities. Early application of the amendments in ASU 2016-02 is permitted. The Company has not yet determined the impact that adoption of ASU 2016-02 will have on its consolidated financial statements.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)&#8221; (&#8220;ASU 2017-11&#8221;)</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Fiscal years beginning on or after December 15, 2018, with early adoption permitted.</font></td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">The Company adopted this amendment as of its period ended June 30, 2017 (see Note 1)</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">ASU No. 2017-12, &#8220;Derivatives and Hedging (Topic 815)&#8221; (&#8220;ASU 2017-12&#8221;)</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 24%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">For public business entities, the amendments in this ASU 2017-12 are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption permitted in any interim period after issuance of this ASU.</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 48%; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">The amendments in ASU 2017-12 (&#8220;Update&#8221;) provide recognition and presentation guidance for qualifying hedges. The amendments in this Update more closely align the results of cash flow and fair value hedge accounting with risk management activities through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results in the financial statements. The amendments address specific limitations in current U.S. GAAP by expanding hedge accounting for both nonfinancial and financial risk components and by refining the measurement of hedge results to better reflect an entity&#8217;s hedging strategies. Thus, the amendments will enable an entity to report more faithfully the economic results of hedging activities for certain fair value and cash flow hedges and will avoid mismatches in earnings by allowing for greater precision when measuring change in fair value of the hedged item for certain fair value hedges. Additionally, by aligning the timing of recognition of hedge results with the earnings effect of the hedged item for cash flow and net investment hedges, and by including the earnings effect of the hedging instrument in the same income statement line item in which the earnings effect of the hedged item is presented, the results of an entity&#8217;s hedging program and the cost of executing that program will be more visible to users of financial statements. Additionally, the amendments in this Update should ease the operational burden of applying hedge accounting by allowing more time to prepare hedge documentation and allowing effectiveness assessments to be performed on a qualitative basis after hedge inception. The Company has not yet determined the impact that adoption of ASU 2017-12 will have on its consolidated financial statements.</font></td></tr> </table> <p style="margin: 0pt"></p> 1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017 1-for-15 reverse stock split effective October 5, 2017 1-for-8 reverse split 1-for-15 reverse stock split 2018-08-02 2017-06-27 2016-02-02 2019-03-21 2017-03-15 2019-09-19 2019-03-21 2019-09-19 2019-09-19 2017-08-31 2019-09-19 2018-08-02 2000000 8400000 15700000 1500000 15700000 2200000 6957830 6957830 2500000 5000000 1616218 341612 168500 5000000 1616218 341612 0.50 0.20 0.20 0.40 500000 750000 50000 3800000 750000 500000 400000 1600000 10850000 4136862 2604000 1384556 2480000 2480000 500000 112.50 4444 6667 141333 34677585 34677585 34677585 11559195 11559195 11559195 100000 33333 66667 0.276 0.0038 180.00 38.70 5.63 0.0038 5.85 5.70 0.78 0.78 0.0038 15.00 26667 1730.1 359281017 3000000 5000000 500000 66667 37.50 1500000 1902700 2500000 1902700 4136862 6400000 6412136 1643175 1384556 17720082 15758851 2500000 2700000 1384556 10362989 0.24 0.24 119746776 381405434 P5Y P18M P5Y P5Y P18M P5Y The Company recognized a discount for 100% of the principal value of the March Debentures and the Exchange Debentures and non-cash interest expense in the amount of $43.7 million in connection with the recognition of these derivative liabilities. On October 19, 2017, the September Debentures were amended so that they began to amortize immediately. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of September Debentures in cash or, in lieu thereof, the conversion price of such September Debentures shall thereafter be 85% of the volume weighted average price at the time of conversion, but not less than the floor of $0.78 per share. The March Debentures are convertible into shares of the Company’s common stock, at a conversion price which has been adjusted pursuant to the terms of the March Debentures to $0.0038 per share as of March 31, 2018, due to prices at which the Company has subsequently issued shares of common stock. The Convertible Debentures began to amortize monthly commencing on the 90th day following the closing date. The Exchange Debentures began to amortize monthly on the closing date. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of the March Debentures in cash or, in lieu thereof, the conversion price of such debentures will thereafter be 85% of the volume weighted average price at the time of conversion. 41300000 15300000 2000000 2100000 4960000 4000000 2000000 2000000 12127634 8424756 4800000 224733 94175 15758851 324000000 1731 4.00 0.0067 200000 100000 300000 300000 700000 5000000 250000 1900000 900000 400000 1900000 1100000 35000 2600000 1000000 700000 0.0497 2 -100382 990540 1090922 17554 7041 9273 5314 8281 1727 179737 167350 19022 576 160715 166774 29441 47660 25477 25477 3964 22183 21078 15883 21078 15883 7756 6029 7756 6029 28834 21912 28834 21912 1078965 1174660 671561 674425 407404 500235 644300 659911 375165 388666 269135 271245 249589 228421 249589 228421 1972854 2062992 1296315 1291512 676539 771480 388832 491848 176578 33685 355147 315270 50356 47473 769 16138 34218 46704 338476 444375 175809 17547 320929 268566 714402 1513645 526533 176202 538199 987111 -797719 -2978 -2978 -800197 2478 421793 -1066292 -347746 641542 -219748 -718545 296313 2464500 440000 6280000 3056675 486032 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table summarizes the Company&#8217;s stock option activity for the three months ended March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>options</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>average&#160;</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>exercise&#160;</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>price</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>average contractual</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>term (Yrs.)</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,478</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,072.75</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8.33</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeit</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,478</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,072.75</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">8.33</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">32,922</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,373.16</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the information related to warrants issued and the activity during the three months ended March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of warrants</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>average&#160;</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>exercise price</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,176,403,218</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.0444</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Increases due to&#160;dilution</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,411,976,939</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercised during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(119,746,776</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.0038</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants expired during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,468,633,381</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.0062</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the 2017 audited financial statements included in the Company&#8217;s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 24, 2018. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All material intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company&#8217;s management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) considered necessary for the fair presentation of the financial position and results of operations and cash flows for the interim periods reported herein. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2018 and 2017, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations. In addition, certain prior year balances have been reclassified to conform to the current presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on new FASB rules for revenue recognition that became effective January 1, 2018, bad debts are now treated similar to contractual adjustments and directly reduce sales revenue. In an abundance of caution through the startup period of our Oneida hospital the Company has reserved a bad debt number of $591,323, which, when set against sales revenues of $2,191,983 means the Company is reporting net revenues for the first quarter of 2018 of $1.6 million. The Company will continue to review its provision for bad debt.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reclassification</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reclassified certain amounts in the 2017 condensed consolidated financial statements to be consistent with the 2018 presentation. These principally relate to classification of certain revenues, cost of revenues and related segment data, as well as balance sheet classifications to assets and liabilities held for sale. Reclassifications relating to the discontinued operations of AMSG and HTS are described further in Note 15. The reclassifications had no impact on operations or cash flows for the three months ended March 31, 2017. The Company also reclassified derivative liability previously reported in 2017 as long term to current liability.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 16 &#8211;&#160;<u>Derivative Financial Instruments and Fair Value</u></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 820, &#8220;<i>Fair Value Measurements and Disclosures</i>,&#8221; the Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; line-height: 107%">&#160;</td> <td style="width: 24px; text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets).</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 applies to assets or liabilities for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including our own assumptions.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of financial instruments is determined by the Company using available market information and valuation methodologies considered to be appropriate. At March 31, 2018 and December 31, 2017, the carrying value of the Company&#8217;s accounts receivable, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of December 31, 2017:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Embedded conversion options</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,577,025</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,577,025</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,858,225</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,858,225</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,435,250</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,435,250</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of March 31, 2018:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Embedded conversion options</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,005,188</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,005,188</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">151,418,187</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">151,418,187</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">152,423,375</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">152,423,375</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2018, total loss realized on instruments valued using Level 3 valuations was $140.0 million.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilized the following methods to value its derivative liabilities for the three months ended March 31, 2018: (i) for embedded conversion options valued at $1.0 million, the Company determined the fair value by comparing the discounted conversion price per share (85% of market price) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company&#8217;s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability; (ii) for warrants valued at $151.4 million, the Company determined the fair value by using a binomial model and monte carlo simulations; and (iii) for warrants valued at $0.1 million and embedded conversion options valued at&#160;$0.2 million, the Company determined the fair value using the Black-Scholes option pricing model. All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,435,250</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Loss on change in fair value included in net loss</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">139,779,232</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Issuance of convertible debt</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">208,893</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">152,423,375</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The increase in the fair value of the derivative liabilities is primarily due to the increase in the Company&#8217;s quoted trading price from $0.003 on December 31, 2017 to $0.009 on March 31, 2018. &#160;&#160;Because the exercise price of a significant portion of the Company&#8217;s outstanding warrants are currently exercisable at $0.0038 per share, and subject to further reduction in their exercise price in the event of further issuances at lower than $0.0038 per share, the fair value of the warrants increased significantly during the three months ended March 31, 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases various assets under capital leases expiring through 2020 as follows. At March 31, 2018 (unaudited) and December 31, 2017, capital lease obligations consisted of the following:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2018</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2017</b></font></td> <td style="text-align: center; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Medical equipment</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 18%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,686,736</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Less accumulated depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(4,010,259</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(3,842,443</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>676,477</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>844,293</b></font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 60000 3430000 1948111 200000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1 &#8211; Organization and Basis of Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rennova Health, Inc. (&#8220;Rennova&#8221;), together with its subsidiaries (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;), is a vertically integrated provider of healthcare related products and services. The Company&#8217;s principal lines of business are (i) clinical laboratory operations; and (ii) Hospital Operations. The Company presents its financial results based upon these two business segments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the 2017 audited financial statements included in the Company&#8217;s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 24, 2018. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All material intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company&#8217;s management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) considered necessary for the fair presentation of the financial position and results of operations and cash flows for the interim periods reported herein. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2018 and 2017, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations. In addition, certain prior year balances have been reclassified to conform to the current presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on new FASB rules for revenue recognition that became effective January 1, 2018, bad debts are now treated similar to contractual adjustments and directly reduce sales revenue. In an abundance of caution through the startup period of our Oneida hospital the Company has reserved a bad debt number of $591,323, which, when set against sales revenues of $2,191,983 means the Company is reporting net revenues for the first quarter of 2018 of $1.6 million. The Company will continue to review its provision for bad debt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reclassification</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reclassified certain amounts in the 2017 condensed consolidated financial statements to be consistent with the 2018 presentation. These principally relate to classification of certain revenues, cost of revenues and related segment data, as well as balance sheet classifications to assets and liabilities held for sale. Reclassifications relating to the discontinued operations of AMSG and HTS are described further in Note 15. The reclassifications had no impact on operations or cash flows for the three months ended March 31, 2017. The Company also reclassified derivative liability previously reported in 2017 as long term to current liability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Splits</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 7, 2017, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s Certificate of Incorporation to effect a 1-for-30 reverse stock split of the Company&#8217;s shares of common stock effective on February 22, 2017 and on September 21, 2017, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s Certificate of Incorporation to effect a 1-for-15 reverse stock split effective October 5, 2017 (the &#8220;Reverse Stock Splits&#8221;). The stockholders of the Company had approved these amendments to the Company&#8217;s Certificate of Incorporation on December 22, 2016 for the February 7, 2017 reverse stock split and on September 20, 2017 for the October 5, 2017 reverse stock split. In both cases, the Company&#8217;s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse splits within certain specified effective dates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Reverse Stock Splits, every 30 shares of the Company&#8217;s then outstanding common stock was combined and automatically converted into one share of the Company&#8217;s common stock, par value $0.01 per share, on February 7, 2017 and every 15 shares of the Company&#8217;s then outstanding common stock was combined and automatically converted into one share of the Company&#8217;s common stock, par value $0.01 per share, on October 5, 2017. In addition, the conversions and exercise prices of all of the Company&#8217;s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the 1:30 reverse split ratio and again at the 1:15 reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Splits, other than as a result of the rounding up of fractional shares in the February reverse split and the payment of cash in lieu of fractional shares in the October reverse split, as no fractional shares were issued in connection with the Reverse Stock Splits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 3,000,000,000 shares of common stock and 5,000,000 shares of preferred stock were also unaffected by the Reverse Stock Splits. On May 9, 2018, the Company amended its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares (see note 17).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All share, per share and capital stock amounts for all periods presented have been restated to give effect to the Reverse Stock Splits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Adoption of ASU 2017-11</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-11 &#8220;Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).&#8221; The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt&#8212;Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under current GAAP, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity&#8217;s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity&#8217;s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and embedded conversion options with down round features are no longer bifurcated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For entities that present EPS in accordance with Topic 260, and when the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Those amendments in Part 1 of this Update are a cost savings relative to current GAAP. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basis of the existence of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic value of the feature only when the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 1 of this Update should be applied in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is effective; or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that this amendment had a material impact on its consolidated financial statements and has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company&#8217;s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid in capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million. A $51 million deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has recently accumulated significant losses and has negative cash flows from operations, and at March 31, 2018, had a working capital deficit of $174.8 million and a stockholders&#8217; deficit of $183.9 million. In addition, the Company&#8217;s cash position as of the date of this report is critically deficient, critical payments, including capital lease obligations are not being made in the ordinary course of business and certain indebtedness, including accrued interest and extension fees, in the amount of $7.8 million matures on May 30, 2018, that the Company does not have the financial resources to satisfy. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of twelve months from the issuance date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to consider efficiencies and is currently using one laboratory for the majority of its toxicology diagnostics thereby reducing the number of employees and associated operating expenses, in order to reduce costs. In addition, the Company received approximately $2 million in cash from the issuances of debentures during the first quarter of 2018 (see Note 6).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the Company announced that it plans to spin off its Advanced Molecular Services Group (&#8220;AMSG&#8221;) and in the third quarter of 2017, the Company&#8217;s Board of Directors voted unanimously to spin off Health Technology Solutions, Inc., a wholly-owned subsidiary (&#8220;HTS&#8221;), as independent publicly traded companies by way of tax-free distributions to its shareholders. Completion of these spinoffs is expected to occur during the second half of 2018. Our Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead of two. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered into by the Company. The intent of the spinoffs of AMSG and HTS is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for &#8220;held for sale&#8221;, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 15.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also announced that the Big South Fork Medical Center received CMS regional office licensure approval and opened on August 8, 2017. In addition, on January 31, 2018, the Company announced that it had entered into a definitive asset purchase agreement to acquire an acute care hospital in Jamestown, Tennessee known as Tennova Healthcare &#8211; Jamestown. The acquisition was completed on June 1, 2018. The Company may amend its current revenue recognition policy and percentage for the hospitals when payments are received to support amended revenue recognition methodologies. Therefore, the Company expects that these hospitals will continue to provide additional revenue and cash flow sources.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There can be no assurance that the Company will be able to achieve its business plan, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues and eventually regain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Recent Events</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Asset Purchase Agreement to Acquire Acute Care Hospital</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2018, the Company entered into an asset purchase agreement (the &#8220;Purchase Agreement&#8221;) to acquire certain assets related to an acute care hospital located in Jamestown, Tennessee. The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Center, Inc., and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services. The acquisition also included a separate physician practice which will now operate under Rennova as Mountain View Physician Practice, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net annual revenues in recent years have been approximately $15 million with government payers including Medicare and Medicaid accounting for in excess of 60% of the payor mix. Rennova does not expect this payer mix to change significantly in the near future. The hospital was acquired for approximately $635,000 from Community Health Systems, Inc. Diligence, legal and other costs associated with the acquisition are estimated to be approximately $500,000 meaning the total cost of acquisition to the Company is approximately $1,100,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jamestown is located 38 miles from the Company&#8217;s existing hospital, the Big South Fork Medical Center, which is located in Oneida, Tennessee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Proposals Submitted to Stockholders</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2018, the Company held a Special Meeting of Stockholders to (1) approve an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares, (2) approve the Company&#8217;s new 2018 Incentive Award Plan, and (3) authorize an adjournment of the Special Meeting if necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proposal 1 was approved while proposal 2 was rejected. Proposal 3 was not voted on.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounts Receivable Financing</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously announced, on March 31, 2016 the Company entered into an agreement to sell certain of its accounts receivable. The agreement was originally scheduled to mature on March 31, 2017, which date was extended to March 31, 2018 by an amendment on March 24, 2017. On April 2, 2018, the Company, the purchaser and Christopher Diamantis, a Director of the Company, as guarantor, entered into a second amendment to extend further the Company&#8217;s obligation to May 30, 2018. In connection with this further extension, the purchaser received a fee of $100,000. As of May 30, 2018, the Company has not made a payment under this agreement and the full balance is now payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Share Issuances</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 6, 2018, the Board of Directors, based on the recommendation of the Compensation Committee, approved grants to employees and directors of an aggregate of 71,333,331 shares of common stock, including the following to the directors of the Company:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%"><font style="font-size: 10pt">Seamus Lagan </font></td> <td style="width: 75%"><font style="font-size: 10pt">26,666,667 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Dr. Kamran Ajami </font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">John Beach</font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Gary L. Blum </font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Christopher Diamantis</font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Trevor Langley </font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as a transaction by an issuer not involving a public offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 9, 2018, holders of the Company&#8217;s Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 exercised their right for the first time under exchange agreements (the &#8220;Exchange Agreements&#8221;) entered into with the Company by electing to exchange an aggregate of $1,384,556 principal amount of such Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Such shares of Preferred Stock were issued in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>NanoVibronix</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2018, the Company entered into a Common Stock Purchase Agreement with two investors pursuant to which the Company agreed to sell an aggregate of 200,000 shares of common stock of NanoVibronix, Inc. owned by the Company at a purchase price of $4.00 per share. The Company had acquired the shares as a result of an investment originally made in 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>March 2018 Offering</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company&#8217;s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Debentures were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act and by Rule 506 of Registration D promulgated thereunder as a transaction by an issuer not involving a public offering.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Splits</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 7, 2017, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s Certificate of Incorporation to effect a 1-for-30 reverse stock split of the Company&#8217;s shares of common stock effective on February 22, 2017 and on September 21, 2017, the Company&#8217;s Board of Directors approved an amendment to the Company&#8217;s Certificate of Incorporation to effect a 1-for-15 reverse stock split effective October 5, 2017 (the &#8220;Reverse Stock Splits&#8221;). The stockholders of the Company had approved these amendments to the Company&#8217;s Certificate of Incorporation on December 22, 2016 for the February 7, 2017 reverse stock split and on September 20, 2017 for the October 5, 2017 reverse stock split. In both cases, the Company&#8217;s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse splits within certain specified effective dates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Reverse Stock Splits, every 30 shares of the Company&#8217;s then outstanding common stock was combined and automatically converted into one share of the Company&#8217;s common stock, par value $0.01 per share, on February 7, 2017 and every 15 shares of the Company&#8217;s then outstanding common stock was combined and automatically converted into one share of the Company&#8217;s common stock, par value $0.01 per share, on October 5, 2017. In addition, the conversions and exercise prices of all of the Company&#8217;s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the 1:30 reverse split ratio and again at the 1:15 reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Splits, other than as a result of the rounding up of fractional shares in the February reverse split and the payment of cash in lieu of fractional shares in the October reverse split, as no fractional shares were issued in connection with the Reverse Stock Splits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 3,000,000,000 shares of common stock and 5,000,000 shares of preferred stock were also unaffected by the Reverse Stock Splits. On May 9, 2018, the Company amended its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares (see note 17).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All share, per share and capital stock amounts for all periods presented have been restated to give effect to the Reverse Stock Splits.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Adoption of ASU 2017-11</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-11 &#8220;Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).&#8221; The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt&#8212;Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under current GAAP, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity&#8217;s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity&#8217;s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and embedded conversion options with down round features are no longer bifurcated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For entities that present EPS in accordance with Topic 260, and when the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Those amendments in Part 1 of this Update are a cost savings relative to current GAAP. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basis of the existence of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic value of the feature only when the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 1 of this Update should be applied in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is effective; or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that this amendment had a material impact on its consolidated financial statements and has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company&#8217;s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid in capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million. A $51 million deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has recently accumulated significant losses and has negative cash flows from operations, and at March 31, 2018, had a working capital deficit of $174.8 million and a stockholders&#8217; deficit of $183.9 million. In addition, the Company&#8217;s cash position as of the date of this report is critically deficient, critical payments, including capital lease obligations are not being made in the ordinary course of business and certain indebtedness, including accrued interest and extension fees, in the amount of $7.8 million matures on May 30, 2018, that the Company does not have the financial resources to satisfy. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of twelve months from the issuance date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to consider efficiencies and is currently using one laboratory for the majority of its toxicology diagnostics thereby reducing the number of employees and associated operating expenses, in order to reduce costs. In addition, the Company received approximately $2 million in cash from the issuances of debentures during the first quarter of 2018 (see Note 6).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the Company announced that it plans to spin off its Advanced Molecular Services Group (&#8220;AMSG&#8221;) and in the third quarter of 2017, the Company&#8217;s Board of Directors voted unanimously to spin off Health Technology Solutions, Inc., a wholly-owned subsidiary (&#8220;HTS&#8221;), as independent publicly traded companies by way of tax-free distributions to its shareholders. Completion of these spinoffs is expected to occur during the second half of 2018. Our Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead of two. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered into by the Company. The intent of the spinoffs of AMSG and HTS is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for &#8220;held for sale&#8221;, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 15.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also announced that the Big South Fork Medical Center received CMS regional office licensure approval and opened on August 8, 2017. In addition, on January 31, 2018, the Company announced that it had entered into a definitive asset purchase agreement to acquire an acute care hospital in Jamestown, Tennessee known as Tennova Healthcare &#8211; Jamestown. The acquisition was completed on June 1, 2018. The Company may amend its current revenue recognition policy and percentage for the hospitals when payments are received to support amended revenue recognition methodologies. Therefore, the Company expects that these hospitals will continue to provide additional revenue and cash flow sources.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There can be no assurance that the Company will be able to achieve its business plan, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues and eventually regain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Recent Events</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Asset Purchase Agreement to Acquire Acute Care Hospital</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2018, the Company entered into an asset purchase agreement (the &#8220;Purchase Agreement&#8221;) to acquire certain assets related to an acute care hospital located in Jamestown, Tennessee. The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Center, Inc., and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services. The acquisition also included a separate physician practice which will now operate under Rennova as Mountain View Physician Practice, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net annual revenues in recent years have been approximately $15 million with government payers including Medicare and Medicaid accounting for in excess of 60% of the payor mix. Rennova does not expect this payer mix to change significantly in the near future. The hospital was acquired for approximately $635,000 from Community Health Systems, Inc. Diligence, legal and other costs associated with the acquisition are estimated to be approximately $500,000 meaning the total cost of acquisition to the Company is approximately $1,100,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jamestown is located 38 miles from the Company&#8217;s existing hospital, the Big South Fork Medical Center, which is located in Oneida, Tennessee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Proposals Submitted to Stockholders</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2018, the Company held a Special Meeting of Stockholders to (1) approve an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares, (2) approve the Company&#8217;s new 2018 Incentive Award Plan, and (3) authorize an adjournment of the Special Meeting if necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Proposal 1 was approved while proposal 2 was rejected. Proposal 3 was not voted on.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounts Receivable Financing</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously announced, on March 31, 2016 the Company entered into an agreement to sell certain of its accounts receivable. The agreement was originally scheduled to mature on March 31, 2017, which date was extended to March 31, 2018 by an amendment on March 24, 2017. On April 2, 2018, the Company, the purchaser and Christopher Diamantis, a Director of the Company, as guarantor, entered into a second amendment to extend further the Company&#8217;s obligation to May 30, 2018. In connection with this further extension, the purchaser received a fee of $100,000. As of May 30, 2018, the Company has not made a payment under this agreement and the full balance is now payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Share Issuances</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 6, 2018, the Board of Directors, based on the recommendation of the Compensation Committee, approved grants to employees and directors of an aggregate of 71,333,331 shares of common stock, including the following to the directors of the Company:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%"><font style="font-size: 10pt">Seamus Lagan </font></td> <td style="width: 75%"><font style="font-size: 10pt">26,666,667 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Dr. Kamran Ajami </font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">John Beach</font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Gary L. Blum </font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Christopher Diamantis</font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 10pt">Trevor Langley </font></td> <td><font style="font-size: 10pt">3,333,333 shares</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as a transaction by an issuer not involving a public offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 9, 2018, holders of the Company&#8217;s Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 exercised their right for the first time under exchange agreements (the &#8220;Exchange Agreements&#8221;) entered into with the Company by electing to exchange an aggregate of $1,384,556 principal amount of such Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Such shares of Preferred Stock were issued in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>NanoVibronix</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2018, the Company entered into a Common Stock Purchase Agreement with two investors pursuant to which the Company agreed to sell an aggregate of 200,000 shares of common stock of NanoVibronix, Inc. owned by the Company at a purchase price of $4.00 per share. The Company had acquired the shares as a result of an investment originally made in 2011.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>March 2018 Offering</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company&#8217;s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Debentures were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act and by Rule 506 of Registration D promulgated thereunder as a transaction by an issuer not involving a public offering.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment on all outstanding debentures as of March 31, 2018 are due as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt"><b><u>Period ended December 31,</u></b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2018</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$&#160;</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,647,271</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 71%; padding-bottom: 1.5pt"><font style="font-size: 10pt">2019</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$&#160;</font></td> <td style="width: 26%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10,111,580</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>15,758,851</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2018 and 2017, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of March 31,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,468,633,381</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 11%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,595,665</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible preferred stock</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">893,098,291</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">595,556</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible debt</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">781,485,502</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,007,141</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock options</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">38,478</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">709,025</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">17,143,255,652</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">41,907,387</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> Every 15 shares of the Company’s then outstanding common stock was combined and automatically converted into one share As a result of the Reverse Stock Splits, every 30 shares of the Company;s then outstanding common stock was combined and automatically converted into one share 174800000 7800000 15000000 10072198 13086381 1478451 8593747 1302579 11783802 1177054 6936429 1150800 9307852 987403 1525972 300000 400000 9798914 9484297 696195 1359472 476548 4686736 222824 1303131 196534 226441 631033 713799 1359484 437029 4686736 232495 1303131 196534 221237 333853 7103474 7122072 24470 13345 897088 1419779 2636057 1402498 1409790 1296146 5000000 8700000 0 1500000 P6M 2017-08-02 2018-08-02 0.06 0.10 0.10 150000 100000 1000000 100000 400000 100000 500000 500000 500000 2600000 400000 300000 3000000 500000 3000000 500000 0.06 0.16 0.06 0.16 0.06 0.06 December 31, 2017 July 12, 2015 through July 12, 2017 December 31, 2017 July 12, 2015 through July 12, 2017 168500 1068500 960000 168500 900000 1068500 5647271 10111580 756000 100000 100000 100000 100000 3500000 600000 4686736 4686736 3842443 4010259 844293 676477 1.00 1.00 1.00 0.85 0.85 0.80 11271 2493 100000 P0Y11M8D 38478 38478 32922 2072.75 2072.75 2373.16 P8Y3M29D P8Y3M29D 2176403218 15468633381 -119746776 0.0444 0.0062 0.0038 17143255652 41907387 893098291 781485502 38478 595556 10007141 709025 15468633381 30595665 2018 0 756000 -756000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amount of all outstanding debentures as of March 31, 2018 (unaudited), and December 31, 2017 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%"><font style="font-size: 10pt">Debentures</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 22%; text-align: right"><font style="font-size: 10pt">15,758,851</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 22%; text-align: right"><font style="font-size: 10pt">17,720,082</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Discount on Debentures</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(8,424,756</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(12,127,634</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Deferred financing fees</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(94,175</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(224,733</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,239,921</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,367,715</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,445,841</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(1,615,693</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Debentures</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>3,794,079</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt"><b>3,752,022</b></font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Notes Payable &#8211; Third Parties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>March 31, 2018</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Loan payable under prepaid forward purchase contract</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">5,000,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Loan payable to TCA Global Master Fund, LP (&#8220;TCA&#8221;) in the original principal amount of $3 million at 16% interest (the &#8220;TCA Debenture&#8221;). Principal and interest payments due in various installments through December 31, 2017.</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,616,218</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,616,218</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the &#8220;Tegal Notes&#8221;). Prinicpal and interest payments are due annually from July 12, 2015 through July 12, 2017</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">341,612</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">341,612</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,957,830</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">6,957,830</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less current portion</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(6,957,830</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(6,957,830</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt"><b>Notes payable - third parties, net of current portion</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p> 635000 500000 1100000 71333331 26666667 3333333 3333333 3333333 3333333 3333333 The Hospital Assets include a 52,000 square foot hospital building and 6,300 square foot professional building on approximately 4.3 acres. Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center 1000000 All payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference. 3752022 3794079 13823699.256 4949270368 3925158519 4949270368 5367715 7239921 24791 881457 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 &#8211; Redeemable Preferred Stock</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has 5,000,000 authorized shares of Preferred Stock at a par value of $0.01. Issuances of the Company&#8217;s Preferred Stock included as part of stockholders&#8217; deficit are discussed in Note 10. The following is a summary of the issuances of the Company&#8217;s Redeemable Preferred Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series I-1 Convertible Preferred Stock</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2017, the Company closed an offering of $4,960,000 stated value of its 4,960 shares of newly-authorized Series&#160;I-1 Convertible Preferred Stock (the &#8220;Series I-1 Preferred Stock&#8221;). Each share of Series I-1 Preferred Stock has a stated value of $1,000. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017 (the &#8220;Purchase Agreement&#8221;), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $4.0 million from the offering. The Purchase Agreement gives the investors the right to participate in up to 50% of any offering of common stock or common stock equivalents by the Company. In the event of any such offering, the investors may also exchange all or some of their Series I-1 Preferred Stock for such new securities on an $0.80 stated value of Series I-1 Preferred Stock for $1.00 of new subscription amount basis. Each share of Series I-1 Preferred Stock is convertible into shares of the Company&#8217;s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to &#8220;full ratchet&#8221; and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-1 Preferred Stock. Upon the occurrence of certain Triggering Events, as defined in the Certificate of Designation of the Series I-1 Preferred Stock, the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-1 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series I-2 Convertible Preferred Stock</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2017, the Company entered into exchange agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Preferred Stock. The exchange agreements permit the holders of the September Debentures to exchange specified principal amounts of the September Debentures on various closing dates starting on December 2, 2017. Any exchange is at the option of the holders. Each holder may reduce the principal amount of September Debentures exchanged on any particular closing date, or elect not to exchange any September Debentures at all on a closing date. If a holder does choose to exchange less principal amount of September Debentures, or no September Debentures at all, it can carry forward such lesser amount to a future closing date and then exchange more than the originally specified principal amount for that later closing date. For each $0.80 of principal amount of September Debenture surrendered to the Company at any closing date, the Company will issue the holder a share of Series I-2 Preferred Stock with a stated value of $1.00. Each share of Series I-2 Preferred Stock is convertible into shares of the Company&#8217;s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to &#8220;full ratchet&#8221; and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-2 Preferred Stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s board of directors has designated up to 11,271 shares of the 5,000,000 authorized shares of preferred stock as the Series&#160;I-2 Preferred Stock. Each share of Series I-2 Preferred Stock has a stated value of $1,000. Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-2 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-2 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 9, 2018, the holders exercised their right to exchange a portion of the September Debentures for shares of the Series I-2 Preferred Stock for the first time. On that date, the holders elected to exchange an aggregate of $1,384,556 principal amount of September Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Preferred Stock.</p> The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Centre, Inc. and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services. 56000000 41000000 16000000 51000000 13411976939 1384556 2695760 140000000 1000000 200000 0.85 151400000 100000 0.009 0.003 12435250 152423375 12435250 1005188 1577025 151418187 10858225 152423375 1005188 151418187 1577025 10858225 -139779232 563617 208893 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of December 31, 2017:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Embedded conversion options</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,577,025</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,577,025</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,858,225</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">10,858,225</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,435,250</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,435,250</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of March 31, 2018:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Embedded conversion options</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,005,188</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,005,188</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Common stock warrants</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">151,418,187</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">151,418,187</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">152,423,375</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">152,423,375</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2018:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 81%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2017</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,435,250</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Loss on change in fair value included in net loss</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">139,779,232</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Issuance of convertible debt</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">208,893</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2018</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">152,423,375</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 1110232133 53300000 1615693 3445841 3600000 3600000 27667 0 0 591323 2191983 1600000 EX-101.SCH 5 rnva-20180331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Debentures link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Capital Lease Obligations link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Redeemable Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Supplemental Disclosure of Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Recently Issued Accounting Standards link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Derivative Financial Instruments and Fair Value link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Organization and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Debentures (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Capital Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Supplemental Disclosure of Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Derivative Financial Instruments and Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Organization and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Accounts Receivable - Schedule of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Notes Payable - Schedule of Notes Payable - Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Notes Payable - Schedule of Notes Payable - Related Parties (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Debentures (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Debentures - Schedule of Debentures (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Debentures - Schedule of Payment on Outstanding Debentures (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Capital Lease Obligations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Capital Lease Obligations - Schedule of Capital Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Redeemable Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Stockholders' Deficit - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Stockholders' Deficit - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Stockholders' Deficit - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Segment Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Segment Information - Schedule of Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Derivative Financial Instruments and Fair Value (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rnva-20180331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 rnva-20180331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 rnva-20180331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series G Preferred Stock [Member] Series H Preferred Stock [Member] Segments [Axis] Corporate [Member] Clinical Laboratory Operations [Member] Debt Instrument [Axis] Notes Payable Related Parties One [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Receivable Type [Axis] Laboratory Service [Member] Property, Plant and Equipment, Type [Axis] Hospital Asset [Member] Medical Equipment [Member] Building [Member] Equipment [Member] Equipment under Capital Leases [Member] Furniture [Member] Leasehold Improvements [Member] Vehicles [Member] Computer Equipment [Member] Software [Member] TCA Debenture [Member] Award Type [Axis] April 2017 Through September 2017 [Member] Title of Individual [Axis] Two Investor [Member] September 2016 Notes [Member] Related Party [Axis] Alcimede LLC [Member] Mr Lagan [Member] Notes Payable Third Parties One [Member] Notes Payable Third Parties Two [Member] Notes Payable Third Parties Three [Member] Notes Payable Related Parties [Member] February 2017 Offering [Member] March 2017 Offerings [Member] Short-term Debt, Type [Axis] 2017 Diamantis Note [Member] March Debentures and Exchange Debenture [Member] March Warrants and Exchange Warrants [Member] Debenture Warrant [Member] June Warrants [Member] Accredited Investor [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Settlement Agreement [Member] Legal Entity [Axis] Epinex Diagnostics Laboratories, Inc. [Member] Income Tax Authority, Name [Axis] Internal Revenue Service (IRS) [Member] Medytox Solutions, Inc [Member] Florida Department of Revenue [Member] TCS-Florida, L.P [Member] Forbearance Agreement [Member] DeLage Landen Financial Services, Inc. [Member] Hospital Operations [Member] Assets of AMSG and HTS Classified As Held For Sale[Member] Eliminations [Member] Series F Preferred Stock [Member] Hospital [Member] Series H Convertible Preferred Stock [Member] Series A Warrant [Member] Series B Warrant [Member] Series C Warrant [Member] July 2017 Offerings [Member] July Offerings [Member] September 2017 Offerings [Member] Employees and Directors [Member] Warrant [Member] July Debentures [Member] September Debenture [Member] Fair Value, Hierarchy [Axis] Level 3 [Member] Notes Payable Related Parties Two [Member] Class of Warrant or Right [Axis] March Warrants [Member] June 2017 Offerings [Member] June Debentures [Member] September Warrants [Member] Series I-1 Preferred Stock [Member] Purchase Agreement [Member] Investor [Member] Advanced Molecular Services Group [Member] Health Technology Solutions, Inc [Member] Redeemable Preferred Stock I-1 [Member] Redeemable Preferred Stock I-2 [Member] Accumulated Deficit [Member] Report Date [Axis] May 30 2018 [Member] May 9, 2018 [Member] Range [Axis] Minimum [Member] Maximum [Member] Seamus Lagan [Member] Dr. Kamran Ajami [Member] John Beach [Member] Gary L. Blum [Member] Christopher Diamantis [Member] Trevor Langley [Member] Series I-2 Convertible Preferred Stock [Member] Nano Vibronix Inc [Member] Scenario [Axis] March 2018 Offering [Member] March 2018 Offering [Member] Subsequent Event Type [Axis] Subsequent Event [Member] March 2017 Debentures [Member] June 18, 2018 [Member] Stipulation Agreement [Member] Genomas, Inc. [Member] Alcimede [Member] Monarch Capital LLC [Member] 2007 Equity Plan [Member] Antidilutive Securities [Axis] Convertible Preferred Stock [Member] Convertible Debt [Member] Stock Options [Member] Warrants [Member] March 2017 Series B Warrants [Member] Asset Purchase Agreement [Member] May 9 2018 [Member] Liability Class [Axis] Embedded Conversion Options [Member] Valuation Approach and Technique [Axis] Black-Scholes Option Pricing Model [Member] Level 1 [Member] Level 2 [Member] Common Stock Warrants [Member] Legal Entity of Counterparty, Type [Axis] Counterparty [Member] Restricted Stock [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Accounts receivable, net Inventory Prepaid expenses and other current assets Income tax refunds receivable Current assets of AMSG and HTS classified as held for sale Total current assets Property and equipment, net Deposits Non-current assets of AMSG and HTS classified as held for sale Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable (includes related parties of $0.3 and $0.2 million, respectively) Accrued expenses (includes related parties of $0.1 and $0.1 million, respectively) Income taxes payable Current portion of notes payable Current portion of notes payable, related parties Current portion of capital lease obligations Current portion of debentures Current portion of derivative liabilities Current liabilities of AMSG and HTS classified as held for sale Total current liabilities Other liabilities: Debentures, net current portion Total liabilities Redeemable Preferred Stock Stockholders' deficit: Preferred stock value Common stock, $0.01 par value, 3,000,000,000 shares authorized, 499,992,133 and 19,750,844 shares issued and outstanding Additional paid-in-capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Accounts payable related parties Accrued expenses related parties Preferred stock par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] Net revenues Operating expenses: Direct costs of revenue General and administrative Sales and marketing expenses Depreciation and amortization Total operating expenses Loss from continuing operations before other income (expense) and income taxes Other income (expense): Other income Change in fair value of derivative instruments Interest expense Total other income (expense), net Net loss from continuing operations before income taxes Provision for income taxes Net loss from continuing operations Net income (loss) from discontinued operations Net loss Net loss to common shareholders Net loss per common share: Basic and diluted: continuing operations Basic and diluted: discontinued operations Total Basic and diluted Weighted average number of common shares outstanding during the period: Basic and diluted Balance - Post Split Balance - Post Split, shares Common stock issued in cashless exercise of warrants Common stock issued in cashless exercise of warrants, shares Conversion of debentures into common stock Conversion of debentures into common stock, shares Stock-based compensation Restricted stock issued to employees Restricted stock issued to employees, shares Shares returned to treasury Shares returned to treasury, shares Beneficial conversion feature of Series 1-2 preferred stock Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows used in operating activities: Non-cash gain on derivative instruments Stock-based compensation Non-cash interest expense Amortization of debt discount Non-cash settlement of debt Change in fair value of derivative instruments Income (loss) from discontinued operations Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Security deposits Accounts payable Accrued expenses Income tax assets and liabilities Net cash used in operating activities of continuing operations Net cash used in discontinued operations Net cash used in operating activities Cash flows from investing activities: Purchase of property and equipment Net cash used in investing activities of continuing operations Net cash provided by (used in) investing activities of discontinued operations Net cash provided by (used in) investing activities Cash flows from financing activities: Proceeds from issuance of related party notes payable and advances Proceeds from issuance of notes payable and debentures Payments on related party notes payable and advances Payments on notes payable Payments on capital lease obligations Net cash provided by financing activities of continuing operations Net cash provided by (used in) financing activities of discontinued operations Net cash provided by financing activities Net increase in cash Cash at beginning of period Cash at end of period Accounting Policies [Abstract] Organization and Basis of Presentation Receivables [Abstract] Accounts Receivable Property, Plant and Equipment [Abstract] Property and Equipment Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Notes Payable Debentures Related Party Transactions [Abstract] Related Party Transactions Capital Lease Obligations Equity [Abstract] Redeemable Preferred Stock Stockholders' Deficit Supplemental Cash Flow Elements [Abstract] Supplemental Disclosure of Cash Flow Information Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Segment Reporting [Abstract] Segment Information Accounting Changes and Error Corrections [Abstract] Recently Issued Accounting Standards Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Financial Instruments and Fair Value Subsequent Events [Abstract] Subsequent Events Basis of Presentation Reclassification Reverse Stock Splits Adoption of ASU 2017-11 Going Concern Recent Events Schedule of Accounts Receivable Schedule of Property and Equipment Schedule of Accrued Expenses Schedule of Notes Payable Schedule of Notes Payable - Related Parties Schedule of Debentures Schedule of Payment on Outstanding Debentures Schedule of Capital Lease Obligations Schedule of Stock Option Activity Schedule of Warrants Activity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Supplemental Cash Flow Information Schedule of Segment Information Schedule of Discontinued Operation of Balance Sheet and Operation Statement Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis Schedule of Changes in Liabilities with Level 3 of Fair Value Bad debts reserve Sales revenue Revenue Reserve stock split, description Common stock conversion description Derivative liability Reversal of interest expense Discount on convertible debenture Deemed dividend, down round feature Deemed dividend Working capital deficit Stockholders' deficit Accrued interest and extension fees Proceeds from issuance debentures Acquisition on assets, description Revenue earned for services Cash acquired from acquisition Estimated acquisition cost Total cost of acquisition Debt fee amount received Number of compensation shares issued Debt maturity date Principal amount Number of shares issued Share issued price per share Proceeds from offering Accounts receivable, gross Less: Allowance for discounts Less: Allowance for bad debts Accounts receivable, net Business acquisition description Payments to acquire assets Depreciation expenses Impairment charge Property and equipment, gross Less accumulated depreciation Property and equipment, net Commissions payable Accrued payroll and related liabilities Accrued interest Other accrued expenses Total accrued expenses Consideration received Estimated value of accounts receivable Adjustment value of debt Investment percentage Debt term Repayment of debt Debt instrument description Due from related party Accrued and unpaid interest Debt instrument periodic payment Debt instrument fee Debt instrument face amount Debt instrument conversion price Warrant to purchase common stock Warrant exercise per share Debt instrument maturity date Warrant exchanged shares of common stock Debt instrument interest rate Debt instrument extended due date Share based payment of exercised options granted Stock options exercise price per share Loan outstanding Repayment of common stock Note payable Less current portion Notes payable - third parties, net of current portion Purchase contract amount Debt instruments interest rate Debt maturity description Total notes payable - related parties Less current portion Total notes payable - related parties, net of current portion Debt instruments maturity date Warrants to purchase common stock Exercise price of warrants Warrant purchase price Debt instrument of exchange price Proceeds from debt Convertible debt Interest expenses Stock of convertible preferred stock Stock converted into debt Debt original issue discount, percentage Warrants exercisable Warrant term Debenture description Stock converted into debt, value Debt instrument original amount Proceeds from issuance warrants Unamortized Discount Non-cash interest and amortization of debt discount expense Warrant consideration in cash Proceeds of offering cost Proceeds from issuance of debenture and warrants Debentures Discount on Debentures Deferred financing fees Total debentures Less current portion Debentures 2018 2019 Payment on outstanding debentures Advances from director Dent instrument interest rate Debt instrument face value Warrants to purchase common stock Consulting fee Fees paid Interest expense Medical equipment Less accumulated depreciation Capital lease obligations Preferred stock, shares authorized Preferred stock, par value Ownership percentage Preferred stock subscription amount Common stock conversion price per share Common stock weighted average market price percentage Debenture surrender value Preferred stock designated shares Debenture aggregate exchange principal amount Number of shares issued for debenture exchange Debt converted into share Number of restricted stock issued Debt converted into share, value Number of common stock issued Warrants purchased Number of restricted stock shares forfeited Recognized stock stock-based compensation Stock issued price per share Unrecognized compensation Weighted average period Number of Options Outstanding, beginning balance Number of Options Granted Number of Options Expired Number of Options Forfeited Number of Options Exercised Number of Options Options Outstanding, ending balance Number of Options Options Exercisable Weighted average exercise price, Outstanding beginning Weighted average exercise price, Granted Weighted average exercise price, Expired Weighted average exercise price, Forfeited Weighted average exercise price, Exercised Weighted average exercise price, Outstanding, ending balance Weighted average exercise price, Exercisable Weighted average contractual term (Yrs.), beginning Weighted average contractual term (Yrs.), ending Number of warrants, balance beginning Warrants issued during the period Increase due to dilution Warrants exercised during the period Warrants expired during the period Number of warrants, balance ending Weighted average exercise price, balance beginning Weighted average exercise price, warrants issued Weighted average exercise price, increase due to dilution Weighted average exercise price, warrants exchanged/exercised Weighted average exercise price, warrants expired Weighted average exercise price, balance ending Antidilutive securities Cash paid for interest Cash paid for income taxes Exchange of I-2 preferred stock for convertible debentures Exchange of convertible debentures for convertible debentures and warrants Note payable and warrants settled through issuance of common stock Debentures converted into common stock Conversions of preferred stock into common stock Common stock issued in cashless excercise of warrants Settlement payable Payment of attorneys' fees Income tax penalties and interest paid Income tax liability refund Income tax penalties and interest accrued Monthly installment payment Due to related party Litigation settlement in judgment Payment in settlement of judgment Implicit interest rate Payment for notes payable Discharge of payment Number of reportable segments Consolidation Items [Axis] Net revenues - External (Loss) income from operations Capital expenditures Total assets Debt Cash Accounts receivable, net Prepaid expenses and other current assets Current assets classified as held for sale Property and equipment, net Deposits Non-current assets classified as held for sale Accounts payable (includes related parties) Accrued expenses Current portion of notes payable Current liabilities classified as held for sale Non-current liabilities classified as held for sale Revenue from services Cost of services Gross profit Operating expenses Other income/expenses Income/(Loss) from discontinued operations Fair Value Hierarchy and NAV [Axis] Loss realized on instrument Embedded conversion option value Conversion price percentage Warrants value Trading price Total Balance at December 31, 2017 Loss on change in fair value included in net loss Issuance of convertible debt Balance at March 31, 2018 Common stock, shares outstanding Number of shares issued for debt conversion Principal amount of debt converted into shares Accredited Investor [Member] Accrued expenses related parties. Accumulated Deficit [Member] Adoption of ASU [Policy Text Block] Advanced Molecular Services Group [Member] Alcimede LLC [Member] Alcimede Member April 1, 2018 [Member] April 2017 Through September 2017 [Member] Non-current assets of AMSG classified as held for sale. Beneficial conversion feature of Series 1-2 preferred stock. Board of Directors [Member] Christopher Diamantis [Member] Clinical Laboratory Operations [Member]. Clinical Laboratory Services [Member] Common Stock Equivalents [Member] Common Stock [Member] Consultants [Member] Conversions of preferred stock into common stock. Convertible Debentures [Member] Convertible Liabilities [Member] Convertible Liabilities One [Member] Convertible Liabilities Two [Member] DeLage Landen Financial Services, Inc. [Member] Debenture description. Debenture Warrant [Member] Debentures converted into common stock Debt original issue discount, percentage. December 2015 Warrant [Member] Decision Support And Informatics [Member] Derivative Liabilities [Member] Derivative Liabilities One [Member] Derivative Liabilities Two [Member] Accounts payable (includes related parties). Cost of services. Deposits. Disposal Group Including Discontinued Operation Notes Payable. Disposal Group Including Discontinued Operation Other Income (Expenses). Dr. Kamran Ajami [Member] Dr. Thomas Mendolia [Member] Eliminations [Member] Employees and Directors [Member] Epinex Diagnostics, Inc. [Member] Epinex Diagnostics Laboratories, Inc. [Member] Exchange Agreement [Member] Exchange of convertible debentures for convertible debentures and warrants. Exchange Warrants [Member] Exercise Price Range Four [Member] Exercise Price Range One [Member] Exercise Price Range Three [Member] Exercise Price Range Two [Member] February 9, 2018 [Member] Florida Department of Revenue [Member] Forbearance Agreement [Member] Former Employee [Member] Gary L. Blum [Member] Genomas acquisition [Member] Genomas, Inc. [Member] Going concern [Policy Text Block] Hartford Healthcare Corporation [Member] Health Technology Solutions, Inc [Member] Hospital Operations [Member] Hospital Asset [Member] Hospital Building [Member] Hospital [Member] Implicit interest rate. Jason Adams [Member] John Beach [Member] July Debentures [Member] July Offerings [Member] June Debentures [Member] June Warrants [Member] Laboratory Service [Member] Current liabilities of AMSG classified as held for sale. March Debentures and Exchange Debenture [Member] March Warrants and Exchange Warrants [Member] March Warrants [Member] Medical Equipment [Member]. Medytox Solutions, Inc [Member] Monarch Capital LLC [Member] Monthly installment payment. Mr Diamantis [Member] Mr Lagan [Member] Non-cash interest and amortization of debt discount expense. Note payable and warrants settled through issuance of common stock. Notes Payable [Member] Notes Payable Related Parties [Member] Notes Payable Related Parties One [Member] Schedule of notes payable - related parties [Table Text Block] Notes Payable Related Parties Three [Member] Notes Payable Related Parties Two [Member] Notes Payable Third Parties Four [Member] Notes Payable Third Parties One [Member] Notes Payable Third Parties Three [Member] Notes Payable Third Parties Two [Member] October 5 2017 [Member] October 30 2017 [Member] Others [Member] Payment in settlement of judgment. Preferred Stock [Member] Proceeds from issuance of debenture and warrants. Proceeds from issuance of notes payable and debentures. Professional Building [Member] Purchase Agreement [Member] Redeemable Preferred Stock I-1 [Member] Redeemable Preferred Stock I-2 [Member] Reserve Stock Split [Member] Reverse stock splits [Policy Text Block] Seamus Lagan [Member] September Debenture [Member] September 2016 Notes [Member] September Warrants [Member] Series A Warrant [Member] Series B Warrant [Member] Series C Warrant [Member] Series H Convertible Preferred Stock [Member] Series I-1 Preferred Stock [Member] Series I-2 Preferred Stock [Member] Settlement Agreement [Member] Stipulation Agreement [Member] Stock Options [Member] Stock Purchase Agreement [Member] Stockholder [Member] Supportive Software Solutions [Member]. TCA Debenture [Member] TCS-Florida, L.P [Member] Tax Cuts and Jobs Act [Member] Trevor Langley [Member] Two Investor [Member] 2007 Equity Plan [Member] 2017 Equity Plan [Member] 2007 Equity Plan [Member] 2017 Diamantis NoteMember Underwriters [Member] Warrant consideration in cash. Warrant purchase price. Warrant term. Warrants [Member] May 20 2018 [Member] Series I 2 Convertible Preferred Stock [Member] Nano Vibronix Inc [Member] Working capital deficit. Revenue earned for services Allowance for discounts Consideration received. Estimated value of accounts receivable. Adjustment value of debt. Debt instrument extended due date. Repayment of common stock. February 2017 Offering [Member] March 2017 Offerings [Member] June 2017 Offerings [Member] July 2017 Offerings [Member] September 2017 Offerings [Member] March 2018 Offering [Member] Common stock issued in cashless excercise of warrants. June 14, 2018 [Member] March 2017 Debentures [Member] Series I Preferred Stock [Member] Preferred stock subscription amount. Common stock conversion price per share. Common stock weighted average market price percentage. Debenture surrender value. Preferred stock designated shares. Weighted average contractual term, Options Outstanding, beginning balance. Series B Warrants [Member] May 9, 2018 [Member] March 2018 Offering [Member] Warrants exercisable. March 2017 Series B Warrants [Member] Acquisition on assets, description. Asset Purchase Agreement [Member] Assets of AMSG and HTS Classified As Held For Sale [Member] May 30 2018 [Member] May 9 2018 [Member] Deemed dividend, down round feature. Deemed dividend. Reversal of interest expense. Increase due to dilution. Exchange of preferred stock for convertible debentures. Embedded Conversion Options [Member] Common Stock Warrants [Member] Issuance of convertible debt. June 18, 2018 [Member] Weighted average exercise price, increase due to dilution. MarchTwoThousandAndEighteenOfferingMember Assets, Current Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Interest Expense, Other Other Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Domestic Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Other Noncash Income Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Repayments of Debt and Capital Lease Obligations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) Preferred Stock [Text Block] AllowanceForDiscounts Allowance for Doubtful Accounts Receivable Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Notes Payable, Related Parties, Noncurrent Debt Instrument, Unamortized Discount, Current Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net Other Long-term Debt Other Long-term Debt, Current Long-term Debt Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation Capital Leases, Balance Sheet, Assets by Major Class, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Disposal Group, Including Discontinued Operation, Cash Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Disposal Group, Including Discontinued Operation, Property, Plant and Equipment DisposalGroupIncludingDiscontinuedOperationDeposits Disposal Group, Including Discontinued Operation, Accrued Liabilities DisposalGroupIncludingDiscontinuedOperationNotesPayable EX-101.PRE 9 rnva-20180331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2018
Jun. 18, 2018
Document And Entity Information    
Entity Registrant Name Rennova Health, Inc.  
Entity Central Index Key 0000931059  
Document Type 10-Q  
Document Period End Date Mar. 31, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   1,110,232,133
Trading Symbol RNVA  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2018  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash $ 35,096
Accounts receivable, net 1,101,758 971,312
Inventory 251,029 236,914
Prepaid expenses and other current assets 35,350 9,842
Income tax refunds receivable 1,915,343 1,940,845
Current assets of AMSG and HTS classified as held for sale 222,051 226,732
Total current assets 3,560,627 3,385,645
Property and equipment, net 2,362,225 2,695,440
Deposits 193,006 180,875
Non-current assets of AMSG and HTS classified as held for sale 21,912 28,834
Total assets 6,137,770 6,290,794
Current liabilities:    
Accounts payable (includes related parties of $0.3 and $0.2 million, respectively) 4,605,123 4,188,678
Accrued expenses (includes related parties of $0.1 and $0.1 million, respectively) 4,131,767 4,967,405
Income taxes payable 1,968,750 1,971,592
Current portion of notes payable 6,957,830 6,957,830
Current portion of notes payable, related parties 1,068,500 1,128,500
Current portion of capital lease obligations 1,715,727 2,079,137
Current portion of debentures 3,445,841 1,615,693
Current portion of derivative liabilities 152,423,375 12,435,250
Current liabilities of AMSG and HTS classified as held for sale 2,062,992 1,972,854
Total current liabilities 178,379,905 37,316,939
Other liabilities:    
Debentures, net current portion 3,794,079 3,752,022
Total liabilities 182,173,984 41,068,961
Stockholders' deficit:    
Common stock, $0.01 par value, 3,000,000,000 shares authorized, 499,992,133 and 19,750,844 shares issued and outstanding 4,999,922 197,508
Additional paid-in-capital 126,619,959 128,351,954
Accumulated deficit (315,545,009) (169,180,425)
Total stockholders' deficit (183,907,626) (40,613,461)
Total liabilities and stockholders' deficit 6,137,770 6,290,794
Redeemable Preferred Stock I-1 [Member]    
Other liabilities:    
Redeemable Preferred Stock 5,835,294 5,835,294
Redeemable Preferred Stock I-2 [Member]    
Other liabilities:    
Redeemable Preferred Stock 2,036,118
Series G Preferred Stock [Member]    
Stockholders' deficit:    
Preferred stock value 2 2
Series H Preferred Stock [Member]    
Stockholders' deficit:    
Preferred stock value
Series F Preferred Stock [Member]    
Stockholders' deficit:    
Preferred stock value $ 17,500 $ 17,500
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Accounts payable related parties $ 300,000 $ 200,000
Accrued expenses related parties $ 100,000 $ 100,000
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 5,000,000 5,000,000
Common stock par value $ 0.01 $ 0.01
Common stock shares authorized 3,000,000,000 3,000,000,000
Common stock shares issued 499,992,133 19,750,844
Common stock shares outstanding 499,992,133 19,750,844
Series G Preferred Stock [Member]    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 14,000 14,000
Preferred stock shares issued 215 215
Preferred stock shares outstanding 215 215
Series H Preferred Stock [Member]    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 14,202 14,202
Preferred stock shares issued 60 60
Preferred stock shares outstanding 60 60
Series F Preferred Stock [Member]    
Preferred stock par value $ 0.01 $ 0.01
Preferred stock shares authorized 1,750,000 1,750,000
Preferred stock shares issued 1,750,000 1,750,000
Preferred stock shares outstanding 1,750,000 1,750,000
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Net revenues $ 1,601,661 $ 684,265
Operating expenses:    
Direct costs of revenue 2,089,366 244,831
General and administrative 2,892,019 3,316,448
Sales and marketing expenses (1,215) 252,314
Depreciation and amortization 333,515 426,929
Total operating expenses 5,313,685 4,240,522
Loss from continuing operations before other income (expense) and income taxes (3,712,024) (3,556,257)
Other income (expense):    
Other income 11,969
Change in fair value of derivative instruments (139,779,232) 563,617
Interest expense (3,307,014) (45,642,525)
Total other income (expense), net (143,074,277) (45,078,908)
Net loss from continuing operations before income taxes (146,786,301) (48,635,165)
Provision for income taxes 76 3,250
Net loss from continuing operations (146,786,377) (48,638,415)
Net income (loss) from discontinued operations 421,793 (1,066,292)
Net loss (146,364,584) (49,704,707)
Net loss to common shareholders $ (146,364,584) $ (49,704,707)
Net loss per common share:    
Basic and diluted: continuing operations $ (0.66) $ (0.66)
Basic and diluted: discontinued operations (0.01)
Total Basic and diluted $ (0.66) $ (0.67)
Weighted average number of common shares outstanding during the period:    
Basic and diluted 221,942,501 73,464,705
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statement of Changes in Stockholders' Deficit (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance - Post Split at Dec. 31, 2017 $ 17,502 $ 197,508 $ 128,351,954 $ (169,180,425) $ (40,613,461)
Balance - Post Split, shares at Dec. 31, 2017 1,750,275 19,750,844      
Common stock issued in cashless exercise of warrants $ 756,000 (756,000) $ 0
Common stock issued in cashless exercise of warrants, shares 75,600,000     286,240,000
Conversion of debentures into common stock $ 3,333,105 (276,431) $ 3,056,674
Conversion of debentures into common stock, shares 333,310,452     333,315,823
Stock-based compensation 24,196 $ 24,196
Restricted stock issued to employees $ 713,333 (72,223) 641,110
Restricted stock issued to employees, shares 71,333,331      
Shares returned to treasury $ (25) 25 0
Shares returned to treasury, shares (2,494)      
Beneficial conversion feature of Series 1-2 preferred stock (651,562) (651,562)
Net loss (146,364,584) (146,364,584)
Balance at Mar. 31, 2018 $ 17,502 $ 4,999,922 $ 126,619,959 $ (315,545,009) $ (183,907,626)
Balance, shares at Mar. 31, 2018 1,750,275 499,992,133      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows used in operating activities:    
Net loss from continuing operations $ (146,786,377) $ (48,638,415)
Depreciation and amortization 333,515 426,929
Non-cash gain on derivative instruments (571,720)
Stock-based compensation 665,307 35,215
Non-cash interest expense 44,074,628
Amortization of debt discount 4,522,329 943,160
Non-cash settlement of debt (50,000)
Change in fair value of derivative instruments 139,779,232 (563,617)
Income (loss) from discontinued operations 421,793 (1,066,292)
Changes in operating assets and liabilities:    
Accounts receivable (130,449) 115,446
Inventory (14,115)
Prepaid expenses and other current assets (25,508) 21,964
Security deposits (12,128) 14,594
Accounts payable 416,445 146,969
Accrued expenses (835,638) (957,683)
Income tax assets and liabilities 22,660 (241,997)
Net cash used in operating activities of continuing operations (1,642,934) (5,739,099)
Net cash used in discontinued operations (698,259) (212,365)
Net cash used in operating activities (2,341,193) (5,951,464)
Cash flows from investing activities:    
Purchase of property and equipment (301) (1,090,922)
Net cash used in investing activities of continuing operations (301) (1,090,922)
Net cash provided by (used in) investing activities of discontinued operations 800,000
Net cash provided by (used in) investing activities 799,699 (1,090,922)
Cash flows from financing activities:    
Proceeds from issuance of related party notes payable and advances 3,395,000
Proceeds from issuance of notes payable and debentures 2,000,000 9,892,500
Payments on related party notes payable and advances (60,000) (3,430,000)
Payments on notes payable (1,948,111)
Payments on capital lease obligations (363,410) (911,042)
Net cash provided by financing activities of continuing operations 1,576,590 6,998,347
Net cash provided by (used in) financing activities of discontinued operations 1,331,113
Net cash provided by financing activities 1,576,590 8,329,460
Net increase in cash 35,096 1,287,074
Cash at beginning of period 77,979
Cash at end of period $ 35,096 $ 1,365,053
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Basis of Presentation
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Organization and Basis of Presentation

Note 1 – Organization and Basis of Presentation

 

Rennova Health, Inc. (“Rennova”), together with its subsidiaries (the “Company”, “we”, “us” or “our”), is a vertically integrated provider of healthcare related products and services. The Company’s principal lines of business are (i) clinical laboratory operations; and (ii) Hospital Operations. The Company presents its financial results based upon these two business segments.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the 2017 audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2018. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). All material intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) considered necessary for the fair presentation of the financial position and results of operations and cash flows for the interim periods reported herein. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

During the three months ended March 31, 2018 and 2017, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations. In addition, certain prior year balances have been reclassified to conform to the current presentation.

 

Based on new FASB rules for revenue recognition that became effective January 1, 2018, bad debts are now treated similar to contractual adjustments and directly reduce sales revenue. In an abundance of caution through the startup period of our Oneida hospital the Company has reserved a bad debt number of $591,323, which, when set against sales revenues of $2,191,983 means the Company is reporting net revenues for the first quarter of 2018 of $1.6 million. The Company will continue to review its provision for bad debt.

 

Reclassification

 

The Company has reclassified certain amounts in the 2017 condensed consolidated financial statements to be consistent with the 2018 presentation. These principally relate to classification of certain revenues, cost of revenues and related segment data, as well as balance sheet classifications to assets and liabilities held for sale. Reclassifications relating to the discontinued operations of AMSG and HTS are described further in Note 15. The reclassifications had no impact on operations or cash flows for the three months ended March 31, 2017. The Company also reclassified derivative liability previously reported in 2017 as long term to current liability.

 

Reverse Stock Splits

 

On February 7, 2017, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017 and on September 21, 2017, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-15 reverse stock split effective October 5, 2017 (the “Reverse Stock Splits”). The stockholders of the Company had approved these amendments to the Company’s Certificate of Incorporation on December 22, 2016 for the February 7, 2017 reverse stock split and on September 20, 2017 for the October 5, 2017 reverse stock split. In both cases, the Company’s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse splits within certain specified effective dates.

 

As a result of the Reverse Stock Splits, every 30 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on February 7, 2017 and every 15 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on October 5, 2017. In addition, the conversions and exercise prices of all of the Company’s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the 1:30 reverse split ratio and again at the 1:15 reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Splits, other than as a result of the rounding up of fractional shares in the February reverse split and the payment of cash in lieu of fractional shares in the October reverse split, as no fractional shares were issued in connection with the Reverse Stock Splits.

 

The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 3,000,000,000 shares of common stock and 5,000,000 shares of preferred stock were also unaffected by the Reverse Stock Splits. On May 9, 2018, the Company amended its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares (see note 17).

 

All share, per share and capital stock amounts for all periods presented have been restated to give effect to the Reverse Stock Splits.

 

Adoption of ASU 2017-11

 

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.

 

Under current GAAP, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity’s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity’s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.

 

The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and embedded conversion options with down round features are no longer bifurcated.

 

For entities that present EPS in accordance with Topic 260, and when the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.

 

Those amendments in Part 1 of this Update are a cost savings relative to current GAAP. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basis of the existence of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic value of the feature only when the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.

 

The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.

 

For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 1 of this Update should be applied in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is effective; or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10.

 

The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect.

 

The Company has determined that this amendment had a material impact on its consolidated financial statements and has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company’s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid in capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million. A $51 million deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature.

 

Going Concern

 

The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has recently accumulated significant losses and has negative cash flows from operations, and at March 31, 2018, had a working capital deficit of $174.8 million and a stockholders’ deficit of $183.9 million. In addition, the Company’s cash position as of the date of this report is critically deficient, critical payments, including capital lease obligations are not being made in the ordinary course of business and certain indebtedness, including accrued interest and extension fees, in the amount of $7.8 million matures on May 30, 2018, that the Company does not have the financial resources to satisfy. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report.

 

The Company continues to consider efficiencies and is currently using one laboratory for the majority of its toxicology diagnostics thereby reducing the number of employees and associated operating expenses, in order to reduce costs. In addition, the Company received approximately $2 million in cash from the issuances of debentures during the first quarter of 2018 (see Note 6).

 

In July 2017, the Company announced that it plans to spin off its Advanced Molecular Services Group (“AMSG”) and in the third quarter of 2017, the Company’s Board of Directors voted unanimously to spin off Health Technology Solutions, Inc., a wholly-owned subsidiary (“HTS”), as independent publicly traded companies by way of tax-free distributions to its shareholders. Completion of these spinoffs is expected to occur during the second half of 2018. Our Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead of two. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered into by the Company. The intent of the spinoffs of AMSG and HTS is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for “held for sale”, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 15.

 

The Company also announced that the Big South Fork Medical Center received CMS regional office licensure approval and opened on August 8, 2017. In addition, on January 31, 2018, the Company announced that it had entered into a definitive asset purchase agreement to acquire an acute care hospital in Jamestown, Tennessee known as Tennova Healthcare – Jamestown. The acquisition was completed on June 1, 2018. The Company may amend its current revenue recognition policy and percentage for the hospitals when payments are received to support amended revenue recognition methodologies. Therefore, the Company expects that these hospitals will continue to provide additional revenue and cash flow sources.

 

There can be no assurance that the Company will be able to achieve its business plan, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues and eventually regain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Recent Events

 

Asset Purchase Agreement to Acquire Acute Care Hospital

 

On January 31, 2018, the Company entered into an asset purchase agreement (the “Purchase Agreement”) to acquire certain assets related to an acute care hospital located in Jamestown, Tennessee. The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Center, Inc., and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services. The acquisition also included a separate physician practice which will now operate under Rennova as Mountain View Physician Practice, Inc.

 

Net annual revenues in recent years have been approximately $15 million with government payers including Medicare and Medicaid accounting for in excess of 60% of the payor mix. Rennova does not expect this payer mix to change significantly in the near future. The hospital was acquired for approximately $635,000 from Community Health Systems, Inc. Diligence, legal and other costs associated with the acquisition are estimated to be approximately $500,000 meaning the total cost of acquisition to the Company is approximately $1,100,000.

 

Jamestown is located 38 miles from the Company’s existing hospital, the Big South Fork Medical Center, which is located in Oneida, Tennessee.

 

Proposals Submitted to Stockholders

 

On May 9, 2018, the Company held a Special Meeting of Stockholders to (1) approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares, (2) approve the Company’s new 2018 Incentive Award Plan, and (3) authorize an adjournment of the Special Meeting if necessary.

 

Proposal 1 was approved while proposal 2 was rejected. Proposal 3 was not voted on.

 

Accounts Receivable Financing

 

As previously announced, on March 31, 2016 the Company entered into an agreement to sell certain of its accounts receivable. The agreement was originally scheduled to mature on March 31, 2017, which date was extended to March 31, 2018 by an amendment on March 24, 2017. On April 2, 2018, the Company, the purchaser and Christopher Diamantis, a Director of the Company, as guarantor, entered into a second amendment to extend further the Company’s obligation to May 30, 2018. In connection with this further extension, the purchaser received a fee of $100,000. As of May 30, 2018, the Company has not made a payment under this agreement and the full balance is now payable.

 

Share Issuances

 

On March 6, 2018, the Board of Directors, based on the recommendation of the Compensation Committee, approved grants to employees and directors of an aggregate of 71,333,331 shares of common stock, including the following to the directors of the Company:

 

Seamus Lagan 26,666,667 shares
Dr. Kamran Ajami 3,333,333 shares
John Beach 3,333,333 shares
Gary L. Blum 3,333,333 shares
Christopher Diamantis 3,333,333 shares
Trevor Langley 3,333,333 shares

 

The shares were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), as a transaction by an issuer not involving a public offering.

 

On February 9, 2018, holders of the Company’s Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 exercised their right for the first time under exchange agreements (the “Exchange Agreements”) entered into with the Company by electing to exchange an aggregate of $1,384,556 principal amount of such Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Convertible Preferred Stock.

 

Such shares of Preferred Stock were issued in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.

 

NanoVibronix

 

On February 14, 2018, the Company entered into a Common Stock Purchase Agreement with two investors pursuant to which the Company agreed to sell an aggregate of 200,000 shares of common stock of NanoVibronix, Inc. owned by the Company at a purchase price of $4.00 per share. The Company had acquired the shares as a result of an investment originally made in 2011.

 

March 2018 Offering

 

On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.

 

The Debentures were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act and by Rule 506 of Registration D promulgated thereunder as a transaction by an issuer not involving a public offering.

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accounts Receivable
3 Months Ended
Mar. 31, 2018
Receivables [Abstract]  
Accounts Receivable

Note 2 – Accounts Receivable

 

Accounts receivable at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

    March 31, 2018     December 31, 2017  
Accounts receivable - laboratory services   $ 1,302,579     $ 1,478,451  
Accounts receivable – hospital     11,783,802       8,593,747  
Total accounts receivable     13,086,381       10,072,198  
Less:                
Allowance for discounts - laboratory services     (1,150,800 )     (1,177,054 )
Allowance for discounts - hospital     (9,307,852 )     (6,936,429 )
Allowance for bad debts     (1,525,972 )     (987,403 )
Accounts receivable, net   $ 1,101,758     $ 971,312  

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment
3 Months Ended
Mar. 31, 2018
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 3 – Property and Equipment

 

Property and equipment at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

    March 31, 2018     December 31, 2017  
Medical equipment   $ 713,799     $ 696,195  
Building     1,359,484       1,359,472  
Equipment     437,029       476,548  
Equipment under capital leases     4,686,736       4,686,736  
Furniture     232,495       222,824  
Leasehold improvements     1,303,131       1,303,131  
Vehicles     196,534       196,534  
Computer equipment     221,237       226,441  
Software     333,853       631,033  
      9,484,297       9,798,914  
Less accumulated depreciation     (7,122,072 )     (7,103,474 )
Property and equipment, net   $ 2,362,225     $ 2,695,440  

 

On January 13, 2017, the Company completed an asset purchase agreement to acquire certain assets related to Scott County Community Hospital, based in Oneida, Tennessee (the “Hospital Assets”). The Hospital Assets include a 52,000 square foot hospital building and 6,300 square foot professional building on approximately 4.3 acres. Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center, is classified as a Critical Access Hospital (rural). The Company acquired the Hospital Assets out of bankruptcy for a purchase price of $1.0 million, and the purchase price has been recorded as property and equipment in the Company’s condensed consolidated balance sheet. The Company opened the hospital on August 8, 2017.

 

Depreciation expense on property and equipment was $0.3 million and $0.4 million for the three months ended March 31, 2018 and 2017, respectively. Management periodically reviews the valuation of long-lived assets, including property and equipment, for potential impairment. Management did not recognize any impairment of these assets during the three months ended March 31, 2018 and 2017

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses
3 Months Ended
Mar. 31, 2018
Payables and Accruals [Abstract]  
Accrued Expenses

Note 4 – Accrued Expenses

 

Accrued expenses at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

    March 31, 2018     December 31, 2017  
Commissions payable   $ 13,345     $ 24,470  
Accrued payroll and related liabilities     1,419,779       897,088  
Accrued interest     1,402,498       2,636,057  
Other accrued expenses     1,296,146       1,409,790  
Total accrued expenses   $ 4,131,767     $ 4,967,405  

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes Payable
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Notes Payable

Note 5 – Notes Payable

 

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2018 (unaudited) and December 31, 2017, notes payable consisted of the following:

 

Notes Payable – Third Parties

 

    March 31, 2018     December 31, 2017  
Loan payable under prepaid forward purchase contract   $ 5,000,000     $ 5,000,000  
                 
Loan payable to TCA Global Master Fund, LP (“TCA”) in the original principal amount of $3 million at 16% interest (the “TCA Debenture”). Principal and interest payments due in various installments through December 31, 2017.     1,616,218       1,616,218  
                 
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the “Tegal Notes”). Prinicpal and interest payments are due annually from July 12, 2015 through July 12, 2017     341,612       341,612  
      6,957,830       6,957,830  
Less current portion     (6,957,830 )     (6,957,830 )
Notes payable - third parties, net of current portion   $ -     $ -  

 

On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract whereby the Company received consideration in the amount of $5.0 million. The receivables had an estimated collectable value of $8.7 million which had been adjusted down to approximately $1.5 million on the Company’s balance sheet as of December 31, 2016 and $0 as of December 31, 2017. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $0.5 million, (ii) all payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference.

 

Christopher Diamantis, a director of the Company, guaranteed the Company’s obligation. On March 24, 2017, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into an amendment to extend the Company’s obligation to March 31, 2018. Also, what the counterparty is to receive was amended to equal (a) the $5,000,000 purchase price plus a 20% per annum investment return thereon, plus (b) $500,000, plus (c) the product of (i) the proceeds received from the accounts receivable, minus the amount set forth in clauses (a) and (b), multiplied by 40%. In connection with this extension, the counterparty received a fee of $1,000,000. On April 2, 2018, the Company, the counterparty and Mr. Diamantis, as guarantor, entered into a second amendment to extend further the Company’s obligation to May 30, 2018. In connection with this further extension, the counterparty received a fee of $100,000. To date, the Company has not recovered any payments against the accounts recievable.

 

The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On February 2, 2017, the Company made a payment to TCA in the amount of $0.4 million which was applied to accrued and unpaid interest and fees, including default interest, as of the date of payment. On March 21, 2017, the Company made a payment to TCA in the amount of $0.75 million, of which approximately $0.1 million was applied to accrued and unpaid interest and fees in accordance with the terms of the TCA Debenture. Also on March 21, 2017, the Company entered into a letter agreement with TCA, which (i) waived any payment defaults through March 21, 2017; (ii) provided for the $0.75 million payment discussed above; (iii) set forth a revised repayment schedule whereby the remaining principal plus interest aggregating to approximately $2.6 million was to be repaid in various monthly installments from April of 2017 through September of 2017; and (iv) provided for payment of an additional service fee in the amount of $150,000, which was due on June 27, 2017, the day after the effective date of the registration statement filed by the Company; which amount is reflected in accrued expenses in the accompanying condensed consolidated balance sheet at December 31, 2017. In addition, TCA entered into an inter-creditor agreement with the purchasers of the convertible debentures (see Note 6) which sets forth rights, preferences and priorities with respect to the security interests in the Company’s assets. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December 31,2017. The debt to TCA remains outstanding and the parties are currently working to amend the Note to extend the maturity.

 

On September 15, 2016, the Company entered into an agreement with two investors whereby the Company sold to the investors convertible notes in the aggregate principal amount of $0.4 million (the “September 2016 Notes”). The September 2016 Notes were convertible into shares of the Company’s common stock at a conversion price of $112.50 per share. In conjunction with the sale of the September 2016 Notes, the Company issued warrants to purchase an aggregate of 4,444 shares of the Company’s common stock at an exercise price of $180.00 per share. Based on the allocation of the net proceeds from the September 2016 Notes to the fair value of the warrants, and the resulting beneficial conversion features, the Company recognized a discount for the entire face value of the September 2016 Notes, which was accreted through the notes’ maturity date of March 15, 2017. On March 13, 2017, the September 2016 Notes, along with the accompanying warrants, were exchanged for 26,667 shares of the Company’s common stock.

 

The Company did not make the principal payments under the Tegal Notes that were due on July 12, 2016. On November 3, 2016, the Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal and accrued interest aggregating to $0.4 million. On December 7, 2016, the Company received a breach of contract complaint with a request for entry of a default judgment (see Note 12). To date, the Company has yet to repay this amount.

 

Notes Payable – Related Parties

 

    March 31, 2018     December 31, 2017  
Loan payable to Alcimede LLC, bearing interest at 6% per annum, with all principal and interest due on August 2, 2018   $ 168,500     $ 168,500  
                 
Loan Payable to Christopher Diamantis     900,000       960,000  
      1,068,500       1,068,500  
Less current portion     (1,068,500 )     (1,068,500 )
Total notes payable - related parties, net of current portion   $ 0     $ 0  

 

On February 3, 2015, the Company borrowed $3.0 million from Alcimede LLC (“Alcimede”). Seamus Lagan, the Company’s President and Chief Executive Officer, is the sole manager of Alcimede. The note has an interest rate of 6% and was originally due on February 2, 2016. Alcimede later agreed to extend the maturity date of the loan to August 2, 2017. On June 29, 2015, Alcimede exercised options granted in October 2012 to purchase 66,667 shares of the Company’s common stock at an exercise price of $37.50 per share, and the loan outstanding was reduced in satisfaction of the aggregate exercise price of $2.5 million. In August of 2016, $0.3 million was repaid by the Company through the issuance of shares of common stock. In March of 2017, the Company and Mr. Lagan agreed that a payment made to Alcimede in the amount of $50,000 would be deducted from the outstanding balance of the note. On August 2, 2017, the Company and Alcimede agreed to further extend the maturity date of the loan to August 2, 2018. The remaining balance due on this loan as of March 31, 2018 was $168,500, including accrued interest.

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debentures
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Debentures

Note 6 – Debentures

 

The carrying amount of all outstanding debentures as of March 31, 2018 (unaudited), and December 31, 2017 is as follows:

 

    March 31, 2018     December 31, 2017  
Debentures   $ 15,758,851     $ 17,720,082  
Discount on Debentures     (8,424,756 )     (12,127,634 )
Deferred financing fees     (94,175 )     (224,733 )
      7,239,921       5,367,715  
Less current portion     (3,445,841 )     (1,615,693 )
Debentures   $ 3,794,079     $ 3,752,022  

 

Payment on all outstanding debentures as of March 31, 2018 are due as follows:

 

Period ended December 31,      
2018   5,647,271  
2019   10,111,580  
    $ 15,758,851  

 

February 2017 Offering

 

On February 2, 2017, the Company issued $1.6 million aggregate principal amount of Original Issue Discount Convertible Debentures due three months from the date of issuance (the “February Debentures”) and warrants to purchase an aggregate of 6,667 shares of common stock, which can be exercised at any time after August 17, 2017 at an exercise price of $38.70 per share (the “February Warrants”), to an accredited investor for a purchase price of $1.5 million. On March 21, 2017, the February Debentures were exchanged for $2.5 million of exchange debentures as more fully discussed below.

 

March 2017 Offerings

 

On March 21, 2017, the Company issued $10.85 million aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due March 21, 2019 (the “Convertible Debentures”). The Company received net proceeds from this transaction in the approximate amount of $8.4 million. The Company used $3.8 million of the net proceeds to repay the 2017 Diamantis Note (see Note 7) and $0.75 million of the net proceeds to make the partial repayment on the TCA Debenture. The remainder of the net proceeds were used for general corporate purposes. In conjunction with the issuance of the Convertible Debentures, the holder of the February Debentures exchanged these debentures for $2.5 million of new debentures (the “Exchange Debentures” and, collectively with the Convertible Debentures, the “March Debentures”) on the same terms as, and pari passu with, the Convertible Debentures and warrants. The Company recorded non-cash interest expense in the amount of $0.4 million as a result of this exchange. Additionally, the holders of an aggregate of $2.2 million stated value of the Company’s Series H Convertible Preferred Stock (the “Series H Preferred Stock”) exchanged such preferred stock into $2.7 million principal amount of Exchange Debentures and warrants. The March Debentures contain a 24% original issue discount, have no regularly scheduled interest payments except in the event of a default and have a maturity date of March 21, 2019.

 

In connection with the March Debentures the Company issued warrants to purchase shares of the Company’s common stock to several accredited investors. At March 31, 2018, these warrants were exercisable into an aggregate of 13,823,699,256 shares of common stock. The warrants were issued to the investors in three tranches, Series A Warrants, Series B Warrants and Series C Warrants (collectively, the “March Warrants”). At March 31, 2018, the Series A Warrants are exercisable for 4,949,270,368 shares of the Company’s common stock. They are immediately exercisable and have a term of exercise equal to five years. At March 31, 2018, the Series B Warrants are exercisable for 3,925,158,519 shares of the Company’s common stock and are exercisable for a period of 18 months commencing immediately. The Series C Warrants are exercisable for 4,949,270,368 shares of the Company’s common stock and have a term of five years provided such warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. At March 31, 2018, the Series A, Series B and Series C Warrants each have an exercise price of $0.0038 per share, which reflects adjustments pursuant to their terms. The Series A, Series B and Series C Warrants are subject to “full ratchet” and other customary anti-dilution protections.

 

The March Debentures are convertible into shares of the Company’s common stock, at a conversion price which has been adjusted pursuant to the terms of the March Debentures to $0.0038 per share as of March 31, 2018, due to prices at which the Company has subsequently issued shares of common stock. The Convertible Debentures began to amortize monthly commencing on the 90th day following the closing date. The Exchange Debentures began to amortize monthly on the closing date. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of the March Debentures in cash or, in lieu thereof, the conversion price of such debentures will thereafter be 85% of the volume weighted average price at the time of conversion. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount. The March Debentures contain customary affirmative and negative covenants. The conversion prices are subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then conversion price, as well as other customary anti-dilution protections as more fully described in the debentures.

 

On October 30, 2017, the Company agreed to amend the March Debentures and March Warrants to remove the floor in the anti-dilution provisions therein. The conversion price of the March Debentures and the exercise price of the March Warrants as of March 31, 2018 stated above reflect the amendment as well as other adjustments for dilutive issuances, which triggered the down round provisions in the March Debentures and March Warrants. The March Debentures are secured by all of the Company’s assets and are guaranteed by substantially all of the Company’s subsidiaries. Between March 22, 2017 and March 31, 2018, holders of the March Debentures converted an aggregate of $10,362,989 of these debentures into 359,281,017 shares of common stock.

 

The exercise prices of the March Warrants issued in connection with the March Debentures are subject to reset in the event of offerings or other issuances of common stock, or rights to purchase common stock, at a price below the then exercise price, as well as other customary anti-dilution protections. As a result of these provisions, both the March Debentures and the March Warrants were deemed to be not indexed to the Company’s common stock, and the Company recognized derivative liabilities for the embedded conversion feature of the March Debentures and the March Warrants in the original amount of $15.3 million and $41.3 million, respectively. The Company recognized a discount for 100% of the principal value of the March Debentures and non-cash interest expense in the amount of $43.7 million in connection with the recognition of these derivative liabilities. As a result of the adoption of ASU 2017-11 in the second quarter of 2017, the interest expense and derivative liability originally recognized were adjusted and extinguished during the three months ended June 30, 2017. See Note 1 for the adoption of ASU 2017-11 for the retrospective adjustments made to the Company’s condensed consolidated financial statements with respect to the derivative liabilities associated with these debentures and warrants.

 

June 2017 Offerings

 

In June 2017, the Company issued debentures due three months from the date of issuance in two issuances (collectively, the “June Debentures”) and warrants to purchase an aggregate of 100,000 shares of common stock (33,333 warrants in the June 2, 2017 transaction and 66,667 in the June 22, 2017 transaction), which can be exercised at any time after nine months at an exercise price of $5.85 per share for the June 2, 2017 warrants and $5.70 per share for the June 22, 2017 warrants (collectively the “June Warrants”), to accredited investors for a purchase price of $1,902,700 and proceeds to the Company of $1.5 million. The Company recorded a discount on the debentures of $107,700 which has been fully amortized. As more fully discussed below, on July 17, 2017, the June Debentures were exchanged.

 

July 2017 Offerings

 

On July 17, 2017, the Company closed an offering of $4,136,862 aggregate principal amount of Original Issue Discount Debentures due October 17, 2017 (the “July Debentures”) and warrants to purchase an aggregate of 141,333 shares of common stock (the “July Warrants”) for consideration of $2,000,000 in cash and the exchange of the full $1,902,700 aggregate principal amount of the June Debentures. Under the Purchase Agreement, the Company was required to hold a stockholders’ meeting to obtain stockholder approval for at least a 1-for-8 reverse split of the Company’s common stock on or before September 20, 2017. Accordingly, the Company’s stockholders approved a reverse stock split on September 20, 2017 and the Company effected a 1-for-15 reverse stock split of its common stock on October 5, 2017, as further discussed in Note 1. The July Debentures were guaranteed by substantially all of the subsidiaries of the Company pursuant to a Subsidiary Guarantee in favor of the holders of the July Debentures. As more fully discussed below, on September 19, 2017, the July Debentures were exchanged for $6.4 million of exchange debentures.

 

The July Warrants are exercisable into shares of the Company’s common stock at any time from and after six months from the closing date at an exercise price of $5.63 per common share (subject to adjustment). The July Warrants will terminate five years after they become exercisable.

 

September 2017 Offerings

 

On September 19, 2017, the Company closed an offering of $2,604,000 principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 (the “New Debentures”) and three series of warrants to purchase an aggregate of 34,677,585 shares of the Company’s common stock (the “Series A Warrants,” the “Series B Warrants,” and the “Series C Warrants,” and collectively, the “September Warrants”). The offering was pursuant to the terms of a Securities Purchase Agreement, dated as of August 31, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $2,100,000 from the offering.

 

Also on September 19, 2017, the Company closed exchanges by which the holders of the Company’s July Debentures exchanged $4,136,862 principal amount of such debentures for $6,412,136 principal amount of new debentures on the same items as, and pari passu with, the New Debentures (the “September Exchange Debentures” and, together with the New Debentures, the “September Debentures”). The Company recorded non-cash interest expense in the amount of $1.0 million as a result of this exchange. All issuance amounts of the September Debentures reflect a 24% original issue discount.

 

The September Debentures contain customary affirmative and negative covenants. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the debentures. The September Debentures may be converted at any time into shares of the Company’s common stock. Originally, the September Debentures begin to amortize monthly commencing on October 1, 2017, and for the first three amortization dates, the amortization amount was $100,000. On October 19, 2017, the September Debentures were amended so that they began to amortize immediately. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of September Debentures in cash or, in lieu thereof, the conversion price of such September Debentures shall thereafter be 85% of the volume weighted average price at the time of conversion, but not less than the floor of $0.78 per share. In the event the Company does not elect to pay such amortization amounts in cash, each investor, in their sole discretion, may increase the conversion amount subject to the alternative conversion price by up to four times the amortization amount. On October 30, 2017, the Company entered into exchange agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Convertible Preferred Stock of the Company (the “Series I-2 Preferred Stock”), which is more fully discussed in Note 9. On February 8, 2018, $1,384,556 of the September Debentures were exchanged for 1,730.1 shares of Series I-2 Preferred Stock as more fully discussed in Note 9.

 

At March 31, 2018, the Series A Warrants are exercisable for an aggregate of 11,559,195 shares of the Company’s common stock. They are immediately exercisable and have a term of exercise equal to five years. The Series B Warrants are exercisable for an aggregate of 11,559,195 shares of the Company’s common stock and are exercisable for a period of 18 months commencing immediately. At March 31, 2018, the Series C Warrants are exercisable for an aggregate of 11,559,195 shares of the Company’s common stock, and have a term of five years provided such Series C Warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. The September Warrants have a fixed exercise price, subject to a floor of $0.78 per share. At December 31, 2017, the exercise price was $0.78 per share, which reflects adjustments made pursuant to their terms due to the down round provisions in the September Warrants. The September Warrants are subject to “full ratchet” and other customary anti-dilution protections.

 

The Company’s obligations under the September Debentures are secured by a security interest in all of the Company’s and its subsidiaries’ assets, pursuant to the terms of the Security Agreement, dated as of March 20, 2017.

 

During the year ended December 31, 2017, the Company realized approximately $15.7 million in proceeds from the issuances of these debentures and warrants. At December 31, 2017, the unamortized discounts were $16.4 million. These discounts represent original issue discounts, the relative fair value of the warrants issued with the debentures and the relative fair value of the beneficial conversion features of the debentures. During the three and nine months ended December 31, 2017, the Company recorded approximately $4.8 million and approximately $14.7 million of non-cash interest and amortization of debt discount expense primarily in connection with the debentures and warrants. See Note 9 for summarized information related to warrants issued and the activity during the twelve months ended December 31, 2017

 

March 2018 Offering

 

On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.

 

See Note 10 for summarized information related to warrants issued and the activity during the three months ended March 31, 2018 and 2017.

 

See Note 10 for a discussion of the dilutive effect of the outstanding debentures and warrants as of March 31, 2018.

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions
3 Months Ended
Mar. 31, 2018
Related Party Transactions [Abstract]  
Related Party Transactions

Note 7 – Related Party Transactions

 

In addition to the transactions discussed in Note 5, the Company had the following related party transactions during the three months ended March 31, 2018 and 2017:

 

In January and February of 2017, the Company received advances aggregating $3.6 million from Christopher Diamantis, a director of the Company. The advances, along with $0.5 million of previously accrued but unpaid interest, were due on demand, bearing interest at 10% per annum. The Company used the advances to pay the purchase price for the Hospital Assets and for general corporate purposes. On March 7, 2017, the Company issued a promissory note to Mr. Diamantis in the amount of $0.5 million (the “2017 Diamantis Note”) in connection with these advances received in 2017, plus accrued and unpaid interest of $0.5 million. In conjunction with the issuance of the 2017 Diamantis Note, the Company also issued to Mr. Diamantis warrants to purchase 27,667 shares of the Company’s common stock, exercisable at $15.00. the 2017 Diamantis Note was repaid on March 21, 2017 with the proceeds received from the issuance of the Convertible Debentures (see Note 6).

 

Alcimede billed the Company $0.1 million for consulting fees pursuant to a consulting agreement for each of the three months ended March 31, 2018 and 2017, respectively.

 

Monarch Capital, LLC (“Monarch”) billed the Company for consulting fees pursuant to a consulting agreement in the amount of $0.1 million for the three months ended March 31, 2017. The agreement expired on August 31, 2017. Michael Goldberg, a director of the Company up until his resignation effective April 24, 2017, is the Managing Director of Monarch.

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Lease Obligations
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Capital Lease Obligations

Note 8 – Capital Lease Obligations

 

The Company leases various assets under capital leases expiring through 2020 as follows. At March 31, 2018 (unaudited) and December 31, 2017, capital lease obligations consisted of the following:

 

    March 31, 2018     December 31, 2017  
Medical equipment   $ 4,686,736     $ 4,686,736  
Less accumulated depreciation     (4,010,259 )     (3,842,443 )
                 
Net   $ 676,477     $ 844,293  

 

During the fourth quarter of 2016, the Company did not meet its payment obligations under two of its capital lease agreements, which comprise substantially all of the Company’s aggregate capital lease obligations. In December 2016, the two counterparties to these lease agreements filed separate lawsuits against the Company and in January of 2017 default judgments were issued against the Company in the aggregate amount of $3.5 million, which includes default interest, late fees, penalties and other fees (see Note 12). As a result, the Company recognized additional interest expense of $0.6 million to recognize the additional obligations under these leases. As of March 31, 2018 the Company did not meet its obligations under these two capital leases, therefore, the aggregate future minimum rentals under capital leases are deemed to be current.

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Redeemable Preferred Stock
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Redeemable Preferred Stock

Note 9 – Redeemable Preferred Stock

 

The Company has 5,000,000 authorized shares of Preferred Stock at a par value of $0.01. Issuances of the Company’s Preferred Stock included as part of stockholders’ deficit are discussed in Note 10. The following is a summary of the issuances of the Company’s Redeemable Preferred Stock.

 

Series I-1 Convertible Preferred Stock

 

On October 30, 2017, the Company closed an offering of $4,960,000 stated value of its 4,960 shares of newly-authorized Series I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”). Each share of Series I-1 Preferred Stock has a stated value of $1,000. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of October 30, 2017 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Company received proceeds of $4.0 million from the offering. The Purchase Agreement gives the investors the right to participate in up to 50% of any offering of common stock or common stock equivalents by the Company. In the event of any such offering, the investors may also exchange all or some of their Series I-1 Preferred Stock for such new securities on an $0.80 stated value of Series I-1 Preferred Stock for $1.00 of new subscription amount basis. Each share of Series I-1 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-1 Preferred Stock. Upon the occurrence of certain Triggering Events, as defined in the Certificate of Designation of the Series I-1 Preferred Stock, the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-1 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

Series I-2 Convertible Preferred Stock

 

On October 30, 2017, the Company entered into exchange agreements with the holders of the September Debentures to provide that the holders may, from time to time, exchange their September Debentures for shares of a newly-authorized Series I-2 Preferred Stock. The exchange agreements permit the holders of the September Debentures to exchange specified principal amounts of the September Debentures on various closing dates starting on December 2, 2017. Any exchange is at the option of the holders. Each holder may reduce the principal amount of September Debentures exchanged on any particular closing date, or elect not to exchange any September Debentures at all on a closing date. If a holder does choose to exchange less principal amount of September Debentures, or no September Debentures at all, it can carry forward such lesser amount to a future closing date and then exchange more than the originally specified principal amount for that later closing date. For each $0.80 of principal amount of September Debenture surrendered to the Company at any closing date, the Company will issue the holder a share of Series I-2 Preferred Stock with a stated value of $1.00. Each share of Series I-2 Preferred Stock is convertible into shares of the Company’s common stock at any time at the option of the holder at a conversion price equal to the lesser of (i) $1.00, subject to adjustment, and (ii) 85% of the lesser of the volume weighted average market price of the common stock on the day prior to conversion or on the day of conversion. The conversion price is subject to “full ratchet” and other customary anti-dilution protections as more fully described in the Certificate of Designation of the Series I-2 Preferred Stock.

 

The Company’s board of directors has designated up to 11,271 shares of the 5,000,000 authorized shares of preferred stock as the Series I-2 Preferred Stock. Each share of Series I-2 Preferred Stock has a stated value of $1,000. Upon the occurrence of certain Triggering Events (as defined in the Certificate of Designation of the Series I-2 Preferred Stock), the holder shall, in addition to any other right it may have, have the right, at its option, to require the Company to either redeem the Series I-2 Preferred Stock in cash or in certain circumstance in shares of common stock at the redemption prices set forth in the Certificate of Designation.

 

On February 9, 2018, the holders exercised their right to exchange a portion of the September Debentures for shares of the Series I-2 Preferred Stock for the first time. On that date, the holders elected to exchange an aggregate of $1,384,556 principal amount of September Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Preferred Stock.

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Deficit
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Stockholders' Deficit

Note 10 – Stockholders’ Deficit

 

Preferred Stock

 

The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of March 31, 2018, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock, shares of Series I-2 Preferred Stock, 215 shares of its Series G Preferred Stock, 60 shares of its Series H Preferred Stock and 1,750,000 shares of its Series F Convertible Preferred Stock.

 

The rights of Preferred F, G, H, I-1 and I-2 shares are disclosed in the 2017 10K. There are no changes in these rights.

 

Common Stock

 

The Company had 499,992,133 and 19,750,844 shares of common stock issued and outstanding at March 31, 2018 and December 31, 2017, respectively. The Company issued 480,249,156 shares of its common stock during the three months ended March 31, 2018 as follows:

 

During the three months ended March 31, 2018, the Company issued an aggregate of 333,315,823 shares of its common stock upon conversion of $3.1 million of the principal amount of the March 2017 Debentures.

 

During the three months ended March 31, 2018, the Company issued 75,600,000 shares of common stock upon exercise of 119,746,776 March 2017 Series B Warrants, on a cashless basis.

 

During the three months ended March 31, 2018 the Company issued an aggregate of 71,333,333 shares of restricted stock as described below.

 

Restricted Stock

 

On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 181,933 shares of restricted common stock of the Company. The grants fully vest on the first anniversary of the date of grant, subject to the grantee’s continued status as an employee or director, as the case may be, on the vesting date. During the three months ended March 31, 2018, 2,493 shares of the restricted stock were forfeited by their terms and returned to treasury.

 

On March 6, 2018, the Company issued an aggregate of 71,333,333 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board. The grants fully vested immediately. The Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $.0067 per share.

 

Stock Options

 

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2018:

 

    Number of
options
    Weighted-
average 
exercise 
price
    Weighted-
average contractual
term (Yrs.)
 
Outstanding at December 31, 2017     38,478     $ 2,072.75       8.33  
Granted     -       -          
Expired     -       -          
Forfeit             -          
Exercised     -       -          
Outstanding at March 31, 2018     38,478     $ 2,072.75       8.33  
Exercisable at March 31, 2018     32,922     $ 2,373.16          

 

As of March 31, 2018, the Company had approximately $0.1 million of unrecognized compensation cost related to stock options granted under the Company’s 2007 Equity Plan, which is expected to be recognized over a weighted-average period of 0.94 years.

 

Warrants

 

The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock. The following summarizes the information related to warrants issued and the activity during the three months ended March 31, 2018:

 

    Number of warrants     Weighted
average 
exercise price
 
Balance at December 31, 2017     2,176,403,218     $ 0.0444  
Warrants issued during the period     -     $ -  
Increases due to dilution     13,411,976,939     $ -  
Warrants exercised during the period     (119,746,776 )   $ 0.0038  
Warrants expired during the period     -     $ -  
Balance at March 31, 2018     15,468,633,381     $ 0.0062  

 

Basic and Diluted Loss per Share

 

Basic loss per share excludes dilution and is computed by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. For the three months ended March 31, 2018 and 2017, basic loss per share is the same as diluted loss per share.

 

Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2018 and 2017, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

 

    As of March 31,  
    2018     2017  
Warrants     15,468,633,381       30,595,665  
Convertible preferred stock     893,098,291       595,556  
Convertible debt     781,485,502       10,007,141  
Stock options     38,478       709,025  
      17,143,255,652       41,907,387  

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Disclosure of Cash Flow Information
3 Months Ended
Mar. 31, 2018
Supplemental Cash Flow Elements [Abstract]  
Supplemental Disclosure of Cash Flow Information

Note 11 – Supplemental Disclosure of Cash Flow Information

 

The supplemental cash flow information for the three months ended March 31, 2018 and 2017 (unaudited) is as follows:

 

    Three Months Ended March 31,  
    2018     2017  
Cash paid for interest   $ 24,791     $ 881,457  
Cash paid for income taxes   $ -     $ 296,313  
                 
Non-cash investing and financing activities:                
Exchange of I-2 preferred stock for convertible debentures   $ 1,384,556     $ 2,695,760  
Exchange of convertible debentures for convertible debentures and warrants   $ -     $ 2,464,500  
Note payable and warrants settled through issuance of common stock   $ -     $ 440,000  
Debentures converted into common stock   $ 3,056,675     $ 486,032  
Conversions of preferred stock into common stock   $ -     $ 6,280,000  
Common stock issued in cashless excercise of warrants   $ 756,000     $ -  

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 12 – Commitments and Contingencies

 

Legal Matters

 

From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.

 

Biohealth Medical Laboratory, Inc, and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans.

 

The Company’s Epinex Diagnostics Laboratories, Inc. subsidiary was sued in a California state court by two former employees who alleged that they were wrongfully terminated, as well as for a variety of unpaid wage claims. The parties entered into a settlement agreement of this matter on July 29, 2016 for approximately $0.2 million, and the settlement was consummated on August 25, 2016. In October of 2016, the plaintiffs in this matter filed a motion with the court seeking payment for attorneys’ fees in the approximate amount of $0.7 million. On March 24, 2017, the court granted plaintiffs’ motion for payment of attorneys’ fees in the amount of $0.3 million, and the Company has accrued this amount in its condensed consolidated financial statements. Additionally, the Company is seeking indemnification for these amounts from Epinex Diagnostics, Inc. (“EDI”), the seller of Epinex Diagnostic Laboratories, Inc. (“EDL”), pursuant to a Stock Purchase Agreement entered into by and among the parties.

 

In February 2016, the Company received notice that the Internal Revenue Service (the “IRS”) placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, in the amount of $5.0 million. The Company paid $0.1 million toward its 2014 tax liability on March 2016. The Company filed its 2015 Federal tax return on March 15, 2016 and the accompanying election to carryback the reported net operating losses was filed in April 2016. On August 24, 2016, the lien was released, and on September of 2016 the Company received a refund from the IRS in the amount of $1.9 million. In November of 2016, the IRS commenced an audit of the Company’s 2015 Federal tax return. The Company is currently unable to predict the outcome of the audit or any liability to the Company that may result from the audit.

 

On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $0.9 million, including penalties and interest. On January 25, 2017, the Company paid the DOR $250,000 as partial payment on this liability, and in February 2017 the Company entered into a Stipulation Agreement with the DOR which allows the Company to make monthly installment payments of $35,000 until February 2018 and negotiate a new payment agreement then, if the balance of $0.3 million cannot be satisfied in a lump sum. If at any time during the Stipulation period the Company fails to timely file any required tax returns with the DOR or does not meet the payment obligations under the Stipulation Agreement, the entire amount due will be accelerated. The Company has managed to pay some but not all of the required payments and $0.5 million remains outstanding to the DOR at March 31, 2018.

 

In December of 2016, TCS-Florida, L.P. (“Tetra”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with Tetra (see Note 8). On January 3, 2017, Tetra received a Default Judgment against the Company in the amount of $2.6 million, representing the balance owed on the leases, as well as additional interest, penalties and fees. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. In January and February of 2017, the Company made payments to Tetra in connection with this judgment aggregating to $0.7 million, and on February 15, 2017, the Company entered into a forbearance agreement with Tetra whereby the remaining $1.9 million due will be paid in 24 equal monthly installments. Payments commenced on May 1, 2017 and a total of $1.1 million remains outstanding to Tetra at March 31, 2018. The Company and Tetra have agreed to dispose of certain equipment and proceeds from the sale of surplus equipment have been applied to the outstanding balance.

 

In December of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 8). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $1.0 million, representing the balance owed on the lease, as well as additional interest, penalties and fees. The Company has recognized this amount in its consolidated financial statements as of December 31, 2016. On February 8, 2017, a Stay of Execution was filed and under its terms the balance due will be paid in variable monthly installments through January of 2019, with an implicit interest rate of 4.97%. The Company and DeLage have now disposed of certain equipment and reduced the balance owed to DeLage. The reduced balance remains outstanding at March 31, 2018.

 

On December 7, 2016, the holders of the Tegal Notes (see Note 5) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of $0.4 million, including accrued interest. A request for entry of default judgment was filed on January 24, 2017. A judgment was entered against the Company on April 23, 2018. These amounts remain outstanding at March 31, 2018.

 

In November 2017 a former shareholder of Genomas filed suit against the Company for payment of a $200,000 Note payable by the subsidiary Genomas. This Note is recorded in the financial statements of the subsidiary and is not payable directly from the Company. Other claims were included in the suit which the Company believes to be frivolous and without merit. The Company has filed a motion to dismiss certain of the claims. The Company has made a $100,000 payment and agreed to a schedule of payments to discharge the remaining balance of the Note. The parties have agreed to dismiss the legal action.

 

The Company and subsidiaries have been party to suits filed by landlords for late payment of rent and have either settled these claims or are in process of agreeing to settlement. The Company does not deem these actions to be material.

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information
3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Segment Information

Note 13 – Segment Information

 

Operating segments are defined under U.S. GAAP as components of an enterprise for which discrete financial information is available and are evaluated regularly by the enterprise’s chief operating decision maker in determining how to allocate resources and assess performance. The Company operates in two reportable business segments:

 

  Clinical Laboratory Operations, which specializes in providing urine and blood toxicology and pain medication testing to physicians, clinics and rehabilitation facilities in the United States.
     
  Hospital Operations, which reflects the purchase of the Hospital Assets (see Note 3) and the operations of Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center.

 

The Company’s Corporate expenses reflect consolidated company wide support services such as finance, legal counsel, human resources, and payroll.

 

The Company’s Decision Support and Informatics segment and its Supportive Software Solutions segment are now included in discontinued operations as they have been classified as held for sale as of March 31, 2018. The accounting policies of the reportable segments are the same as those described in Note 1. Selected financial information for the Company’s operating segments is as follows:

 

    Three Months Ended March 31,  
    2018     2017  
Net revenues – External                
Clinical Laboratory Operations   $ 45,586     $ 684,265  
Hospital Operations     1,556,075       -  
    $ 1,601,661     $ 684,265  
                 
(Loss) income from operations                
Clinical Laboratory Operations   $ (756,083 )   $ (1,292,275 )
Hospital Operations     (1,472,600 )     (467,316 )
Corporate     (1,483,341 )     (1,804,517 )
Eliminations     -       7,851  
    $ (3,712,024 )   $ (3,556,257 )
Depreciation and amortization                
Clinical Laboratory Operations   $ 295,474     $ 434,468  
Hospital Operations     37,728       -  
Corporate     314       312  
Eliminations     -       (7,851 )
    $ 333,515     $ 426,929  
Capital expenditures                
Clinical Laboratory Operations   $ -     $ (100,382 )
Hospital Operations     -       1,090,922  
    $ -     $ 990,540  

 

***` Intersegment revenues are eliminated in consolidation.

 

    March 31, 2018     December 31, 2017  
Total assets                
Clinical Laboratory Operations   $ 1,019,946     $ 1,503,520  
Hospital Operations     2,788,059       2,549,504  
Corporate     3,510,297       3,436,773  
Assets of AMSG and HTS classified as held for sale     243,963       255,566  
Eliminations     (1,424,496 )     (1,454,570 )
    $ 6,137,769     $ 6,290,794  

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Recently Issued Accounting Standards
3 Months Ended
Mar. 31, 2018
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Standards

Note 14 – Recently Issued Accounting Standards

 

The following table provides a brief description of recently issued accounting standards:

 

Title and reference   Prescribed 
Effective Date
  Commentary
ASU No. 2015-11, “Inventory” (Topic 330): Simplifying the Measurement of Inventory.   Fiscal years beginning after December 15, 2016 and for interim periods therein.   In July 2015, the FASB issued ASU No. 2015-11, “Inventory” (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”). ASU 2015-11 simplifies the measurement of inventory by requiring certain inventory to be subsequently measured at the lower of cost and net realizable value. The amendments in this guidance are effective for fiscal years beginning after December 15, 2016 and for interim periods therein and did not have a significant impact on the Company’s consolidated financial statements upon adoption.
         
ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”   Fiscal years beginning after December 15, 2017 and for interim periods therein.   In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most recent current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also specifies the accounting for certain incremental costs of obtaining a contract and costs to fulfill a contract with a customer. Entities have the option of applying either a full retrospective approach to all periods presented or a modified approach that reflects differences prior to the date of adoption as an adjustment to equity. The Company has adopted this guidance for this financial statement.
         
ASU No. 2014-15, “Presentation of Financial Statements - Going Concern” (Subtopic 205-40): Disclosure of Uncertainty about an Entity’s Ability to Continue as a Going Concern.   Fiscal years, and interim periods within those years, beginning on or after December 15, 2016, with early adoption permitted.   In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern” (Subtopic 205-40): Disclosure of Uncertainty about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 provides guidance that establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and setting rules for how this information should be disclosed in the financial statements. Adoption of this new standard did not have a significant impact on the Company’s consolidated financial statements. See Note 1 regarding management’s current disclosures regarding the Company’s ability to continue as a going concern.

 

ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes”   Fiscal years beginning on or after December 15, 2016, with early adoption permitted.   In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). Topic 740, Income Taxes, requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. Deferred tax liabilities and assets that are not related to an asset or liability for financial reporting are classified according to the expected reversal date of the temporary difference. To simplify the presentation of deferred income taxes, the amendments in ASU 2015-17 require that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Adoption of ASU 2015-17 did not have a material impact on the Company’s consolidated financial statements.
         
Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842)”    Annual and interim periods within the annual period beginning after December 15, 2018.   In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The amendments in this update create Topic 842, Leases, and supersede the leases requirements in Topic 840, Leases. Topic 842 specifies the accounting for leases. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. The main difference between Topic 842 and Topic 840 is the recognition of lease assets and lease liabilities for those leases classified as operating leases under Topic 840. Topic 842 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years for public business entities. Early application of the amendments in ASU 2016-02 is permitted. The Company has not yet determined the impact that adoption of ASU 2016-02 will have on its consolidated financial statements.
         
ASU No. 2017-11, “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)” (“ASU 2017-11”)   Fiscal years beginning on or after December 15, 2018, with early adoption permitted.   The Company adopted this amendment as of its period ended June 30, 2017 (see Note 1)

 

ASU No. 2017-12, “Derivatives and Hedging (Topic 815)” (“ASU 2017-12”)   For public business entities, the amendments in this ASU 2017-12 are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption permitted in any interim period after issuance of this ASU.   The amendments in ASU 2017-12 (“Update”) provide recognition and presentation guidance for qualifying hedges. The amendments in this Update more closely align the results of cash flow and fair value hedge accounting with risk management activities through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results in the financial statements. The amendments address specific limitations in current U.S. GAAP by expanding hedge accounting for both nonfinancial and financial risk components and by refining the measurement of hedge results to better reflect an entity’s hedging strategies. Thus, the amendments will enable an entity to report more faithfully the economic results of hedging activities for certain fair value and cash flow hedges and will avoid mismatches in earnings by allowing for greater precision when measuring change in fair value of the hedged item for certain fair value hedges. Additionally, by aligning the timing of recognition of hedge results with the earnings effect of the hedged item for cash flow and net investment hedges, and by including the earnings effect of the hedging instrument in the same income statement line item in which the earnings effect of the hedged item is presented, the results of an entity’s hedging program and the cost of executing that program will be more visible to users of financial statements. Additionally, the amendments in this Update should ease the operational burden of applying hedge accounting by allowing more time to prepare hedge documentation and allowing effectiveness assessments to be performed on a qualitative basis after hedge inception. The Company has not yet determined the impact that adoption of ASU 2017-12 will have on its consolidated financial statements.

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations
3 Months Ended
Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations

Note 15 – Discontinued Operations

 

On July 12, 2017, the Company announced plans to spin off its Advanced Molecular Services Group (“AMSG”) and in the third quarter of 2017 the Company’s Board of Directors voted unanimously to spin off the Company’s wholly-owned subsidiary, Health Technology Solutions, Inc. (“HTS”), as independent publicly traded companies by way of tax-free distributions to the Company’s stockholders. Completion of these spinoffs is expected to occur in the second half of 2018. The Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead off two. The spinoffs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission, and consents, including under various funding agreements previously entered into by the Company. A record date to determine those stockholders entitled to receive shares in the spinoffs should be approximately 30 to 60 days prior to the dates of the spinoffs. The strategic goal of the spinoffs is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In addition, after the spinoffs, each company will provide a distinct and targeted investment opportunity.

 

The Company has reflected the amounts relating to AMSG and HTS as disposal groups classified as held for sale and included in discontinued operations in the Company’s accompanying consolidated financial statements. Prior to being classified as held for sale, AMSG had been included in the Decision Support and Informatics division, except for the Company’s subsidiary, Alethea Laboratories, Inc., which had been included in the Clinical Laboratories division and HTS had been included in the Company’s Supportive Software Solutions division. The segment disclosures included in our results of operations no longer include amounts relating to AMSG and HTS following the reclassification to discontinued operations except that the inter-company debt from HTS to the Company of $14,461,338 and from AMSG of $7,181,685 has not been separated. The Company hopes to complete the spin off(s) in a manner to permit it to recognize these amounts as investment in the divisions.

 

Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:

 

AMSG Assets and Liabilities:

 

    March 31, 2018     December 31, 2017  
    (unaudited)     (unaudited)  
Cash   $ 5,314     $ 9,273  
Accounts receivable, net     576       19,022  
Prepaid expenses and other current assets     25,477       25,477  
Current assets classified as held for sale   $ 31,367     $ 53,772  
                 
Property and equipment, net   $ -     $ -  
Deposits     -       -  
Non-current assets classified as held for sale   $ -     $ -  
                 
Accounts payable (includes related parties)   $ 674,425     $ 671,561  
Accrued expenses     388,666       375,165  
Current portion of notes payable     228,421       249,589  
Current liabilities classified as held for sale   $ 1,291,512     $ 1,296,315  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

HTS Assets and Liabilities:

 

    March 31, 2018     December 31, 2017  
    (unaudited)     (unaudited)  
Cash   $ 1,727     $ 8,281  
Accounts receivable, net     166,774       160,715  
Prepaid expenses and other current assets     22,183       3,964  
Current assets classified as held for sale   $ 190,684     $ 172,960  
                 
Property and equipment, net   $ 15,883     $ 21,078  
Deposits     6,029       7,756  
Non-current assets classified as held for sale   $ 21,912     $ 28,834  
                 
Accounts payable (includes related parties)   $ 500,235     $ 407,404  
Accrued expenses     271,245       269,135  
Current liabilities classified as held for sale   $ 771,480     $ 676,539  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

Consolidated Discontinued Operations Assets and Liabilities:

 

    March 31, 2018     December 31, 2017  
    (unaudited)     (unaudited)  
Cash   $ 7,041     $ 17,554  
Accounts receivable, net     167,350       179,737  
Prepaid expenses and other current assets     47,660       29,441  
Current assets classified as held for sale   $ 222,051     $ 226,732  
                 
Property and equipment, net   $ 15,883     $ 21,078  
Deposits     6,029       7,756  
Non-current assets classified as held for sale   $ 21,912     $ 28,834  
                 
Accounts payable (includes related parties)   $ 1,174,660     $ 1,078,965  
Accrued expenses     659,911       644,300  
Current portion of notes payable     228,421       249,589  
Current liabilities classified as held for sale   $ 2,062,992     $ 1,972,854  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

Major line items constituting loss from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2018 and 2017 consisted of the following:

 

AMSG Income (Loss) from Discontinued Operations:

 

    Three Months Ended March 31,  
    2018     2017  
    (unaudited)     (unaudited)  
Revenue from services   $ 33,685     $ 176,578  
Cost of services     16,138       769  
Gross profit     17,547       175,809  
Operating expenses     176,202       526,533  
Other income/expenses     (800,197 )     (2,978 )
Income/(Loss) from discontinued operations   $ 641,542     $ (347,746 )

 

HTS Income (Loss) from Discontinued Operations:

 

    Three Months Ended March 31,  
    2018     2017  
    (unaudited)     (unaudited)  
Revenue from services   $ 355,147     $ 315,270  
Cost of services     34,218       46,704  
Gross profit     320,929       268,566  
Operating expenses     538,199       987,111  
Other income/expenses     2,478       -  
Income/(Loss) from discontinued operations   $ (219,748 )   $ (718,545 )

 

Consolidated Income/(Loss) from Discontinued Operations:

 

    Three Months Ended March 31,  
    2018     2017  
    (unaudited)     (unaudited)  
Revenue from services   $ 388,832     $ 491,848  
Cost of services     50,356       47,473  
Gross profit     338,476       444,375  
Operating expenses     714,402       1,513,645  
Other income (expenses)     (797,719 )     (2,978 )
Income/(Loss) from discontinued operations   $ 421,793     $ (1,066,292 )

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Financial Instruments and Fair Value
3 Months Ended
Mar. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments and Fair Value

Note 16 – Derivative Financial Instruments and Fair Value

 

In accordance with ASC 820, “Fair Value Measurements and Disclosures,” the Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

  Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date.
     
  Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets).
     
  Level 3 applies to assets or liabilities for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including our own assumptions.

 

The estimated fair value of financial instruments is determined by the Company using available market information and valuation methodologies considered to be appropriate. At March 31, 2018 and December 31, 2017, the carrying value of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to their short-term nature.

 

The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and March 31, 2018:

 

    Level 1     Level 2     Level 3     Total  
As of December 31, 2017:                                
Embedded conversion options   $ -     $ -     $ 1,577,025     $ 1,577,025  
Common stock warrants     -       -       10,858,225       10,858,225  
Total   $ -     $ -     $ 12,435,250     $ 12,435,250  
                                 
As of March 31, 2018:                                
Embedded conversion options   $ -     $ -     $ 1,005,188     $ 1,005,188  
Common stock warrants     -       -       151,418,187       151,418,187  
Total   $ -     $ -     $ 152,423,375     $ 152,423,375  

 

For the three months ended March 31, 2018, total loss realized on instruments valued using Level 3 valuations was $140.0 million.

 

The Company utilized the following methods to value its derivative liabilities for the three months ended March 31, 2018: (i) for embedded conversion options valued at $1.0 million, the Company determined the fair value by comparing the discounted conversion price per share (85% of market price) multiplied by the number of shares issuable at the balance sheet date to the actual price per share of the Company’s common stock multiplied by the number of shares issuable at that date with the difference in value recorded as a liability; (ii) for warrants valued at $151.4 million, the Company determined the fair value by using a binomial model and monte carlo simulations; and (iii) for warrants valued at $0.1 million and embedded conversion options valued at $0.2 million, the Company determined the fair value using the Black-Scholes option pricing model. All inputs for the derivative liabilities are observable and, therefore, there is no sensitivity in the valuation to unobservable inputs.

 

The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2018:

 

Balance at December 31, 2017   $ 12,435,250  
Loss on change in fair value included in net loss     139,779,232  
Issuance of convertible debt     208,893  
Balance at March 31, 2018   $ 152,423,375  

 

The increase in the fair value of the derivative liabilities is primarily due to the increase in the Company’s quoted trading price from $0.003 on December 31, 2017 to $0.009 on March 31, 2018.   Because the exercise price of a significant portion of the Company’s outstanding warrants are currently exercisable at $0.0038 per share, and subject to further reduction in their exercise price in the event of further issuances at lower than $0.0038 per share, the fair value of the warrants increased significantly during the three months ended March 31, 2018.

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events
3 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events

Note 17 – Subsequent Events

 

Common Stock

 

Outstanding shares as of June 18, 2018: 1,110,232,133

 

Since the period ended March 31, 2018, the Company has issued 610,240,000 shares of common stock through June 18, 2018 as follows:

 

The Company has issued 324,000,000 shares of its common stock upon conversion of $1,643,175 of the principal amount of the March 2017 Debentures.

 

The Company issued 286,240,000 shares of common stock to the holders of 381,405,434 March 2017 Series B warrants that were exercised on a cashless basis.

 

On May 9, 2018, the Company held a Special Meeting of Stockholders, in part, to approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares. The proposal was approved and on May 9, 2018 the Company filed an amendment to its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares.

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Basis of Presentation (Policies)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the 2017 audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2018. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC, and therefore omit or condense certain footnotes and other information normally included in consolidated interim financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). All material intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) considered necessary for the fair presentation of the financial position and results of operations and cash flows for the interim periods reported herein. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

During the three months ended March 31, 2018 and 2017, comprehensive loss was equal to the net loss amounts presented in the accompanying condensed consolidated statements of operations. In addition, certain prior year balances have been reclassified to conform to the current presentation.

 

Based on new FASB rules for revenue recognition that became effective January 1, 2018, bad debts are now treated similar to contractual adjustments and directly reduce sales revenue. In an abundance of caution through the startup period of our Oneida hospital the Company has reserved a bad debt number of $591,323, which, when set against sales revenues of $2,191,983 means the Company is reporting net revenues for the first quarter of 2018 of $1.6 million. The Company will continue to review its provision for bad debt.

Reclassification

Reclassification

 

The Company has reclassified certain amounts in the 2017 condensed consolidated financial statements to be consistent with the 2018 presentation. These principally relate to classification of certain revenues, cost of revenues and related segment data, as well as balance sheet classifications to assets and liabilities held for sale. Reclassifications relating to the discontinued operations of AMSG and HTS are described further in Note 15. The reclassifications had no impact on operations or cash flows for the three months ended March 31, 2017. The Company also reclassified derivative liability previously reported in 2017 as long term to current liability.

Reverse Stock Splits

Reverse Stock Splits

 

On February 7, 2017, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017 and on September 21, 2017, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-15 reverse stock split effective October 5, 2017 (the “Reverse Stock Splits”). The stockholders of the Company had approved these amendments to the Company’s Certificate of Incorporation on December 22, 2016 for the February 7, 2017 reverse stock split and on September 20, 2017 for the October 5, 2017 reverse stock split. In both cases, the Company’s stockholders had granted authorization to the Board of Directors to determine in its discretion the specific ratio, subject to limitations, and the timing of the reverse splits within certain specified effective dates.

 

As a result of the Reverse Stock Splits, every 30 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on February 7, 2017 and every 15 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock, par value $0.01 per share, on October 5, 2017. In addition, the conversions and exercise prices of all of the Company’s outstanding preferred stock, common stock purchase warrants, stock options, restricted stock, equity incentive plans and convertible notes payable were proportionately adjusted at the 1:30 reverse split ratio and again at the 1:15 reverse split ratio in accordance with the terms of such instruments. In addition, proportionate voting rights and other rights of common stockholders were not affected by the Reverse Stock Splits, other than as a result of the rounding up of fractional shares in the February reverse split and the payment of cash in lieu of fractional shares in the October reverse split, as no fractional shares were issued in connection with the Reverse Stock Splits.

 

The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 3,000,000,000 shares of common stock and 5,000,000 shares of preferred stock were also unaffected by the Reverse Stock Splits. On May 9, 2018, the Company amended its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares (see note 17).

 

All share, per share and capital stock amounts for all periods presented have been restated to give effect to the Reverse Stock Splits.

Adoption of ASU 2017-11

Adoption of ASU 2017-11

 

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.

 

Under current GAAP, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity’s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity’s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.

 

The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and embedded conversion options with down round features are no longer bifurcated.

 

For entities that present EPS in accordance with Topic 260, and when the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.

 

Those amendments in Part 1 of this Update are a cost savings relative to current GAAP. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basis of the existence of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic value of the feature only when the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.

 

The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.

 

For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part 1 of this Update should be applied in either of the following ways: 1. Retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is effective; or 2. Retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10.

 

The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect.

 

The Company has determined that this amendment had a material impact on its consolidated financial statements and has early adopted this accounting standard update. The cumulative effect of the adoption of ASU 2017-11 resulted in the reclassification of the derivative liability recorded of $56 million and the reversal of $41 million of interest expense recorded in the Company’s first fiscal quarter of 2017. The remaining $16 million was offset to additional paid in capital (discount on convertible debenture). Additionally, the Company recognized a deemed dividend from the trigger of the down round provision feature of $53.3 million. A $51 million deemed dividend was recorded retrospectively as of the beginning of the issuance of the debentures issued in March 2017 where the initial derivative liability was recorded as a result of the down round provision feature.

Going Concern

Going Concern

 

The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has recently accumulated significant losses and has negative cash flows from operations, and at March 31, 2018, had a working capital deficit of $174.8 million and a stockholders’ deficit of $183.9 million. In addition, the Company’s cash position as of the date of this report is critically deficient, critical payments, including capital lease obligations are not being made in the ordinary course of business and certain indebtedness, including accrued interest and extension fees, in the amount of $7.8 million matures on May 30, 2018, that the Company does not have the financial resources to satisfy. These matters raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report.

 

The Company continues to consider efficiencies and is currently using one laboratory for the majority of its toxicology diagnostics thereby reducing the number of employees and associated operating expenses, in order to reduce costs. In addition, the Company received approximately $2 million in cash from the issuances of debentures during the first quarter of 2018 (see Note 6).

 

In July 2017, the Company announced that it plans to spin off its Advanced Molecular Services Group (“AMSG”) and in the third quarter of 2017, the Company’s Board of Directors voted unanimously to spin off Health Technology Solutions, Inc., a wholly-owned subsidiary (“HTS”), as independent publicly traded companies by way of tax-free distributions to its shareholders. Completion of these spinoffs is expected to occur during the second half of 2018. Our Board of Directors is currently considering if AMSG and HTS would be better as one combined spinoff instead of two. The spin offs are subject to numerous conditions, including effectiveness of Registration Statements on Form 10 to be filed with the Securities and Exchange Commission and consents, including under various funding agreements previously entered into by the Company. The intent of the spinoffs of AMSG and HTS is to create three (or two) public companies, each of which can focus on its own strengths and operational plans. In accordance with ASC 205-20 and having met the criteria for “held for sale”, the Company has reflected amounts relating to AMSG and HTS as disposal groups classified as held for sale and included as part of discontinued operations. AMSG and HTS are no longer included in the segment reporting following the reclassification to discontinued operations. The discontinued operations of AMSG and HTS are described further in Note 15.

 

The Company also announced that the Big South Fork Medical Center received CMS regional office licensure approval and opened on August 8, 2017. In addition, on January 31, 2018, the Company announced that it had entered into a definitive asset purchase agreement to acquire an acute care hospital in Jamestown, Tennessee known as Tennova Healthcare – Jamestown. The acquisition was completed on June 1, 2018. The Company may amend its current revenue recognition policy and percentage for the hospitals when payments are received to support amended revenue recognition methodologies. Therefore, the Company expects that these hospitals will continue to provide additional revenue and cash flow sources.

 

There can be no assurance that the Company will be able to achieve its business plan, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to significantly reduce its operating costs, increase its revenues and eventually regain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Recent Events

Recent Events

 

Asset Purchase Agreement to Acquire Acute Care Hospital

 

On January 31, 2018, the Company entered into an asset purchase agreement (the “Purchase Agreement”) to acquire certain assets related to an acute care hospital located in Jamestown, Tennessee. The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Center, Inc., and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services. The acquisition also included a separate physician practice which will now operate under Rennova as Mountain View Physician Practice, Inc.

 

Net annual revenues in recent years have been approximately $15 million with government payers including Medicare and Medicaid accounting for in excess of 60% of the payor mix. Rennova does not expect this payer mix to change significantly in the near future. The hospital was acquired for approximately $635,000 from Community Health Systems, Inc. Diligence, legal and other costs associated with the acquisition are estimated to be approximately $500,000 meaning the total cost of acquisition to the Company is approximately $1,100,000.

 

Jamestown is located 38 miles from the Company’s existing hospital, the Big South Fork Medical Center, which is located in Oneida, Tennessee.

 

Proposals Submitted to Stockholders

 

On May 9, 2018, the Company held a Special Meeting of Stockholders to (1) approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares, (2) approve the Company’s new 2018 Incentive Award Plan, and (3) authorize an adjournment of the Special Meeting if necessary.

 

Proposal 1 was approved while proposal 2 was rejected. Proposal 3 was not voted on.

 

Accounts Receivable Financing

 

As previously announced, on March 31, 2016 the Company entered into an agreement to sell certain of its accounts receivable. The agreement was originally scheduled to mature on March 31, 2017, which date was extended to March 31, 2018 by an amendment on March 24, 2017. On April 2, 2018, the Company, the purchaser and Christopher Diamantis, a Director of the Company, as guarantor, entered into a second amendment to extend further the Company’s obligation to May 30, 2018. In connection with this further extension, the purchaser received a fee of $100,000. As of May 30, 2018, the Company has not made a payment under this agreement and the full balance is now payable.

 

Share Issuances

 

On March 6, 2018, the Board of Directors, based on the recommendation of the Compensation Committee, approved grants to employees and directors of an aggregate of 71,333,331 shares of common stock, including the following to the directors of the Company:

 

Seamus Lagan 26,666,667 shares
Dr. Kamran Ajami 3,333,333 shares
John Beach 3,333,333 shares
Gary L. Blum 3,333,333 shares
Christopher Diamantis 3,333,333 shares
Trevor Langley 3,333,333 shares

 

The shares were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), as a transaction by an issuer not involving a public offering.

 

On February 9, 2018, holders of the Company’s Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019 exercised their right for the first time under exchange agreements (the “Exchange Agreements”) entered into with the Company by electing to exchange an aggregate of $1,384,556 principal amount of such Debentures and the Company issued an aggregate 1,730.7 shares of its Series I-2 Convertible Preferred Stock.

 

Such shares of Preferred Stock were issued in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act.

 

NanoVibronix

 

On February 14, 2018, the Company entered into a Common Stock Purchase Agreement with two investors pursuant to which the Company agreed to sell an aggregate of 200,000 shares of common stock of NanoVibronix, Inc. owned by the Company at a purchase price of $4.00 per share. The Company had acquired the shares as a result of an investment originally made in 2011.

 

March 2018 Offering

 

On March 5, 2018, the Company closed an offering of $2,480,000 aggregate principal amount of Senior Secured Original Issue Discount Convertible Debentures due September 19, 2019. The Company received proceeds of $2,000,000 in the offering. The terms of these Debentures are the same as those issued under the previously-announced Securities Purchase Agreement, dated as of August 31, 2017. These Debentures may also be exchanged for shares of the Company’s Series I-2 Convertible Preferred Stock under the terms of the Exchange Agreements.

 

The Debentures were issued in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act and by Rule 506 of Registration D promulgated thereunder as a transaction by an issuer not involving a public offering.

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accounts Receivable (Tables)
3 Months Ended
Mar. 31, 2018
Receivables [Abstract]  
Schedule of Accounts Receivable

Accounts receivable at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

    March 31, 2018     December 31, 2017  
Accounts receivable - laboratory services   $ 1,302,579     $ 1,478,451  
Accounts receivable – hospital     11,783,802       8,593,747  
Total accounts receivable     13,086,381       10,072,198  
Less:                
Allowance for discounts - laboratory services     (1,150,800 )     (1,177,054 )
Allowance for discounts - hospital     (9,307,852 )     (6,936,429 )
Allowance for bad debts     (1,525,972 )     (987,403 )
Accounts receivable, net   $ 1,101,758     $ 971,312  

XML 35 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2018
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

    March 31, 2018     December 31, 2017  
Medical equipment   $ 713,799     $ 696,195  
Building     1,359,484       1,359,472  
Equipment     437,029       476,548  
Equipment under capital leases     4,686,736       4,686,736  
Furniture     232,495       222,824  
Leasehold improvements     1,303,131       1,303,131  
Vehicles     196,534       196,534  
Computer equipment     221,237       226,441  
Software     333,853       631,033  
      9,484,297       9,798,914  
Less accumulated depreciation     (7,122,072 )     (7,103,474 )
Property and equipment, net   $ 2,362,225     $ 2,695,440  

XML 36 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2018
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses at March 31, 2018 (unaudited) and December 31, 2017 consisted of the following:

 

    March 31, 2018     December 31, 2017  
Commissions payable   $ 13,345     $ 24,470  
Accrued payroll and related liabilities     1,419,779       897,088  
Accrued interest     1,402,498       2,636,057  
Other accrued expenses     1,296,146       1,409,790  
Total accrued expenses   $ 4,131,767     $ 4,967,405  

XML 37 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes Payable (Tables)
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Schedule of Notes Payable

Notes Payable – Third Parties

 

    March 31, 2018     December 31, 2017  
Loan payable under prepaid forward purchase contract   $ 5,000,000     $ 5,000,000  
                 
Loan payable to TCA Global Master Fund, LP (“TCA”) in the original principal amount of $3 million at 16% interest (the “TCA Debenture”). Principal and interest payments due in various installments through December 31, 2017.     1,616,218       1,616,218  
                 
Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $500,000, bearing interest at 6% per annum (the “Tegal Notes”). Prinicpal and interest payments are due annually from July 12, 2015 through July 12, 2017     341,612       341,612  
      6,957,830       6,957,830  
Less current portion     (6,957,830 )     (6,957,830 )
Notes payable - third parties, net of current portion   $ -     $ -  

Schedule of Notes Payable - Related Parties

Notes Payable – Related Parties

 

    March 31, 2018     December 31, 2017  
Loan payable to Alcimede LLC, bearing interest at 6% per annum, with all principal and interest due on August 2, 2018   $ 168,500     $ 168,500  
                 
Loan Payable to Christopher Diamantis     900,000       960,000  
      1,068,500       1,068,500  
Less current portion     (1,068,500 )     (1,068,500 )
Total notes payable - related parties, net of current portion   $ 0     $ 0  

XML 38 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debentures (Tables)
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Schedule of Debentures

The carrying amount of all outstanding debentures as of March 31, 2018 (unaudited), and December 31, 2017 is as follows:

 

    March 31, 2018     December 31, 2017  
Debentures   $ 15,758,851     $ 17,720,082  
Discount on Debentures     (8,424,756 )     (12,127,634 )
Deferred financing fees     (94,175 )     (224,733 )
      7,239,921       5,367,715  
Less current portion     (3,445,841 )     (1,615,693 )
Debentures   $ 3,794,079     $ 3,752,022  

Schedule of Payment on Outstanding Debentures

Payment on all outstanding debentures as of March 31, 2018 are due as follows:

 

Period ended December 31,      
2018   5,647,271  
2019   10,111,580  
    $ 15,758,851  

XML 39 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Lease Obligations (Tables)
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Schedule of Capital Lease Obligations

The Company leases various assets under capital leases expiring through 2020 as follows. At March 31, 2018 (unaudited) and December 31, 2017, capital lease obligations consisted of the following:

 

    March 31, 2018     December 31, 2017  
Medical equipment   $ 4,686,736     $ 4,686,736  
Less accumulated depreciation     (4,010,259 )     (3,842,443 )
                 
Net   $ 676,477     $ 844,293  

XML 40 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Deficit (Tables)
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Schedule of Stock Option Activity

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2018:

 

    Number of
options
    Weighted-
average 
exercise 
price
    Weighted-
average contractual
term (Yrs.)
 
Outstanding at December 31, 2017     38,478     $ 2,072.75       8.33  
Granted     -       -          
Expired     -       -          
Forfeit             -          
Exercised     -       -          
Outstanding at March 31, 2018     38,478     $ 2,072.75       8.33  
Exercisable at March 31, 2018     32,922     $ 2,373.16          

Schedule of Warrants Activity

The following summarizes the information related to warrants issued and the activity during the three months ended March 31, 2018:

 

    Number of warrants     Weighted
average 
exercise price
 
Balance at December 31, 2017     2,176,403,218     $ 0.0444  
Warrants issued during the period     -     $ -  
Increases due to dilution     13,411,976,939     $ -  
Warrants exercised during the period     (119,746,776 )   $ 0.0038  
Warrants expired during the period     -     $ -  
Balance at March 31, 2018     15,468,633,381     $ 0.0062  

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

As of March 31, 2018 and 2017, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive:

 

    As of March 31,  
    2018     2017  
Warrants     15,468,633,381       30,595,665  
Convertible preferred stock     893,098,291       595,556  
Convertible debt     781,485,502       10,007,141  
Stock options     38,478       709,025  
      17,143,255,652       41,907,387  

XML 41 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Disclosure of Cash Flow Information (Tables)
3 Months Ended
Mar. 31, 2018
Supplemental Cash Flow Elements [Abstract]  
Schedule of Supplemental Cash Flow Information

The supplemental cash flow information for the three months ended March 31, 2018 and 2017 (unaudited) is as follows:

 

    Three Months Ended March 31,  
    2018     2017  
Cash paid for interest   $ 24,791     $ 881,457  
Cash paid for income taxes   $ -     $ 296,313  
                 
Non-cash investing and financing activities:                
Exchange of I-2 preferred stock for convertible debentures   $ 1,384,556     $ 2,695,760  
Exchange of convertible debentures for convertible debentures and warrants   $ -     $ 2,464,500  
Note payable and warrants settled through issuance of common stock   $ -     $ 440,000  
Debentures converted into common stock   $ 3,056,675     $ 486,032  
Conversions of preferred stock into common stock   $ -     $ 6,280,000  
Common stock issued in cashless excercise of warrants   $ 756,000     $ -  

XML 42 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Schedule of Segment Information

Selected financial information for the Company’s operating segments is as follows:

 

    Three Months Ended March 31,  
    2018     2017  
Net revenues – External                
Clinical Laboratory Operations   $ 45,586     $ 684,265  
Hospital Operations     1,556,075       -  
    $ 1,601,661     $ 684,265  
                 
(Loss) income from operations                
Clinical Laboratory Operations   $ (756,083 )   $ (1,292,275 )
Hospital Operations     (1,472,600 )     (467,316 )
Corporate     (1,483,341 )     (1,804,517 )
Eliminations     -       7,851  
    $ (3,712,024 )   $ (3,556,257 )
Depreciation and amortization                
Clinical Laboratory Operations   $ 295,474     $ 434,468  
Hospital Operations     37,728       -  
Corporate     314       312  
Eliminations     -       (7,851 )
    $ 333,515     $ 426,929  
Capital expenditures                
Clinical Laboratory Operations   $ -     $ (100,382 )
Hospital Operations     -       1,090,922  
    $ -     $ 990,540  

 

***` Intersegment revenues are eliminated in consolidation.

 

    March 31, 2018     December 31, 2017  
Total assets                
Clinical Laboratory Operations   $ 1,019,946     $ 1,503,520  
Hospital Operations     2,788,059       2,549,504  
Corporate     3,510,297       3,436,773  
Assets of AMSG and HTS classified as held for sale     243,963       255,566  
Eliminations     (1,424,496 )     (1,454,570 )
    $ 6,137,769     $ 6,290,794  

XML 43 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations (Tables)
3 Months Ended
Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Discontinued Operation of Balance Sheet and Operation Statement

Carrying amounts of major classes of assets and liabilities classified as held for sale and included as part of discontinued operations in the condensed consolidated balance sheets consisted of the following:

 

AMSG Assets and Liabilities:

 

    March 31, 2018     December 31, 2017  
    (unaudited)     (unaudited)  
Cash   $ 5,314     $ 9,273  
Accounts receivable, net     576       19,022  
Prepaid expenses and other current assets     25,477       25,477  
Current assets classified as held for sale   $ 31,367     $ 53,772  
                 
Property and equipment, net   $ -     $ -  
Deposits     -       -  
Non-current assets classified as held for sale   $ -     $ -  
                 
Accounts payable (includes related parties)   $ 674,425     $ 671,561  
Accrued expenses     388,666       375,165  
Current portion of notes payable     228,421       249,589  
Current liabilities classified as held for sale   $ 1,291,512     $ 1,296,315  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

HTS Assets and Liabilities:

 

    March 31, 2018     December 31, 2017  
    (unaudited)     (unaudited)  
Cash   $ 1,727     $ 8,281  
Accounts receivable, net     166,774       160,715  
Prepaid expenses and other current assets     22,183       3,964  
Current assets classified as held for sale   $ 190,684     $ 172,960  
                 
Property and equipment, net   $ 15,883     $ 21,078  
Deposits     6,029       7,756  
Non-current assets classified as held for sale   $ 21,912     $ 28,834  
                 
Accounts payable (includes related parties)   $ 500,235     $ 407,404  
Accrued expenses     271,245       269,135  
Current liabilities classified as held for sale   $ 771,480     $ 676,539  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

Consolidated Discontinued Operations Assets and Liabilities:

 

    March 31, 2018     December 31, 2017  
    (unaudited)     (unaudited)  
Cash   $ 7,041     $ 17,554  
Accounts receivable, net     167,350       179,737  
Prepaid expenses and other current assets     47,660       29,441  
Current assets classified as held for sale   $ 222,051     $ 226,732  
                 
Property and equipment, net   $ 15,883     $ 21,078  
Deposits     6,029       7,756  
Non-current assets classified as held for sale   $ 21,912     $ 28,834  
                 
Accounts payable (includes related parties)   $ 1,174,660     $ 1,078,965  
Accrued expenses     659,911       644,300  
Current portion of notes payable     228,421       249,589  
Current liabilities classified as held for sale   $ 2,062,992     $ 1,972,854  
                 
Non-current liabilities classified as held for sale   $ -     $ -  

 

Major line items constituting loss from discontinued operations in the consolidated statements of operations for the three months ended March 31, 2018 and 2017 consisted of the following:

 

AMSG Income (Loss) from Discontinued Operations:

 

    Three Months Ended March 31,  
    2018     2017  
    (unaudited)     (unaudited)  
Revenue from services   $ 33,685     $ 176,578  
Cost of services     16,138       769  
Gross profit     17,547       175,809  
Operating expenses     176,202       526,533  
Other income/expenses     (800,197 )     (2,978 )
Income/(Loss) from discontinued operations   $ 641,542     $ (347,746 )

 

HTS Income (Loss) from Discontinued Operations:

 

    Three Months Ended March 31,  
    2018     2017  
    (unaudited)     (unaudited)  
Revenue from services   $ 355,147     $ 315,270  
Cost of services     34,218       46,704  
Gross profit     320,929       268,566  
Operating expenses     538,199       987,111  
Other income/expenses     2,478       -  
Income/(Loss) from discontinued operations   $ (219,748 )   $ (718,545 )

 

Consolidated Income/(Loss) from Discontinued Operations:

 

    Three Months Ended March 31,  
    2018     2017  
    (unaudited)     (unaudited)  
Revenue from services   $ 388,832     $ 491,848  
Cost of services     50,356       47,473  
Gross profit     338,476       444,375  
Operating expenses     714,402       1,513,645  
Other income (expenses)     (797,719 )     (2,978 )
Income/(Loss) from discontinued operations   $ 421,793     $ (1,066,292 )

XML 44 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Financial Instruments and Fair Value (Tables)
3 Months Ended
Mar. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis

The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2017 and March 31, 2018:

 

    Level 1     Level 2     Level 3     Total  
As of December 31, 2017:                                
Embedded conversion options   $ -     $ -     $ 1,577,025     $ 1,577,025  
Common stock warrants     -       -       10,858,225       10,858,225  
Total   $ -     $ -     $ 12,435,250     $ 12,435,250  
                                 
As of March 31, 2018:                                
Embedded conversion options   $ -     $ -     $ 1,005,188     $ 1,005,188  
Common stock warrants     -       -       151,418,187       151,418,187  
Total   $ -     $ -     $ 152,423,375     $ 152,423,375  

Schedule of Changes in Liabilities with Level 3 of Fair Value

The following table reconciles the changes in the liabilities categorized within Level 3 of the fair value hierarchy for the three months ended March 31, 2018:

 

Balance at December 31, 2017   $ 12,435,250  
Loss on change in fair value included in net loss     139,779,232  
Issuance of convertible debt     208,893  
Balance at March 31, 2018   $ 152,423,375  

XML 45 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Organization and Basis of Presentation (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 06, 2018
Mar. 05, 2018
Feb. 14, 2018
Feb. 09, 2018
Jan. 31, 2018
Oct. 05, 2017
Sep. 21, 2017
Feb. 22, 2017
Feb. 07, 2017
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Mar. 07, 2017
Bad debts reserve                   $ 591,323      
Sales revenue                   2,191,983      
Revenue                   $ 1,600,000      
Reserve stock split, description             1-for-15 reverse stock split effective October 5, 2017   1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017        
Common stock conversion description           Every 15 shares of the Company’s then outstanding common stock was combined and automatically converted into one share   As a result of the Reverse Stock Splits, every 30 shares of the Company;s then outstanding common stock was combined and automatically converted into one share          
Common stock par value           $ 0.01     $ 0.01 $ 0.01   $ 0.01  
Common stock shares authorized                 500,000,000 3,000,000,000   3,000,000,000  
Preferred stock shares authorized                 5,000,000 5,000,000   5,000,000  
Derivative liability                     $ 56,000,000    
Reversal of interest expense                   41,000,000    
Deemed dividend, down round feature                   53,300,000      
Deemed dividend                     $ 51,000,000    
Working capital deficit                   174,800,000      
Stockholders' deficit                   183,907,626   $ 40,613,461  
Proceeds from issuance debentures                   2,000,000   15,700,000  
Revenue earned for services                   15,000,000      
Cash acquired from acquisition                   635,000      
Estimated acquisition cost                   500,000      
Total cost of acquisition                   $ 1,100,000      
Number of shares issued                   286,240,000      
March 2018 Offering [Member]                          
Debt maturity date   Sep. 19, 2019                      
Principal amount   $ 2,480,000                      
Proceeds from offering   $ 2,000,000                      
Nano Vibronix Inc [Member]                          
Number of shares issued     200,000                    
Share issued price per share     $ 4.00                    
Series I-2 Convertible Preferred Stock [Member]                          
Preferred stock shares authorized                   5,000,000      
Debt maturity date       Sep. 19, 2019                  
Principal amount       $ 1,384,556                  
Number of shares issued       1,731                  
Seamus Lagan [Member]                          
Number of compensation shares issued 26,666,667                        
Dr. Kamran Ajami [Member]                          
Number of compensation shares issued 3,333,333                        
John Beach [Member]                          
Number of compensation shares issued 3,333,333                        
Gary L. Blum [Member]                          
Number of compensation shares issued 3,333,333                        
Christopher Diamantis [Member]                          
Number of compensation shares issued 3,333,333                        
Principal amount                         $ 500,000
Trevor Langley [Member]                          
Number of compensation shares issued 3,333,333                        
Employees and Directors [Member]                          
Number of compensation shares issued 71,333,331                        
Asset Purchase Agreement [Member]                          
Acquisition on assets, description         The purchase was completed on June 1, 2018. The hospital was acquired by a newly formed subsidiary, Jamestown TN Medical Centre, Inc. and is an 85-bed facility of approximately 90,000 square feet on over eight acres of land, which offers a 24-hour Emergency Department with two spacious trauma bays and seven private exam rooms, inpatient and outpatient medical services and a Progressive Care Unit which provides telemetry services.                
May 30 2018 [Member]                          
Accrued interest and extension fees                   $ 7,800,000      
Debt fee amount received                   $ 100,000      
May 9 2018 [Member]                          
Common stock shares authorized                   3,000,000,000      
May 9, 2018 [Member] | Minimum [Member]                          
Common stock shares authorized                   500,000,000      
May 9, 2018 [Member] | Maximum [Member]                          
Common stock shares authorized                   3,000,000,000      
Additional Paid-in Capital [Member]                          
Discount on convertible debenture                   $ 16,000,000      
Stockholders' deficit                   $ (126,619,959)   $ (128,351,954)  
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accounts Receivable - Schedule of Accounts Receivable (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Accounts receivable, gross $ 13,086,381 $ 10,072,198
Less: Allowance for bad debts (1,525,972) (987,403)
Accounts receivable, net 1,101,758 971,312
Laboratory Service [Member]    
Accounts receivable, gross 1,302,579 1,478,451
Less: Allowance for discounts (1,150,800) (1,177,054)
Hospital [Member]    
Accounts receivable, gross 11,783,802 8,593,747
Less: Allowance for discounts $ (9,307,852) $ (6,936,429)
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment (Details Narrative) - USD ($)
3 Months Ended
Jan. 13, 2017
Mar. 31, 2018
Mar. 31, 2017
Business acquisition description The Hospital Assets include a 52,000 square foot hospital building and 6,300 square foot professional building on approximately 4.3 acres. Scott County Community Hospital, which has since been renamed as Big South Fork Medical Center    
Depreciation expenses   $ 300,000 $ 400,000
Impairment charge  
Hospital Asset [Member]      
Payments to acquire assets   $ 1,000,000  
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Property and equipment, gross $ 9,484,297 $ 9,798,914
Less accumulated depreciation (7,122,072) (7,103,474)
Property and equipment, net 2,362,225 2,695,440
Medical Equipment [Member]    
Property and equipment, gross 713,799 696,195
Building [Member]    
Property and equipment, gross 1,359,484 1,359,472
Equipment [Member]    
Property and equipment, gross 437,029 476,548
Equipment under Capital Leases [Member]    
Property and equipment, gross 4,686,736 4,686,736
Furniture [Member]    
Property and equipment, gross 232,495 222,824
Leasehold Improvements [Member]    
Property and equipment, gross 1,303,131 1,303,131
Vehicles [Member]    
Property and equipment, gross 196,534 196,534
Computer Equipment [Member]    
Property and equipment, gross 221,237 226,441
Software [Member]    
Property and equipment, gross $ 333,853 $ 631,033
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Payables and Accruals [Abstract]    
Commissions payable $ 13,345 $ 24,470
Accrued payroll and related liabilities 1,419,779 897,088
Accrued interest 1,402,498 2,636,057
Other accrued expenses 1,296,146 1,409,790
Total accrued expenses $ 4,131,767 $ 4,967,405
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes Payable (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Aug. 02, 2017
Mar. 21, 2017
Mar. 13, 2017
Mar. 07, 2017
Feb. 02, 2017
Nov. 03, 2016
Sep. 15, 2016
Mar. 31, 2016
Jun. 29, 2015
Feb. 03, 2015
Mar. 31, 2017
Feb. 28, 2017
Jan. 31, 2017
Aug. 31, 2016
Mar. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Consideration received               $ 5,000,000                  
Estimated value of accounts receivable               $ 8,700,000                  
Adjustment value of debt                               $ 0 $ 1,500,000
Investment percentage               20.00%                  
Debt term               6 months                  
Repayment of debt               $ 500,000                  
Debt instrument description               All payments recovered from the accounts receivable up to $5.25 million, if paid in full within six months, or $5.5 million, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty had not been paid $6.0 million, the Company was required to pay the difference.                  
Debt instrument periodic payment           $ 400,000                      
Warrant exercise per share                             $ 0.0038 $ 0.276  
Stock options exercise price per share                                
Loan outstanding                             $ 6,957,830 $ 6,957,830  
Alcimede LLC [Member]                                  
Due from related party                   $ 3,000,000              
Debt instrument maturity date                   Feb. 02, 2016              
Debt instrument interest rate                   6.00%              
Debt instrument extended due date Aug. 02, 2018                 Aug. 02, 2017              
Share based payment of exercised options granted                 66,667                
Stock options exercise price per share                 $ 37.50                
Loan outstanding                 $ 2,500,000           $ 168,500    
Repayment of common stock                           $ 300,000      
Mr Lagan [Member]                                  
Repayment of debt                     $ 50,000            
TCA Debenture [Member]                                  
Repayment of debt   $ 750,000                              
Accrued and unpaid interest   100,000     $ 400,000                        
Debt instrument fee   $ 150,000                              
Debt instrument maturity date   Jun. 27, 2017                              
TCA Debenture [Member] | April 2017 Through September 2017 [Member]                                  
Debt instrument periodic payment   $ 2,600,000                              
September 2016 Notes [Member]                                  
Debt instrument conversion price             $ 112.50                    
Warrant to purchase common stock             4,444                    
Warrant exercise per share             $ 180.00                    
Debt instrument maturity date             Mar. 15, 2017                    
Warrant exchanged shares of common stock     26,667                            
Christopher Diamantis [Member]                                  
Accrued and unpaid interest       $ 500,000               $ 500,000 $ 500,000        
Debt instrument face amount       $ 500,000                          
Warrant exercise per share       $ 15.00                          
Debt instrument interest rate                       10.00% 10.00%        
Two Investor [Member] | September 2016 Notes [Member]                                  
Debt instrument face amount             $ 400,000                    
Counterparty [Member]                                  
Investment percentage                             40.00%    
Due from related party                             $ 500,000    
Debt instrument fee                             $ 100,000    
Counterparty [Member] | Christopher Diamantis [Member]                                  
Investment percentage                             20.00%    
Due from related party                             $ 5,000,000    
Debt instrument fee                             $ 1,000,000    
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes Payable - Schedule of Notes Payable (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Note payable $ 6,957,830 $ 6,957,830
Less current portion (6,957,830) (6,957,830)
Notes payable - third parties, net of current portion
Notes Payable Third Parties One [Member]    
Note payable 5,000,000 5,000,000
Notes Payable Third Parties Two [Member]    
Note payable 1,616,218 1,616,218
Notes Payable Third Parties Three [Member]    
Note payable $ 341,612 $ 341,612
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Notes Payable Third Parties Two [Member]    
Purchase contract amount $ 3,000,000 $ 3,000,000
Debt instruments interest rate 16.00% 16.00%
Debt maturity description December 31, 2017 December 31, 2017
Notes Payable Third Parties Three [Member]    
Purchase contract amount $ 500,000 $ 500,000
Debt instruments interest rate 6.00% 6.00%
Debt maturity description July 12, 2015 through July 12, 2017 July 12, 2015 through July 12, 2017
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes Payable - Schedule of Notes Payable - Related Parties (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Less current portion $ 1,068,500 $ 1,128,500
Notes Payable Related Parties One [Member]    
Total notes payable - related parties 168,500 168,500
Notes Payable Related Parties Two [Member]    
Total notes payable - related parties 900,000 960,000
Notes Payable Related Parties [Member]    
Total notes payable - related parties 1,068,500 1,068,500
Less current portion (1,068,500) (1,068,500)
Total notes payable - related parties, net of current portion $ 0 $ 0
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Notes Payable - Schedule of Notes Payable - Related Parties (Details) (Parenthetical) - Notes Payable Related Parties One [Member]
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Debt instruments interest rate 6.00% 6.00%
Debt instruments maturity date Aug. 02, 2018 Aug. 02, 2018
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debentures (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 05, 2018
Feb. 08, 2018
Oct. 05, 2017
Sep. 21, 2017
Sep. 19, 2017
Jul. 17, 2017
Mar. 21, 2017
Mar. 21, 2017
Feb. 07, 2017
Feb. 02, 2017
Mar. 31, 2016
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Dec. 31, 2017
Jun. 30, 2017
Jun. 22, 2017
Jun. 02, 2017
Exercise price of warrants                       $ 0.0038   $ 0.0038 $ 0.276      
Proceeds from debt                       $ 2,000,000     $ 15,700,000      
Repayment of debt                     $ 500,000              
Convertible debt                       15,758,851   $ 15,758,851 17,720,082      
Interest expenses                       $ 44,074,628          
Amortization of debt discount                       4,522,329 $ 943,160   14,700,000      
Proceeds from issuance warrants                             15,700,000      
Unamortized Discount                       (8,424,756)   (8,424,756) (12,127,634)      
Non-cash interest and amortization of debt discount expense                             $ 4,800,000      
Reserve stock split, description       1-for-15 reverse stock split effective October 5, 2017         1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017                  
Proceeds from issuance of debenture and warrants                                  
June Warrants [Member] | Accredited Investor [Member]                                    
Warrant purchase price                       1,902,700            
Amortization of debt discount                       107,700            
Proceeds from issuance warrants                       1,500,000            
March 2017 Offerings [Member] | March Warrants and Exchange Warrants [Member]                                    
Debt instrument original amount                       $ 41,300,000            
March 2017 Offerings [Member] | Debenture Warrant [Member]                                    
Debenture description                       The Company recognized a discount for 100% of the principal value of the March Debentures and the Exchange Debentures and non-cash interest expense in the amount of $43.7 million in connection with the recognition of these derivative liabilities.            
February 2017 Offering [Member]                                    
Debt instrument face amount                   $ 1,600,000                
Warrants to purchase common stock                   6,667                
Exercise price of warrants                   $ 38.70                
Warrant purchase price                   $ 1,500,000                
Debt instrument of exchange price               $ 2,500,000                    
March 2017 Offerings [Member]                                    
Debt instrument face amount             $ 10,850,000 $ 10,850,000                    
Debt instrument maturity date               Mar. 21, 2019                    
Proceeds from debt               $ 8,400,000                    
Repayment of debt               750,000                    
Convertible debt             2,500,000 2,500,000                    
Interest expenses               400,000                    
Stock converted into debt               2,700,000                    
March 2017 Offerings [Member] | Series H Convertible Preferred Stock [Member]                                    
Stock of convertible preferred stock               $ 2,200,000                    
2017 Diamantis Note [Member] | March 2017 Offerings [Member]                                    
Repayment of debt             $ 3,800,000                      
March Debentures and Exchange Debenture [Member] | March 2017 Offerings [Member]                                    
Debt instrument maturity date               Mar. 21, 2019                    
Stock converted into debt                           $ 10,362,989        
Debt original issue discount, percentage             24.00% 24.00%                    
Warrants exercisable                       13,823,699.256   13,823,699.256        
Debenture description                       The March Debentures are convertible into shares of the Company’s common stock, at a conversion price which has been adjusted pursuant to the terms of the March Debentures to $0.0038 per share as of March 31, 2018, due to prices at which the Company has subsequently issued shares of common stock. The Convertible Debentures began to amortize monthly commencing on the 90th day following the closing date. The Exchange Debentures began to amortize monthly on the closing date. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of the March Debentures in cash or, in lieu thereof, the conversion price of such debentures will thereafter be 85% of the volume weighted average price at the time of conversion.            
Stock converted into debt, value                           359,281,017        
Debt instrument original amount                       $ 15,300,000            
March Debentures and Exchange Debenture [Member] | March 2017 Offerings [Member] | Series A Warrant [Member]                                    
Warrants exercisable                       4,949,270,368   4,949,270,368        
Warrant term                       5 years            
March Debentures and Exchange Debenture [Member] | March 2017 Offerings [Member] | Series B Warrant [Member]                                    
Warrants exercisable                       3,925,158,519   3,925,158,519        
Warrant term                       18 months            
March Debentures and Exchange Debenture [Member] | March 2017 Offerings [Member] | Series C Warrant [Member]                                    
Warrants exercisable                       4,949,270,368   4,949,270,368        
Warrant term                       5 years            
March Debentures and Exchange Debenture [Member] | March 2017 Offerings [Member] | March Warrants [Member]                                    
Exercise price of warrants                       $ 0.0038   $ 0.0038        
June Debentures [Member] | June 2017 Offerings [Member]                                    
Warrants to purchase common stock                               100,000    
June 2017 Offerings [Member]                                    
Warrants to purchase common stock                                 66,667 33,333
Exercise price of warrants                                 $ 5.70 $ 5.85
July 2017 Offerings [Member]                                    
Debt instrument face amount           $ 4,136,862                        
Warrants to purchase common stock           141,333                        
Exercise price of warrants                       $ 5.63   $ 5.63        
Reserve stock split, description     1-for-15 reverse stock split                              
July Offerings [Member]                                    
Debt instrument of exchange price           $ 1,902,700                        
Warrant consideration in cash           $ 2,000,000                        
Reserve stock split, description           1-for-8 reverse split                        
July Debentures [Member]                                    
Debt instrument of exchange price         $ 6,400,000                          
September 2017 Offerings [Member]                                    
Debt instrument face amount         2,604,000                          
Debt instrument of exchange price         $ 4,136,862                          
Debt instrument maturity date         Sep. 19, 2019                          
Interest expenses                       $ 1,000,000            
Debt original issue discount, percentage                       24.00%   24.00%        
Amortization of debt discount                       $ 100,000            
Debenture description                       On October 19, 2017, the September Debentures were amended so that they began to amortize immediately. On each monthly amortization date, the Company may elect to repay 5% of the original principal amount of September Debentures in cash or, in lieu thereof, the conversion price of such September Debentures shall thereafter be 85% of the volume weighted average price at the time of conversion, but not less than the floor of $0.78 per share.            
Proceeds of offering cost         $ 2,100,000                          
September 2017 Offerings [Member] | Series A Warrant [Member]                                    
Warrants to purchase common stock         34,677,585             11,559,195   11,559,195        
Warrant term                       5 years            
September 2017 Offerings [Member] | Series B Warrant [Member]                                    
Warrants to purchase common stock         34,677,585             11,559,195   11,559,195        
Warrant term                       18 months            
September 2017 Offerings [Member] | Series C Warrant [Member]                                    
Warrants to purchase common stock         34,677,585             11,559,195   11,559,195        
Warrant term                       5 years            
September 2017 Offerings [Member] | September Warrants [Member]                                    
Exercise price of warrants                       $ 0.78   $ 0.78 $ 0.78      
September Debenture [Member]                                    
Debt instrument of exchange price         $ 6,412,136                          
Stock converted into debt   $ 1,384,556                                
Stock converted into debt, value   1,730.1                                
March 2018 Offering [Member]                                    
Debt instrument face amount $ 2,480,000                                  
Debt instrument maturity date Sep. 19, 2019                                  
Proceeds of offering cost $ 2,000,000                                  
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debentures - Schedule of Debentures (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Debt Disclosure [Abstract]    
Debentures $ 15,758,851 $ 17,720,082
Discount on Debentures (8,424,756) (12,127,634)
Deferred financing fees (94,175) (224,733)
Total debentures 7,239,921 5,367,715
Less current portion (3,445,841) (1,615,693)
Debentures $ 3,794,079 $ 3,752,022
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debentures - Schedule of Payment on Outstanding Debentures (Details)
Mar. 31, 2018
USD ($)
Debt Disclosure [Abstract]  
2018 $ 5,647,271
2019 10,111,580
Payment on outstanding debentures $ 15,758,851
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Mar. 07, 2017
Feb. 28, 2017
Jan. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Exercise price of warrants       $ 0.0038   $ 0.276
Christopher Diamantis [Member]            
Advances from director   $ 3,600,000 $ 3,600,000      
Accrued and unpaid interest $ 500,000 $ 500,000 $ 500,000      
Dent instrument interest rate   10.00% 10.00%      
Debt instrument face value $ 500,000          
Warrants to purchase common stock 27,667          
Exercise price of warrants $ 15.00          
Alcimede [Member]            
Consulting fee       $ 100,000 $ 100,000  
Monarch Capital LLC [Member]            
Consulting fee         $ 100,000  
Debt instrument maturity date       Aug. 31, 2017    
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Lease Obligations (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jan. 31, 2017
Mar. 31, 2018
Debt Disclosure [Abstract]    
Fees paid $ 3,500,000  
Interest expense   $ 600,000
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Capital Lease Obligations - Schedule of Capital Lease Obligations (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Debt Disclosure [Abstract]    
Medical equipment $ 4,686,736 $ 4,686,736
Less accumulated depreciation (4,010,259) (3,842,443)
Capital lease obligations $ 676,477 $ 844,293
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
Redeemable Preferred Stock (Details Narrative) - USD ($)
Feb. 09, 2018
Oct. 30, 2017
Mar. 31, 2018
Dec. 31, 2017
Feb. 07, 2017
Mar. 31, 2016
Preferred stock, shares authorized     5,000,000 5,000,000 5,000,000  
Preferred stock, par value     $ 0.01 $ 0.01    
Ownership percentage           20.00%
Series I-1 Preferred Stock [Member]            
Preferred stock, shares authorized   4,960        
Preferred stock, par value   $ 1,000        
Proceeds from offering   $ 4,960,000        
Ownership percentage   50.00%        
Series I-1 Preferred Stock [Member] | Investor [Member]            
Preferred stock, par value   $ 0.80        
Preferred stock subscription amount   1.00        
Common stock conversion price per share   $ 1.00        
Common stock weighted average market price percentage   85.00%        
Series I-1 Preferred Stock [Member] | Purchase Agreement [Member]            
Proceeds from offering   $ 4,000,000        
Series I-2 Convertible Preferred Stock [Member]            
Preferred stock, shares authorized     5,000,000      
Preferred stock, par value   $ 1.00 $ 1,000      
Common stock conversion price per share   $ 1.00        
Common stock weighted average market price percentage   85.00%        
Debenture surrender value   $ 0.80        
Preferred stock designated shares     11,271      
Debenture aggregate exchange principal amount $ 1,384,556          
Number of shares issued for debenture exchange 1,731          
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Deficit (Details Narrative) - USD ($)
3 Months Ended
Mar. 06, 2018
Aug. 14, 2017
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Feb. 07, 2017
Preferred stock shares authorized     5,000,000   5,000,000 5,000,000
Preferred stock par value     $ 0.01   $ 0.01  
Common stock shares issued     499,992,133   19,750,844  
Common stock shares outstanding     499,992,133   19,750,844  
Debt converted into share     333,315,823      
Debt converted into share, value     $ 3,056,674      
Number of common stock issued     286,240,000      
Number of restricted stock shares forfeited     2,493      
Recognized stock stock-based compensation     $ 665,307 $ 35,215    
Restricted Stock [Member]            
Number of common stock issued     71,333,333      
2007 Equity Plan [Member]            
Unrecognized compensation     $ 100,000      
Weighted average period     11 months 8 days      
March 2017 Series B Warrants [Member]            
Warrants purchased     119,746,776      
Common Stock [Member]            
Debt converted into share     333,310,452      
Number of restricted stock issued     71,333,331      
Debt converted into share, value     $ 3,333,105      
Number of common stock issued     75,600,000      
Employees and Directors [Member]            
Number of restricted stock issued 71,333,333 181,933        
Recognized stock stock-based compensation $ 477,933          
Stock issued price per share $ 0.0067          
Series G Preferred Stock [Member]            
Preferred stock shares authorized     14,000   14,000  
Preferred stock par value     $ 0.01   $ 0.01  
Preferred stock shares outstanding     215   215  
Series H Preferred Stock [Member]            
Preferred stock shares authorized     14,202   14,202  
Preferred stock par value     $ 0.01   $ 0.01  
Preferred stock shares outstanding     60   60  
Series F Preferred Stock [Member]            
Preferred stock shares authorized     1,750,000   1,750,000  
Preferred stock par value     $ 0.01   $ 0.01  
Preferred stock shares outstanding     1,750,000   1,750,000  
Common Stock [Member]            
Common stock shares issued     480,249,156      
Common Stock [Member] | June 18, 2018 [Member]            
Debt converted into share, value     $ 3,100,000      
Number of common stock issued     610,240,000      
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Deficit - Schedule of Stock Option Activity (Details)
3 Months Ended
Mar. 31, 2018
$ / shares
shares
Equity [Abstract]  
Number of Options Outstanding, beginning balance | shares 38,478
Number of Options Granted | shares
Number of Options Expired | shares
Number of Options Exercised | shares
Number of Options Options Outstanding, ending balance | shares 38,478
Number of Options Options Exercisable | shares 32,922
Weighted average exercise price, Outstanding beginning $ 2,072.75
Weighted average exercise price, Granted
Weighted average exercise price, Expired
Weighted average exercise price, Forfeited
Weighted average exercise price, Exercised
Weighted average exercise price, Outstanding, ending balance 2,072.75
Weighted average exercise price, Exercisable $ 2,373.16
Weighted average contractual term (Yrs.), beginning 8 years 3 months 29 days
Weighted average contractual term (Yrs.), ending 8 years 3 months 29 days
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Deficit - Schedule of Warrant Activity (Details) - Warrant [Member]
3 Months Ended
Mar. 31, 2018
$ / shares
shares
Number of warrants, balance beginning | shares 2,176,403,218
Warrants issued during the period | shares
Increase due to dilution | shares 13,411,976,939
Warrants exercised during the period | shares (119,746,776)
Warrants expired during the period | shares
Number of warrants, balance ending | shares 15,468,633,381
Weighted average exercise price, balance beginning | $ / shares $ 0.0444
Weighted average exercise price, warrants issued | $ / shares
Weighted average exercise price, increase due to dilution | $ / shares
Weighted average exercise price, warrants exchanged/exercised | $ / shares 0.0038
Weighted average exercise price, warrants expired | $ / shares
Weighted average exercise price, balance ending | $ / shares $ 0.0062
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Stockholders' Deficit - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Antidilutive securities 17,143,255,652 41,907,387
Warrants [Member]    
Antidilutive securities 15,468,633,381 30,595,665
Convertible Preferred Stock [Member]    
Antidilutive securities 893,098,291 595,556
Convertible Debt [Member]    
Antidilutive securities 781,485,502 10,007,141
Stock Options [Member]    
Antidilutive securities 38,478 709,025
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Supplemental Cash Flow Elements [Abstract]    
Cash paid for interest $ 24,791 $ 881,457
Cash paid for income taxes 296,313
Exchange of I-2 preferred stock for convertible debentures 1,384,556 2,695,760
Exchange of convertible debentures for convertible debentures and warrants 2,464,500
Note payable and warrants settled through issuance of common stock 440,000
Debentures converted into common stock 3,056,675 486,032
Conversions of preferred stock into common stock 6,280,000
Common stock issued in cashless excercise of warrants $ 756,000
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended
May 01, 2017
Feb. 15, 2017
Feb. 08, 2017
Jan. 25, 2017
Jan. 24, 2017
Jan. 03, 2017
Nov. 30, 2017
Feb. 29, 2016
Feb. 28, 2017
Mar. 31, 2018
Mar. 31, 2017
Mar. 24, 2017
Dec. 07, 2016
Oct. 31, 2016
Sep. 30, 2016
Sep. 27, 2016
Jul. 29, 2016
Mar. 31, 2016
Income tax penalties and interest accrued                         $ 400,000          
Payment for notes payable                   $ 1,948,111              
Florida Department of Revenue [Member]                                    
Settlement payable                   300,000                
Income tax penalties and interest paid       $ 250,000                            
Income tax penalties and interest accrued                               $ 900,000    
Due to related party                   500,000                
TCS-Florida, L.P [Member]                                    
Monthly installment payment $ 1,100,000                                  
Litigation settlement in judgment           $ 2,600,000                        
Payment in settlement of judgment                 $ 700,000                  
DeLage Landen Financial Services, Inc. [Member]                                    
Litigation settlement in judgment         $ 1,000,000                          
Implicit interest rate     4.97%                              
Epinex Diagnostics Laboratories, Inc. [Member]                                    
Payment of attorneys' fees                       $ 300,000   $ 700,000        
Medytox Solutions, Inc [Member] | Internal Revenue Service (IRS) [Member]                                    
Settlement payable                                   $ 100,000
Income tax penalties and interest paid               $ 5,000,000                    
Income tax liability refund                             $ 1,900,000      
Genomas, Inc. [Member]                                    
Payment for notes payable             $ 200,000                      
Discharge of payment             $ 100,000                      
Settlement Agreement [Member] | Epinex Diagnostics Laboratories, Inc. [Member]                                    
Settlement payable                                 $ 200,000  
Stipulation Agreement [Member] | Florida Department of Revenue [Member]                                    
Monthly installment payment                   $ 35,000                
Forbearance Agreement [Member] | TCS-Florida, L.P [Member]                                    
Monthly installment payment   $ 1,900,000                                
XML 68 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Details Narrative)
3 Months Ended
Mar. 31, 2018
Segment
Segment Reporting [Abstract]  
Number of reportable segments 2
XML 69 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information - Schedule of Segment Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Net revenues - External $ 1,601,661 $ 684,265  
(Loss) income from operations (3,712,024) (3,556,257)  
Depreciation and amortization 333,515 426,929  
Capital expenditures 990,540  
Total assets 6,137,770   $ 6,290,794
Clinical Laboratory Operations [Member]      
Net revenues - External 45,586 684,265  
(Loss) income from operations (756,083) (1,292,275)  
Depreciation and amortization 295,474 434,468  
Capital expenditures (100,382)  
Total assets 1,019,946   1,503,520
Hospital Operations [Member]      
Net revenues - External 1,556,075  
(Loss) income from operations (1,472,600) (467,316)  
Depreciation and amortization 37,728  
Capital expenditures 1,090,922  
Total assets 2,788,059   2,549,504
Corporate [Member]      
(Loss) income from operations (1,483,341) (1,804,517)  
Depreciation and amortization 314 312  
Total assets 3,510,297   3,436,773
Eliminations [Member]      
(Loss) income from operations 7,851  
Depreciation and amortization $ (7,851)  
Total assets (1,424,496)   (1,454,570)
Assets of AMSG and HTS Classified As Held For Sale[Member]      
Total assets $ 243,963   $ 255,566
XML 70 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations (Details Narrative) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Debt $ 3,445,841 $ 1,615,693
Health Technology Solutions, Inc [Member]    
Debt 14,461,338  
Advanced Molecular Services Group [Member]    
Debt $ 7,181,685  
XML 71 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Cash $ 7,041   $ 17,554
Accounts receivable, net 167,350   179,737
Prepaid expenses and other current assets 47,660   29,441
Current assets classified as held for sale 222,051   226,732
Property and equipment, net 15,883   21,078
Deposits 6,029   7,756
Non-current assets classified as held for sale 21,912   28,834
Accounts payable (includes related parties) 1,174,660   1,078,965
Accrued expenses 659,911   644,300
Current portion of notes payable 228,421   249,589
Current liabilities classified as held for sale 2,062,992   1,972,854
Non-current liabilities classified as held for sale  
Revenue from services 388,832 $ 491,848  
Cost of services 50,356 47,473  
Gross profit 338,476 444,375  
Operating expenses 714,402 1,513,645  
Other income/expenses (797,719) (2,978)  
Income/(Loss) from discontinued operations 421,793 (1,066,292)  
Advanced Molecular Services Group [Member]      
Cash 5,314   9,273
Accounts receivable, net 576   19,022
Prepaid expenses and other current assets 25,477   25,477
Current assets classified as held for sale 31,367   53,772
Property and equipment, net  
Deposits  
Non-current assets classified as held for sale  
Accounts payable (includes related parties) 674,425   671,561
Accrued expenses 388,666   375,165
Current portion of notes payable 228,421   249,589
Current liabilities classified as held for sale 1,291,512   1,296,315
Non-current liabilities classified as held for sale  
Revenue from services 33,685 176,578  
Cost of services 16,138 769  
Gross profit 17,547 175,809  
Operating expenses 176,202 526,533  
Other income/expenses (800,197) (2,978)  
Income/(Loss) from discontinued operations 641,542 (347,746)  
Health Technology Solutions, Inc [Member]      
Cash 1,727   8,281
Accounts receivable, net 166,774   160,715
Prepaid expenses and other current assets 22,183   3,964
Current assets classified as held for sale 190,684   172,960
Property and equipment, net 15,883   21,078
Deposits 6,029   7,756
Non-current assets classified as held for sale 21,912   28,834
Accounts payable (includes related parties) 500,235   407,404
Accrued expenses 271,245   269,135
Current liabilities classified as held for sale 771,480   676,539
Non-current liabilities classified as held for sale  
Revenue from services 355,147 315,270  
Cost of services 34,218 46,704  
Gross profit 320,929 268,566  
Operating expenses 538,199 987,111  
Other income/expenses 2,478  
Income/(Loss) from discontinued operations $ (219,748) $ (718,545)  
XML 72 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Financial Instruments and Fair Value (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Embedded conversion option value $ 1,000,000  
Conversion price percentage 85.00%  
Warrants value $ 151,400,000  
Trading price $ 0.009 $ 0.003
Exercise price of warrants 0.0038 $ 0.276
Maximum [Member]    
Exercise price of warrants $ 0.0038  
Black-Scholes Option Pricing Model [Member]    
Embedded conversion option value $ 200,000  
Warrants value 100,000  
Level 3 [Member]    
Loss realized on instrument $ 140,000,000  
XML 73 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Total $ 152,423,375 $ 12,435,250
Level 1 [Member]    
Total
Level 2 [Member]    
Total
Level 3 [Member]    
Total 152,423,375 12,435,250
Embedded Conversion Options [Member]    
Total 1,005,188 1,577,025
Embedded Conversion Options [Member] | Level 1 [Member]    
Total
Embedded Conversion Options [Member] | Level 2 [Member]    
Total
Embedded Conversion Options [Member] | Level 3 [Member]    
Total 1,005,188 1,577,025
Common Stock Warrants [Member]    
Total 151,418,187 10,858,225
Common Stock Warrants [Member] | Level 1 [Member]    
Total
Common Stock Warrants [Member] | Level 2 [Member]    
Total
Common Stock Warrants [Member] | Level 3 [Member]    
Total $ 151,418,187 $ 10,858,225
XML 74 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1
Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Balance at December 31, 2017 $ 12,435,250  
Loss on change in fair value included in net loss 139,779,232 $ (563,617)
Issuance of convertible debt 208,893  
Balance at March 31, 2018 $ 152,423,375  
XML 75 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Events (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2018
Jun. 18, 2018
May 09, 2018
Dec. 31, 2017
Feb. 07, 2017
Common stock, shares outstanding 499,992,133     19,750,844  
Number of common stock issued 286,240,000        
Common stock shares authorized 3,000,000,000     3,000,000,000 500,000,000
March 2017 Series B Warrants [Member]          
Warrants purchased 381,405,434        
March 2017 Debentures [Member]          
Number of shares issued for debt conversion 324,000,000        
Principal amount of debt converted into shares $ 1,643,175        
June 18, 2018 [Member] | Common Stock [Member]          
Number of common stock issued 610,240,000        
Subsequent Event [Member]          
Common stock, shares outstanding   1,110,232,133      
Subsequent Event [Member] | Minimum [Member]          
Common stock shares authorized     500,000,000    
Subsequent Event [Member] | Maximum [Member]          
Common stock shares authorized     3,000,000,000    
EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -"&TTP?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ T(;33&;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " #0AM-,:N2MRN\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+/3L,P#(=?!>7>NEE%!5&7"]-.("$Q"<0M2KPMHOFCQ*C=V].6 MK1."!^ 8^Y?/GR6W.@H=$CZG$#&1Q7PSN,YGH>.:'8FB ,CZB$[ED/=4!8554##DD910HF8!$7(I.MT4(G5!32&6_T@H^?J9MA1@-V MZ-!3!EYR8'*:&$]#U\(5,,$(D\O?!30+<:[^B9T[P,[)(=LEU?=]V==S;MR! MP]O3X\N\;F%])N4UCK^R%72*N&:7R:_UPV:W97)5\;NB:@I^O^.-N*U%S=\G MUQ]^5V$7C-W;?VQ\$90M_+H+^0502P,$% @ T(;33)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " #0AM-,/2^C_V4" 6" & 'AL+W=O&M7(;5TIUSP#(.HBSX7;&ZI4<1R7O3$/%[3QGO MMS&,WS=>ZENES 8HBX[JOG='H5=@M'*I&]K*FK>1H-=MO(//!Y@:@D7\ MJ&DO)_/(A'+B_-4L/E^V<6(\HHR>E3%!]/"@!\J8L:3]^#48C4=-0YS.WZU_ MM,'K8$Y$T@-G/^N+JK;Q.HXN]$KN3+WP_A,= LKB:(C^"WU0IN'&$ZUQYDS: MW^A\EXHW@Q7M2D/>W%BW=NS=20H'6IB !@(:"2C_+P$/!#P27#:!\\R&^H$H M4A:"]Y%P7ZLCYE+ 9ZR3>3:;-G?V3$ZC3 KP,&8&Q-XAT 0!1P30MD?343 M<(C,(EJ+V&"89)NP2AY4R3V5]4S%1RP(K(("*X\.YSU,\J3=J'23'A>,7I69KO11D !@ !X;"]W;W)K28N $J%T4+= "BRVVO582)3;6MEQ)B;=O7TIV M#'MFF"87L23_I'X..1\/GA^:]GNWJNM^\F.[V76WTU7?[V]FL^YA56^K[G.S MKW?IFZ>FW59]NFV?9]V^K:O'L=!V,\.B\+-MM=Y-[^;CLR_MW;QYZ3?K7?VE MG70OVVW5_KNH-\WA=@K3MP=?U\^K?G@PNYOOJ^?ZS[K_MO_2IKO9N9;'];;> M=>MF-VGKI]OI3W"SY'(H,"K^6M>'[N)Z,C3EOFF^#S>_/=Y.B\%1O:D?^J&* M*GV\ULMZLQEJ2C[^.54Z/;]S*'AY_5;[+V/C4V/NJZY>-IN_UX_]ZG9:3B>/ M]5/ULNF_-H=?ZU.#W'1R:OWO]6N]2?+!27K'0[/IQO^3AY>N;[:G6I*5;?7C M^+G>C9^'4_UOQ>P">"J YP+ [Q:@4P$2!69'9V-3?Z[ZZF[>-H=)>^RM?34, M"KBA%,R'X>$8N_&[U-HN/7V]0Y[/7H=Z3I+%48*7DFO%TE"XLV26WG\V@:8) M',O397EOER>S/(WE^;)\$(TX2L(HV8T20H<1=& M H(KA16M"X&($#;CC/M.&6'"F''J=>@@T*Z7AHR\A'8=N---UZ[ >'&J]>0 M2_TDS&A5+#D3F&!:"=J*&-.+H/LI@B,F8<;2<5%R)@%*TT^I_8CW+$K= XB% M$Q%<6C(?*!.=:+J)VHUD0C0ZRA=>IMW2T%'I?"XZ4-B0*K0C)RE56$,TQ-)<-3Z-:P5T M0U:6E$EWL*D,FJ942C^D7N2!0@@RYRTAQB+$G"<;T,!JJJ&8J<%F*FBHLH0J M:%RR3[F*$AZ6$,K2A\RL S990:.5)5I!4Y/3?!*\3%E+&'W@(C<:;<2"9BQ+ MQH(%3Y_&O>I]2QC Q0S7P,8L:,Y*GB] $S31(91RYEQ^0'CMR88M:-JR6H%I MC$+A2U8N:MRQYBQJCD'HDJ"G $&+*6[A@T[4GF[>H>9*62";90D=%ICA'-KL1)]F+!E)+ MA$!I+2U=:2D/_(D>,K9L_&*I@YU+.!N6J&'I)"Q1,Y!C^D,UL@U8QC3W9.9> MLEE)FI5.LI(,5J+W$*.3(\"4EN0@YA*.;%Z2YJ63O"2-P4\$SG&:,)0Q0YOR M+:U3.;?9)YN:I*GIU'9=H_ 3E)06?![5IMW0&+48)DP\(KSW9B".- MN&QOVS0B@T:YN-@T(DTC'1<-&2S( \CS'J.R[-F332+6)/*9>8-M9C!\&-!L MYS;KW/9RA?KTGN?9AIS+K5/:9 <:9HSR]4\S&PDX\UCM%'0NM0742 M^*[FVHF=P&PD<(;9;*<;AX]'PTXWUGLO'8VCYO*4%H+>Y?RO[.AG=G$&/OPH M\4?5/J]WW>2^Z?MF.QYZ/S5-7ZCS?;.JG?K@,Z;H]_AAPO.F; M_>F'CMGYUY:[_P!02P,$% @ T(;33.)&FWP: P ^@X !@ !X;"]W M;W)KW47U5E\XE\Y[GA7UVKU( M63Y[7GVX\)S53Z+DA7IS$E7.I&I69Z\N*\Z.35">>=3W8R]G:>%N5LVSEVJS M$E>9I05_J9SZFN>L^K?EF;BO7>)^/'A-SQ>I'WB;57O\J72K6\/LLQ MS7E1IZ)P*GY:NY_(\XZ&.J!1_$[YO1[<.[J4O1!ONO'MN'9]3<0S?I Z!5.7 M&]_Q+-.9%,??+JG;]ZD#A_>*;DF47T<1%8WW\[A6DN1=UD42L[>VVM:--=[^R8.NS \ M@'8!M \@CP."+B 8!7@M65/J9R;99E6)NU.UOU;)]*0@SX$:S(-^V(Q=\TY5 M6ZNGMTT?$0F445-FT 0H30!I%B.: '1#,!JKS* )49H0TBQ'-*UD,>C&?_+)B,4B M,D@BE"0"),FHX&TKB0:=1#XV,':=P1.C/#'D&16]C>>,C$5DD"0H20))1DMD MFX"*V_F+#,XLJ4&U0*D6D"H842U 5^%2?2@)1LH=5))E$OF+,,21EBC2$B*% M(Z3E;"2H?(Q$?-P!?;C"Z$2&"0\E]C7::2Q3T:8R:7 S)=!-P3KM-,;8A7 F M6F4F#VZG!/II$HUY M 1)=&8YK'(9,'-E$ W3<#?73B'Y;'(9,'ME$ _C:=F M+FZ !#H@G'>S+-"F,FEP$R2("X)Y![V-A-0'^PF;S.3![8\@_@?F';2U&"R" MAQJ3!'<]@M@>F'70S2#)0XVYS\*]CB)>-[53P[V.SO Z.LOK;"J39F+C.,/K M*&)B283M'>U"DPGW.SK#[RBTL@DFN]!DPGV/SO ]"BUM@LDN;)F\P2%$GPI_ ML.J<%K6S%U*=9YI3QTD(R552_TFENZB#:-_(^$GJVT3=5^UIK&U(478G3:\_ M[F[^ U!+ P04 " #0AM-,.L@%TOD# #Q$ & 'AL+W=O1X^_:E#O$ZG&%S8TGT/^0_0^FCJ,6E;KZW>^^[V8^J/+:/\WW7G1ZR MK-WL?56T]_7)'\,_KW53%5VX;'99>VI\L1V"JC)#(4Q6%8?C?+D8VIZ;Y:(^ M=^7AZ)^;67NNJJ+Y=^7+^O(XA_E[P[?#;M_U#=ER<2IV_@_?_7EZ;L)5=NUE M>ZC\L3W4QUGC7Q_G3_"PQKP/&!1_'?REO3F?]:F\U/7W_N+7[>-<](Y\Z3== MWT41#F]^[N0?$CFI6C]NB[_/FR[_>,\G\^V M_K4XE]VW^O*+GQ+2\]F4_6_^S9=!WCL)8VSJLAU^9YMSV]75U$NP4A4_QN/A M.!POXS_636%\ $X!> T(8_]?@)P"Y,\ -20_.AM2_5)TQ7+1U)=9,\[6J>AO M"GB0H9B;OG&HW?!?R+8-K6]+:Q?96]_/)%F-$KR1P%61AR=BRU(R,[E@Z3 M.Q3@(CM4)R68X(CWD[-^ .E3FK@-@:<62)J7B_.2Q"V ,_%SP72%*3,\ H$R MT,4,G#0?'POIK'4H8Z0S6FVD@521>1*"IJX@=J69"97""B!3SRB5-BH\M0D^ M P]8H(1U,6&!HO,.5/"E,%Y@UYQ6:6%S)U*SR*,6*&M=S%J@$ W&C,V-%/%J MQFE5$&I(K6C ,Q0*!+R\$4*7Q?#%SFF@HUG>.TQPONDB;3]55 ME^:;GN=8Z/?5&1>YPUU5.D6:EO=OTSQ[JW:9Z;O.LU ^UU3P7 M15K_CG1>W;8VLU\??,V>+FWWP-EMKNF3_E>W_UT?:G/G3%Y.6:'+)JM*J];G MK?V9W2=,=08]\2W3M^;-M=5)>:RJ']W-WZ>M[781Z5P?V\Y%:CY>]%[G>>?) MQ/%S=&I/8W:&;Z]?O2>]>"/F,6WTOLJ_9Z?VLK4#VSKI<_J>)*%4@#]F+QC*F2!*S@H2T*@PE7,$XK1R?#(9'A$,H#,:& D3(8/ M0MH37)\.(>B(!!F1("+R0$28X2#I>X'RXTOENBZHC4 QWU'<87W$!(^X,"TE MJ5L2NL'\B#"#=$LD:- #%248Y('B8D;.PE9DV(H(&RXAF$%A*Y0\S[S0:A0K M7"_N*^&!'_!A?<^G-WB74@]TU(B D?V0DTN\M;#UL MH?M@."#NPH PA -B>#.$&V8\0K.)")C#!P9+"#]+=:#[#T8T(!PV( 2$97-B M,13APOK%Z : $1T AQT >%HUIF8X1;A3DDF%8>%6'>6?,#9/ %TO\'PUA[" ME9!@L/YU)OX J:K5QZWXR#B\Z/4TWN3ZW MW:5OKNOA=#W&PO=V]R:W-H965T&ULA9E?C^(V%,6_"N*=);[7 M=N(1@S105:W42JNMMGW.@&= 2PA-,L/VV]<)619\CW?G84C"L7VN__Q\8Q;G MNOG2[KSO)E^KP[%]G.ZZ[O0PG[>;G:_*]D-]\L?PS4O=5&47;IO7>7MJ?+D= M"E6'.669G5?E_CA=+H9G'YOEHG[K#ONC_]A,VK>J*IO_5OY0GQ^G:OKMP:?] MZZ[K'\R7BU/YZO_RW>?3QR;5/[;[^CAI_,OC]$D]K'76%Q@4?^_] MN;VYGO2A/-?UE_[F]^WC-.L=^8/?='T59?AX]VM_./0U!1__CI5.KVWV!6^O MO]7^ZQ!\".:Y;/VZ/ORSWW:[QVDQG6S]2_EVZ#[5Y]_\&)"93L;H__#O_A#D MO9/0QJ8^M,/_R>:M[>IJK"58JRGQ3J@4-G;OJ'0]\-WX5HV_#T?:G( M+.;O?46C9G71T*WFJIB'VJ]-$&IB1:(XW3>PEHJ\P"TP#(*'\GP7A,45:%B! M'BK0-Q6XN!,NDGR0' ?)3&F;%Y;S/ H'2'70%5H9;,I 4T:8*F)3%XFY:8F9 MC8ID:RG39!TY[,9"-U:X410%OI(:*B(K5EB9F5SEE&$O.?222R\J]I*+AJPU MG,5C)65L*#5.!713@)Z)PEY)C>B90@Z2SG)M*;$4'#3C@!D7F7&R)4/$L6XM M=4ZSLHFA4AD&3"8=<1831HI$_XR:^ZF3A;^$G03OE%SJPHT2+2EV>>Y"'\6F MI'1F+-N;Z7CO"B+R21'H)!7;(K",5>XX]B1U,Y592XX2IC!5%< JIZK 7%42 MK(HYCDL#OYQI'<]'(%3*:)U O<)859*K M0).,R<0*D3I2SNJ$(#*.G8DL3E3)+"W!CJEC4LYPGQ5 + L%LD25$B M:Z,%L :R&6GE7()KA&E+DK8J#G]%@*%AZ,C%TVZ-E"9GE[G$\!'&+2''()$UA0#( M9)R.K1@!$GD".M:<3MTY\98/ &EB0 *1'#F 1N5TH52":XS1R""[-7'RQB"[ M91N0+;H)")U2F4XL$<:P90!;$\.6)4952#A,_"JT!L*PN@O6B3R ,6X9X-;$ MN 4B.702MN&%(@Q<(E5BS%H&K#4Q:QDDK[B3 )3#V[1.O2DS)BX#XIJ8N"Q) MRB9S-K8$TEPJ\BQ/;/Z,>I_-$VJ8QNC5 MXG1/8KR MGW00D(4,WF0FGDCSFY/4RC>OPZ%S.]G4;\>N/[.\>7H]V'ZB_B0V>KY2#^O+ M\?3W:BZGY7^6S>O^V$Z>ZZZKJ^$T]J6N.Q]\9A]"E^U\N;W>'/Q+UU_FX;JY MG%)?;KKZ-)[ SZ\_ RS_!U!+ P04 " #0AM-,P%!3?+8! #2 P & M 'AL+W=O5=2VYRV MSG4'QFS9@N+V"CO0_J9&H[CSIFF8[0SP*H*49&F2W##%A:9%%GTG4V38.RDT MG RQO5+<_#R"Q"&G&_KA>!9-ZX*#%5G'&_@&[GMW,MYB,TLE%&@K4!,#=4[O M-H?C+L3'@!45%#S7KIG'!Y@JN>:DJGX1[B ].%!B<]1 MHK1Q)65O':J)Q4M1_'W9P8&8 ML?<=#T^\.:2^-V5PQE;$.R_>>N^EV%SO,W8)1%/,<8Q)ES%S!//L>KL.WJPJW$;[]0^'M.L%NE6 7"7;_+7$EYB;Y*PE;]%2!:>(T65)BK^,D M+[SSP-ZE\4U^AX_3_L1-([0E9W3^96/_:T0'7DIRY4>H]1]L-B34+AP_^;,9 MQVPT'';3#V+S-RY^ 5!+ P04 " #0AM-,(LG?NK,! #2 P & 'AL M+W=OO&G5N9RVWO<' MQES9@A;NRO30X4UMK!8>3=LPUUL0501IQ?AN=\VTD!TMLN@[V2(S@U>R@Y,E M;M!:V!]'4&;,:4+?'4^R:7UPL"+K10-?P7_K3Q8MMK!44D/GI.F(A3JGM\GA MN _Q,>"[A-&MSB14D-)1748E#^R8P/,-?S@9*Y^,]P 87A00GF*(UR M<27EX+S1,PM*T>)MVF47]W&ZX>D,VP;P&< 7P$W,PZ9$4?DGX46163,2._6^ M%^&)DP/'WI3!&5L1[U"\0^^E2*Z3C%T"T1QSG&+X.F:)8,B^I.!;*8[\+SC? MAJ>;"M,(3W]3^ ^"_2;!/A+L_UOB5DSZ1Q*VZJD&V\1I>5=!O:6 MQS?Y%3Y-^Q=A&]DY7S;VOS;& TK97>$(M?C!%D-![4U-#P0;HG'#_!7,\M)7/Q7^ *TH<')3Y'A=+&E52#=:AF M%B]%\==I%SKNXW23)3-L&Y#.@'0!W,4\;$H4E3]RQ\OAR=.CJGO M316(#KR4W8T?H&UL?5-A;]L@$/TKB!]0$CMKL\BVU'2:5JF5HD[;/A/[;*," MYP&.VW\_P*[GM=:^ '?<>_?N.+(!S;-M 1QY45+;G+;.=0?&;-F"XO8*.]#^ MID:CN/.F:9CM#/ J@I1DR69SS107FA99])U,D6'OI-!P,L3V2G'S>@2)0TZW M],WQ))K6!01F_)TXZIPS Y?F-_6NLW==RYA;N M4/X2E6MSNJ>D@IKWTCWA\ VF>CY1,A7_ !>0/CPH\3E*E#:NI.RM0S6Q>"F* MOXR[T'$?QILTG6#K@&0")#-@'_.P,5%4_H4[7F0&!V+&WG<\//'VD/C>E,$9 M6Q'OO'CKO9=B>WV3L4L@FF*.8TRRC)DCF&>?4R1K*8[)!WBR#D]7%:81GOZC M<+].L%LEV$6"W7]+7(OY_"X)6_14@6GB-%E28J_C)"^\\\#>)O%-_H:/T_[( M32.T)6=T_F5C_VM$!U[*YLJ/4.L_V&Q(J%TXWOBS&<=L-!QVTP]B\SF.S 0 T@, !D !X;"]W;W)K&UL?5/;;MLP#/T501]0.4K6%(%MH.E0=, &!!VV/BLV?4%U<24Y M[OY^E.RZWN;U11(IGL-#BDH'8Y]= ^#)JY+:9;3QOCLPYHH&E'!7I@.--Y6Q M2G@T;09LCHAKXY M'MNZ\<'!\K03-7P'_Z,[6;38S%*V"K1KC286JHS>;@['78B/ 3];&-SB3$(E M9V.>@_&ES&@2!(&$P@<&@=L%[D#*0(0R7B9..J<,P.7YC?T^UHZUG(6#.R.? MVM(W&;VAI(1*]-(_FN$!IGH^43(5_Q4N(#$\*,$ZOC/HPW?#_!U@%\ O 9)&GU@S$CKWO1'CBS8%C;XK@C*V( M=RC>H?>2;_9)RBZ!:(HYCC%\&3-',&2?4_"U%$?^#YROP[>K"K<1OOU#X7_R M[U8)=I%@]V&):S%_JV2+GBJP=9PF1PK3ZSC)"^\\L+<\OLE[^#CMWX2M6^W( MV7A\V=C_RA@/*"6YPA%J\(/-AH3*A^,>SW8&PO=V]R:W-H965T[^?I3L MNM[F]442*9[#0XI*!V.?70/@R:N2VF6T\;X[,.:*!I1P5Z8#C3>5L4IX-&W- M7&=!E!&D)..;S353HM4T3Z/O9//4]%ZV&DZ6N%XI87\=09HAHUOZYGALZ\8' M!\O33M3P'?R/[F318C-+V2K0KC6:6*@R>KL]'),0'P-^MC"XQ9F$2L[&/ ?C M2YG131 $$@H?& 1N%[@#*0,1RGB9..F<,@"7YS?V^U@[UG(6#NZ,?&I+WV3T MAI(2*M%+_VB&!YCJ^43)5/Q7N(#$\* $J(D%I2CQ.NZMCOLP MWO#]!%L'\ G 9\!-S,/&1%'Y9^%%GEHS$#OVOA/AB;<'CKTI@C.V(MZA>(?> M2[[=[U)V"413S'&,XM6.W(V'E\V M]K\RQ@-*V5SA"#7XP69#0N7#<8]G.X[9:'C333^(S=\X_PU02P,$% @ MT(;33(:$RS:T 0 T@, !D !X;"]W;W)K&UL M?5-A;]L@$/TKB!]0$I(V461;:CI-F[1)4:=MGXE]ME&!\P#'W;\?8-?S-FM? M@#ONO7MW'-F ]L6U )Z\:F5<3EOONQ-CKFQ!"W>''9AP4Z/5P@?3-LQU%D25 M0%HQOMD\,"VDH466?!=;9-A[)0U<+'&]UL+^/(/"(:=;^N9XEDWKHX,562<: M^ +^:W>QP6(S2R4U&"?1$ MU3A^WI_,^QJ> ;Q(&MSB36,D5\24:'ZN<;J(@ M4%#ZR"#"=H,G4"H2!1D_)DXZIXS Y?F-_7VJ/=1R%0Z>4'V7E6]S>J2D@EKT MRC_C\ &F>NXIF8K_!#=0(3PJ"3E*5"ZMI.R=1SVQ!"E:O(Z[-&D?QIO=<8*M M _@$X#/@F/*P,5%2_DYX4606!V+'WG-G4_QK1 M0Y"RN0LCU(8/-AL*:A^/AW"VXYB-AL=N^D%L_L;%+U!+ P04 " #0AM-, M'F1Q7+,! #2 P &0 'AL+W=O,)IILSJB?V7;:D@.F MV>_UZ@O5JU^@688=Z; M-\.0#6B?7 O@R;-6QN6T];X[,>;*%K1P=]B!"3.; MS6NFA32TR)+O8HL,>Z^D@8LEKM=:V!]G4#CD=$M?'(^R:7UTL"+K1 .?P7_I M+C98;&:II ;C)!IBH<[I_?9TWL?X%/!5PN 69Q(KN2(^1>-#E=--% 0*2A\9 M1-AN\ !*1:(@X_O$2>>4$;@\O["_2[6'6J["P0.J;[+R;4Z/E%10BU[Y1QS> MPU3/*TJFXC_"#50(CTI"CA*52RLI>^=13RQ!BA;/XRY-VH?QAA\FV#J 3P ^ M XXI#QL3)>5OA1=%9G$@=NQ])^(3;T\\]*:,SM2*=!?$N^"]%=O#,6.W2#3% MG,<8OHR9(UA@GU/PM11G_A>$_\N]7"?:)8/_?$M=BWOR1 MA"UZJL$V:9H<*;$W:9(7WGE@[WEZDU_AX[1_$K:1QI$K^O"RJ?\UHH<@97,7 M1J@-'VPV%-0^'@_A;,&UL?5/;;MP@$/T5 MQ <$F]TDJY5M*9LJ:J566J5J^\S:8QL%/"[@=?KW!>PX5F/U!9CAG#,7AFQ$ M\V); $=>M>IL3EOG^B-CMFQ!"WN#/73^ID:CA?.F:9CM#8@JDK1B/$GNF!:R MHT46?6=39#@X)3LX&V('K87Y4 MS,5_A2LH#P^9^!@E*AM74@[6H9Y5?"I:O$Z[[.(^3C?\?J9M$_A,X OA$..P M*5#,_)-PHL@,CL1,O>]%>.+TR'UORN",K8AW/GGKO=?B+LG8->C,D-,$X2M( MNB"8%U\B\*T()_Z!SK?IN\T$=Y&^6T<_)-L"^TV!?138_Z_"CY#T\&^-;-51 M#::)LV1)B4,7YWCE7<;U@<<7>8=/L_Y-F$9VEES0^7>-W:\1'?A4DAL_0*W_ M7HNAH';A>._/9AJRR7#8S_^'+9^X^ M02P,$% @ T(;33!Z1!LNS 0 MT@, !D !X;"]W;W)K&UL?5/;CM,P$/T5RQ^P M3MT"595$VBY"((%4+8)]=I-)8JTOP7::Y>\9.]D0(.+%]HSGG#DS'N>C=<^^ M PCD12OC"]J%T)\8\U4'6O@[VX/!F\8Z+0*:KF6^=R#J!-**\2Q[R[20AI9Y M\EUBA:\0OO47AQ9;6&JI MP7AI#7'0%/1^=SH?8GP*^"YA]*LSB95ZH%D4! JJ$!D$;C=X *4B M$%1">:HK/)I)=7@@]4S"TK1XF7:I4G[.-UP/L.V 7P&\ 5P3'G8E"@I M?R^"*'-G1^*FWORMW1YZS6R2:8\Y3#%_'+!$, MV9<4?"O%F?\#Y]OP_:;"?8+O_U"8;1,<-@D.B>#PWQ*W8O9_)6&KGFIP;9HF M3RH[F#3)*^\RL/?I$=GO\&G:OPC72N/)U09\V=3_QMH *"6[PQ'J\(,MAH(F MQ.,[/+MIS"8CV'[^06SYQN4O4$L#!!0 ( -"&TTSS9O^?M0$ -(# 9 M >&PO=V]R:W-H965T^>-FEA0BN(OXRYTW(?Q)OT\P=8!R01(9L ^YF%CHJC\GGM> M9-8,Q(Z][WAXXNTAP=Z4P1E;$>]0O$/OI=CNTXQ= M$4KQ.DJP1I)$@_+'$MYN9-$K;HJ0+;Q&ERI#2] MCI.\\,X#>YO$-_D7/D[[=VX;H1TY&X\O&_M?&^,!I6RN<(1:_&"S(:'VX?@) MSW8&PO=V]R:W-H965T/&ME7$Y; M[[LC8ZYL00MW@QV8<%.CU<('TS;,=19$E4!:,;[9O&-:2$.++/G.MLBP]TH: M.%OB>JV%_7T"A4-.M_3%\2B;UD<'*[).-/ -_/?N;(/%9I9*:C!.HB$6ZIS> M;X^G?8Q/ 3\D#&YQ)K&2"^)3-#Y7.=U$0:"@])%!A.T*#Z!4) HR?DV<=$X9 M@=VG2/HPWMWR"K0/X!. SX)#RL#%14OY!>%%D%@=B MQ]YW(C[Q]LA#;\KH3*U(=T&\"]YKL3W<9>P:B::8TQC#ES%S! OL:K!-FB9'2NQ-FN2% M=Q[8^_2([&_X..U?A6VD<>2"/KQLZG^-Z"%(V=R$$6K#!YL-!;6/Q[MPMN.8 MC8;';OI!;/[&Q1]02P,$% @ T(;33/G*F+>S 0 T@, !D !X;"]W M;W)K&UL?5/;CM0P#/V5*!^PZ60&V!VUE786(9! M&BT"GC.MVT:;2TG2Z?+W.&FW%"B\)+'C,RVDH66>?&=7YG8(2AHX.^(' MK87[<0)EQX+NZ(OC4;9=B Y6YKUHX3.$+_W9H<46EEIJ,%Y:0QPT!;W?'4^' M&)\"ODH8_>I,8B47:Y^B\:$N:!8%@8(J1 :!VQ4>0*E(A#*^SYQT21F!Z_,+ M^[M4.]9R$1X>K/HFZ] 5]):2&AHQJ/!HQ_%1">:HK/)I M)=7@@]4S"TK1XGG:I4G[.-WPNQFV#> S@"^ VY2'38F2\KO==R=Y?E[!J)YIC3%,/7,4L$0_8E!=]*<>)_P?DV M?+^I<)_@^]\4_B/_89/@D @._RUQ*^9/E6S54PVN3=/D264'DR9YY5T&]IZG M-_D5/DW[)^%::3RYV( OF_K?6!L I60W.$(=?K#%4-"$>'R#9S>-V60$V\\_ MB"W?N/P)4$L#!!0 ( -"&TTP7N3GDM0$ -(# 9 >&PO=V]R:W-H M965T-V@3N0,A"AC.>)D\XI W!Y?F7_&FO' M6L[TJFXG_ !22&!R68HS32Q964O?-& M32PH1?&7<1=B8*"K_PCTO,FL&8L?>=SP\\?:0 M8&_*X(RMB'QL?D;V% MC]/^D]M&:$?.QN/+QO[7QGA *9LK'*$6/]AL2*A].'["LQW';#2\Z:8?Q.9O M7/P%4$L#!!0 ( -"&TTP#V,&@M0$ -(# 9 >&PO=V]R:W-H965T M552VXPVSK4'QFS1@.+V"EO0 M_J9"H[CSIJF9;0WP,H*49,EJ=L+^'L9X=)6/Q/^ "TH<')3Y'@=+&E12==:A&%B]% M\==A%SKN_7"SVXVP94 R I()L(]YV) H*O_*'<]3@STQ0^];'IYX?4A\;XK@ MC*V(=UZ\]=Y+OOYRG;)+(!ICCD-,,H^9(IAGGU(D2RF.R0=XL@S?+"K<1/CF M'X4WRP3;18)M)-A^6N)2S/Z_)&S64P6FCM-D28&=CI,\\TX#>YO$-WD/'Z;] M)S>UT):&PO=V]R:W-H965T:9M<,;NB; MXTG6C0L.EJ>=J.$GN%_=R7B+S2JEU-!:B2TQ4&7T;G,X[@(^ GY+&.SB3$(E M9\278'PK,YJ$A$!!X8*"\-L%[D&I(.33^#-ITCED("[/;^J/L79?RUE8N$?U M+$O79'1/20F5Z)5[PN$K3/5<4S(5_QTNH#P\9.)C%*AL7$G16X=Z4O&I:/$Z M[K*-^S#>W.PGVCJ!3P0^$_8Q#AL#Q.>3M]Y[R3>WMRF[!*$)&PO=V]R:W-H965T++/I.ILAP<$IV<#+$#EH+\W($A6-.=_35\2B; MU@4'*[)>-/ =W(_^9+S%%I9*:NBLQ(X8J'-ZNSL6?A1-%9G D9NI]+\(3[P[<]Z8,SMB*>.?% M6^^]%#SA&;L$HCGF.,7P5?4G!MU(<^3LXWX;O-Q7N(WS_C\+]-D&Z M29!&@O2_)6[%I&^2L%5/-9@F3I,E)0Y=G.25=QG86Q[?Y&_X-.T/PC2RL^2, MSK]L['^-Z,!+2:[\"+7^@RV&@MJ%X[4_FVG,)L-A/_\@MGSCX@]02P,$% M @ T(;33/)$*R7X 0 RP4 !D !X;"]W;W)K&UL=51M;]L@$/XK%C^@."3.FVQ+3:=IDS8IZK3N,[$OL54P'I"X^_<#['B> M>_UBX'A>[L!TI-48'DYD&UT+B=L]*26[?4%VI: M#;P,)"DHB^,UE;QN2)Z&V%'GJ;I:43=PU)&Y2LGUGP,(U65D0>Z!Y_I261^@ M>=KR"_P ^[,]:K>BHTI92VA,K9I(PSDCCXO]8>?Q ?!20V@;OA!D\@A!=R:?P>-,EHZ8G3^5W]2]ZX MZ"UG<9+2FQ<:,(<>PR:8Q8B@3GVT8)C%@;VC,YR^1#-N+W5CHI.R[DF'AW=6RH)+)7YP_T?E.NNX$'"V?KIQ<]WW MEWYA53NT3CKV[_PO4$L#!!0 ( -"&TTR+[.KWN $ -(# 9 >&PO M=V]R:W-H965T- VSO0%119)6C"?)+=-"=K3(HN]LB@P'IV0'9T/L MH+4P?TZ@<,QI2I\=#[)I77"P(NM% ]_!_>C/QEML4:FDALY*[(B!.J=WZ?&T M#_@(^"EAM*LS"95<$!^#\:7*:1(2 @6E"PK";U>X!Z6"D$_C]ZQ)EY"!N#X_ MJW^*M?M:+L+"/:I?LG)M3@^45%"+0;D''#_#7,\[2N;BO\(5E(>'3'R,$I6- M*RD'ZU#/*CX5+9ZF779Q'Z>;'9]IVP0^$_A".,0X; H4,_\HG"@R@R,Q4^][ M$9XX/7+?FS(X8ROBG4_>>N^UX.DA8]<@-&-.$X:O,.F"8%Y]"<&W0ISX*SK? MIN\V,]Q%^FX=_?8-@?VFP#X*[/\K\<.+$C

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end XML 77 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 279 319 1 false 116 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://rennovahealth.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://rennovahealth.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://rennovahealth.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://rennovahealth.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Deficit (Unaudited) Sheet http://rennovahealth.com/role/StatementOfChangesInStockholdersDeficit Condensed Consolidated Statement of Changes in Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://rennovahealth.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Basis of Presentation Sheet http://rennovahealth.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Accounts Receivable Sheet http://rennovahealth.com/role/AccountsReceivable Accounts Receivable Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://rennovahealth.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Accrued Expenses Sheet http://rennovahealth.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://rennovahealth.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Debentures Sheet http://rennovahealth.com/role/Debentures Debentures Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://rennovahealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Capital Lease Obligations Sheet http://rennovahealth.com/role/CapitalLeaseObligations Capital Lease Obligations Notes 14 false false R15.htm 00000015 - Disclosure - Redeemable Preferred Stock Sheet http://rennovahealth.com/role/RedeemablePreferredStock Redeemable Preferred Stock Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders' Deficit Sheet http://rennovahealth.com/role/StockholdersDeficit Stockholders' Deficit Notes 16 false false R17.htm 00000017 - Disclosure - Supplemental Disclosure of Cash Flow Information Sheet http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformation Supplemental Disclosure of Cash Flow Information Notes 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies Sheet http://rennovahealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Segment Information Sheet http://rennovahealth.com/role/SegmentInformation Segment Information Notes 19 false false R20.htm 00000020 - Disclosure - Recently Issued Accounting Standards Sheet http://rennovahealth.com/role/RecentlyIssuedAccountingStandards Recently Issued Accounting Standards Notes 20 false false R21.htm 00000021 - Disclosure - Discontinued Operations Sheet http://rennovahealth.com/role/DiscontinuedOperations Discontinued Operations Notes 21 false false R22.htm 00000022 - Disclosure - Derivative Financial Instruments and Fair Value Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue Derivative Financial Instruments and Fair Value Notes 22 false false R23.htm 00000023 - Disclosure - Subsequent Events Sheet http://rennovahealth.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 00000024 - Disclosure - Organization and Basis of Presentation (Policies) Sheet http://rennovahealth.com/role/OrganizationAndBasisOfPresentationPolicies Organization and Basis of Presentation (Policies) Policies http://rennovahealth.com/role/RecentlyIssuedAccountingStandards 24 false false R25.htm 00000025 - Disclosure - Accounts Receivable (Tables) Sheet http://rennovahealth.com/role/AccountsReceivableTables Accounts Receivable (Tables) Tables http://rennovahealth.com/role/AccountsReceivable 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Tables) Sheet http://rennovahealth.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://rennovahealth.com/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Accrued Expenses (Tables) Sheet http://rennovahealth.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://rennovahealth.com/role/AccruedExpenses 27 false false R28.htm 00000028 - Disclosure - Notes Payable (Tables) Notes http://rennovahealth.com/role/NotesPayableTables Notes Payable (Tables) Tables http://rennovahealth.com/role/NotesPayable 28 false false R29.htm 00000029 - Disclosure - Debentures (Tables) Sheet http://rennovahealth.com/role/DebenturesTables Debentures (Tables) Tables http://rennovahealth.com/role/Debentures 29 false false R30.htm 00000030 - Disclosure - Capital Lease Obligations (Tables) Sheet http://rennovahealth.com/role/CapitalLeaseObligationsTables Capital Lease Obligations (Tables) Tables http://rennovahealth.com/role/CapitalLeaseObligations 30 false false R31.htm 00000031 - Disclosure - Stockholders' Deficit (Tables) Sheet http://rennovahealth.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://rennovahealth.com/role/StockholdersDeficit 31 false false R32.htm 00000032 - Disclosure - Supplemental Disclosure of Cash Flow Information (Tables) Sheet http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformationTables Supplemental Disclosure of Cash Flow Information (Tables) Tables http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformation 32 false false R33.htm 00000033 - Disclosure - Segment Information (Tables) Sheet http://rennovahealth.com/role/SegmentInformationTables Segment Information (Tables) Tables http://rennovahealth.com/role/SegmentInformation 33 false false R34.htm 00000034 - Disclosure - Discontinued Operations (Tables) Sheet http://rennovahealth.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://rennovahealth.com/role/DiscontinuedOperations 34 false false R35.htm 00000035 - Disclosure - Derivative Financial Instruments and Fair Value (Tables) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValueTables Derivative Financial Instruments and Fair Value (Tables) Tables http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue 35 false false R36.htm 00000036 - Disclosure - Organization and Basis of Presentation (Details Narrative) Sheet http://rennovahealth.com/role/OrganizationAndBasisOfPresentationDetailsNarrative Organization and Basis of Presentation (Details Narrative) Details http://rennovahealth.com/role/OrganizationAndBasisOfPresentationPolicies 36 false false R37.htm 00000037 - Disclosure - Accounts Receivable - Schedule of Accounts Receivable (Details) Sheet http://rennovahealth.com/role/AccountsReceivable-ScheduleOfAccountsReceivableDetails Accounts Receivable - Schedule of Accounts Receivable (Details) Details 37 false false R38.htm 00000038 - Disclosure - Property and Equipment (Details Narrative) Sheet http://rennovahealth.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://rennovahealth.com/role/PropertyAndEquipmentTables 38 false false R39.htm 00000039 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://rennovahealth.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 39 false false R40.htm 00000040 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://rennovahealth.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 40 false false R41.htm 00000041 - Disclosure - Notes Payable (Details Narrative) Notes http://rennovahealth.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://rennovahealth.com/role/NotesPayableTables 41 false false R42.htm 00000042 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://rennovahealth.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 42 false false R43.htm 00000043 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Notes http://rennovahealth.com/role/NotesPayable-ScheduleOfNotesPayableDetailsParenthetical Notes Payable - Schedule of Notes Payable (Details) (Parenthetical) Details 43 false false R44.htm 00000044 - Disclosure - Notes Payable - Schedule of Notes Payable - Related Parties (Details) Notes http://rennovahealth.com/role/NotesPayable-ScheduleOfNotesPayable-RelatedPartiesDetails Notes Payable - Schedule of Notes Payable - Related Parties (Details) Details 44 false false R45.htm 00000045 - Disclosure - Notes Payable - Schedule of Notes Payable - Related Parties (Details) (Parenthetical) Notes http://rennovahealth.com/role/NotesPayable-ScheduleOfNotesPayable-RelatedPartiesDetailsParenthetical Notes Payable - Schedule of Notes Payable - Related Parties (Details) (Parenthetical) Details 45 false false R46.htm 00000046 - Disclosure - Debentures (Details Narrative) Sheet http://rennovahealth.com/role/DebenturesDetailsNarrative Debentures (Details Narrative) Details http://rennovahealth.com/role/DebenturesTables 46 false false R47.htm 00000047 - Disclosure - Debentures - Schedule of Debentures (Details) Sheet http://rennovahealth.com/role/Debentures-ScheduleOfDebenturesDetails Debentures - Schedule of Debentures (Details) Details 47 false false R48.htm 00000048 - Disclosure - Debentures - Schedule of Payment on Outstanding Debentures (Details) Sheet http://rennovahealth.com/role/Debentures-ScheduleOfPaymentOnOutstandingDebenturesDetails Debentures - Schedule of Payment on Outstanding Debentures (Details) Details 48 false false R49.htm 00000049 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://rennovahealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://rennovahealth.com/role/RelatedPartyTransactions 49 false false R50.htm 00000050 - Disclosure - Capital Lease Obligations (Details Narrative) Sheet http://rennovahealth.com/role/CapitalLeaseObligationsDetailsNarrative Capital Lease Obligations (Details Narrative) Details http://rennovahealth.com/role/CapitalLeaseObligationsTables 50 false false R51.htm 00000051 - Disclosure - Capital Lease Obligations - Schedule of Capital Lease Obligations (Details) Sheet http://rennovahealth.com/role/CapitalLeaseObligations-ScheduleOfCapitalLeaseObligationsDetails Capital Lease Obligations - Schedule of Capital Lease Obligations (Details) Details 51 false false R52.htm 00000052 - Disclosure - Redeemable Preferred Stock (Details Narrative) Sheet http://rennovahealth.com/role/RedeemablePreferredStockDetailsNarrative Redeemable Preferred Stock (Details Narrative) Details http://rennovahealth.com/role/RedeemablePreferredStock 52 false false R53.htm 00000053 - Disclosure - Stockholders' Deficit (Details Narrative) Sheet http://rennovahealth.com/role/StockholdersDeficitDetailsNarrative Stockholders' Deficit (Details Narrative) Details http://rennovahealth.com/role/StockholdersDeficitTables 53 false false R54.htm 00000054 - Disclosure - Stockholders' Deficit - Schedule of Stock Option Activity (Details) Sheet http://rennovahealth.com/role/StockholdersDeficit-ScheduleOfStockOptionActivityDetails Stockholders' Deficit - Schedule of Stock Option Activity (Details) Details 54 false false R55.htm 00000055 - Disclosure - Stockholders' Deficit - Schedule of Warrant Activity (Details) Sheet http://rennovahealth.com/role/StockholdersDeficit-ScheduleOfWarrantActivityDetails Stockholders' Deficit - Schedule of Warrant Activity (Details) Details 55 false false R56.htm 00000056 - Disclosure - Stockholders' Deficit - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://rennovahealth.com/role/StockholdersDeficit-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Stockholders' Deficit - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 56 false false R57.htm 00000057 - Disclosure - Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) Sheet http://rennovahealth.com/role/SupplementalDisclosureOfCashFlowInformation-ScheduleOfSupplementalCashFlowInformationDetails Supplemental Disclosure of Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) Details 57 false false R58.htm 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://rennovahealth.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://rennovahealth.com/role/CommitmentsAndContingencies 58 false false R59.htm 00000059 - Disclosure - Segment Information (Details Narrative) Sheet http://rennovahealth.com/role/SegmentInformationDetailsNarrative Segment Information (Details Narrative) Details http://rennovahealth.com/role/SegmentInformationTables 59 false false R60.htm 00000060 - Disclosure - Segment Information - Schedule of Segment Information (Details) Sheet http://rennovahealth.com/role/SegmentInformation-ScheduleOfSegmentInformationDetails Segment Information - Schedule of Segment Information (Details) Details 60 false false R61.htm 00000061 - Disclosure - Discontinued Operations (Details Narrative) Sheet http://rennovahealth.com/role/DiscontinuedOperationsDetailsNarrative Discontinued Operations (Details Narrative) Details http://rennovahealth.com/role/DiscontinuedOperationsTables 61 false false R62.htm 00000062 - Disclosure - Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) Sheet http://rennovahealth.com/role/DiscontinuedOperations-ScheduleOfDiscontinuedOperationOfBalanceSheetAndOperationStatementDetails Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) Details 62 false false R63.htm 00000063 - Disclosure - Derivative Financial Instruments and Fair Value (Details Narrative) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValueDetailsNarrative Derivative Financial Instruments and Fair Value (Details Narrative) Details http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValueTables 63 false false R64.htm 00000064 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue-ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Derivative Financial Instruments and Fair Value - Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) Details 64 false false R65.htm 00000065 - Disclosure - Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details) Sheet http://rennovahealth.com/role/DerivativeFinancialInstrumentsAndFairValue-ScheduleOfChangesInLiabilitiesWithLevel3OfFairValueDetails Derivative Financial Instruments and Fair Value - Schedule of Changes in Liabilities with Level 3 of Fair Value (Details) Details 65 false false R66.htm 00000066 - Disclosure - Subsequent Events (Details Narrative) Sheet http://rennovahealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://rennovahealth.com/role/SubsequentEvents 66 false false All Reports Book All Reports rnva-20180331.xml rnva-20180331.xsd rnva-20180331_cal.xml rnva-20180331_def.xml rnva-20180331_lab.xml rnva-20180331_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 82 0001493152-18-008940-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-008940-xbrl.zip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

"0@ M@CZ=.#.S4EWLC? TU@S5:XRA+.W(XV=\&1.6W,=![MC MD"VF7GW$0X9_*]B;OCSSUW4[ O7XG::PMVD20R:_/:9!4]I[_@.2J1GA!DYO M841V0PZ7ZH+%J <:*.V%4::'&"0%AA&E&S]\K@FC#P0\;%('([03T$V"!R1^ M4X2#YE! VCO@!D]-@!,- .LD38'ZBKV>8(.XZ#Y MPHCO=41%PB:@_+"BR#Z;L,$Z<*YAJR<;' .3+DC10-4F#-EA'B[-:MJ)^ 1N M>AOA&R@YLS4V".Q I JB4E!A0S@,DQ,VK#;0MD2[6P9'P@)N#)XN6R/V@'L:)R6,_+%EAWL$N MD*UIV>(9OG*WY< 2S? ,"-9AIFU#SJSQ[V#CS-[L[/ ,NP9C2[T%BF$)%TRA M?#J>E\4FF\+/<;X FMFV>'?&XB]VVF)VP*6AK]3<6.[,,E^.NX^ A M3LK(^8UEY2Q61&-RQZ,I9>ZSW , EYO.2'(MV-71:X'T7^+\Z1H_X^14X')( M46Y*Q(#':*Q#(!#>1'(8)&&1E.[FFOW>@,"O.28L-ZSQ<*+[N";"_LP1'2W_ M.T8C5$.)_PQ(A)8H4 /'L/2KKX,T"#YA5*Y<,_LWRYTBOB41\7]E:1)'?,D% M59A0A:JBNJ8[2<,&K0F__)/2ILHK4LL;/M,@>RBO^139Z#$(YH?<% YQDF?U M7TKC&!T=5[=]_E3]^9]+3W'._(%PJ#P)'G!2OO:?U;C6L$-W!/.46D_G\FF; M/,$.SFB(4LJ*H$\'QS6:@(8-[/3WE)G$,AR]NX-SCO-A(C%$PI)TZ5 N';.V5=$>[@4[I@M.J5 MTQP%4\:I4V6H^/).^+<4SX.XWGCF"7K^A"G0JX* 8:IZYU15%E+P3H-7A,5W M?!^\8L7-+]4\4@Z':>D'QQ/*P*EW>EER]'><1),7^\LW/9]#H<9,2?0#A MB#; XT?"UE;'ALQX.E&$=;G.!$ UUH/:NCJ/!JZJV^-=!T6]"C1%M9IA[TRK M.DIL8V$&$-_4(AZV[52+(@C4/Q5^?#K#)]\Q0, 7]Z(."NID?OE(7WKW- M:B_'M1DJF+X^.-37YKQY.NT$9D!UNU?5KF8V[5'E5.[.7:?D\1[3&7?3-RD) MNYR>$C'@#/WNE)/+//UZ_SA5X]JK%N]\6%JSV-7E/*?7!YL.L9KQ>^ MO/FM8]4[B^('^U,"T8D\TO43D/*!TP2SO;,9WDZX(OYK(?KU- M:2GL/*?Q0Y&7+?!2GMNE)&>"9%0]7I$<4YR9=M2'>)?K>+FA:0PG=IB%.=R$ ML1&38:"1S9\.VUQ>L]]W=VU!W>FD<8?A=),[#.A- _.?A[Z+T?%UB09#[V , MK5&B=(K62-&;[R1@5L_&_-GA58V*(/+8;KFOJ-7EH4Z+CBP?3[^F:53.,$R? MXQ!G$S9W3.6''L9US-4J0JI#NOCV+N8N/SV5,'+/HEE,XBQ?WA:K.-7KJQ/0 M=32$*@TH >\T-\%ET&5T?POHKUC@U+!F9(!Q'9:A^NKFVSM57> YQ6%I(BM8?TSQ M,J6?@XCO#1C4V MR;X)AI]I[E*5_TY=O";&:-6U*HS-L=L&Y9FE)3@?]]2#G M'@BD!-5F7I--[ZSK.Z%L[L2_X^AK$!,^Q<9D?>+"X&$Z 9U[CTU4!A2'=VJL M5[$J[DK>];I3CW:>2V^B,!/C_L7\=2!;-JLK&RDQ3M>K.)_Q-*58N -[P?Z1 MY7%HTN862%T[UAXDHDL!%5G#%DN[PSFJ 40 FTF^.;$;G$-*E-8PKZ?S-K/6 M_>14*D1Y71\B ^_LK4FZNO4=$\%XRN9<).J=S32D?]3[L((HT"\>[R=A:R02OWKJ_PCY0,%6*PSNUB8Z^_'Y87I:]!V9_@/%]^/Z5SOAJ!7-^3'T3! #%YIUK7 M&Z'#W;0?1,6;;Y1ZM07WQUCT'>[6_P[JY&%6B=U;&>4]7B[P\O]71&[:;C0@ M #1P#>5H[XP#++E]T'O='][81*(##*CI_5LNZY;5/JBXV5?>1LMM2*"B]VR- M#"JQ?=!U]=G)1=4PV&I.R[! ?>_9"AI<:MY5 ?KH4W7>VR1HKT"!ZMZS=3:P MS/9#VZW^LI8*EZ"!.M^[U3FXY/9 [<+1.KLD30 #*GK/UNI LO).PW!1]+%[ MOT_;V?IC.7W8CF]V .1)O02A-XTMT>[/1KC&6GH1JW?&HA$++TJS 8X!@?&Z M[(\7+,IC6_?I6?A;$5.L_5Z-GGT;')[Z44L3:'?>LQ:B?X4P7#!]S(-],@2[ M@&IK2;[Y2"!/?014"[2>!E2XM?0B5N^,12.6Z@OGO0=4,%ZW'[@+,8[*C2_A M(PX+?@C"$$*-4)[Z2DLURQ_&ZQ34\%W?12JNLJS@G<3*$RLL6!>T;,4F?I9# MH4&.QAJ+I_YL0XUN) )/7=H=GE?9W'@*G[]F*$]/T6XW?R&"\B_-%:GNF-@* M/C>9Q#M?Z^]/K< )ZY%*N?$Q3Z/Y" ],R5TX/#V,VY_:84+TSQ#@@NDC\]RG MM,RNA+6U)-]".)"G/DI8"[3[D_)9E+#68O736#"-TZB]$=9A"1H8UTZAFY^- M-X;L=+AK^^Z+<=.:CI>-P_MBW.0)?+N^+S8!9*D*[T? $I=;5F>R%*9Y"ZQQ MG?TO:(2X@TK2C!6E[!<1$0H([R;.4/%+[$UDPU[(-QR ;9#_8YO\&A"IC@T/ M0VN]MZ'^JL!ITOVO374&C$API2]2AY!UA/.-&U_SDF)KN'V1YU^!H!8\J!$/W M/8$U>#E^WZ99V;)E<'*+^7QYM2Y(UM2L6[9> .EL%N?EL@-?<"C+AD?,DA"=EY$"H("AC"HM' ,K"#_R-W?J00J$%> N M1)BC0C#2GXKL%0#3"E.JRN,G='?*C5,I$NQN5UP M[(QHL?(P42S%WD;]L3-RUW6%B5@IY*[!=D:I)KTWD'TJA5MMDK\S+A1)LXD# M*=YJNAWNBGIX#FWB2HJ^MIGT[AB6[$Y6>'G["NSL^HE+CNLRISS78:"4N/- 3.4RYY? M$F%?:9IE&S#4A'.].PA14[N7%T@4PY_4/$M82.6G"B]36G<34^W6\\&:L:ZW M*&VD;V!#*W''YV\:Y*;%0SXM$INF.%!XUQNNFTPB*]%TJ-;!?JNJ,(>%=JEJ MU)7HNP_E*J:$8&[@6UZX-SE=BZ0ZD8'XM8I<*HF0<+/*<]F<<8__ IE M1@?FVJEWJD>>N]U2\,ZA?YG-DW2!<74&Q\88 :"N7;"M#L'2\$Z/=2_W:C.H M4WFZ\1Z4=E8:,_/MG9K*+U]LX/B[X%S?A+-5&TP.WIUZ%G=J0=7W._.941=% MM\B#D'XI6%-S).W$-3EJ)EYJ;CWB\3;@!O?$LFM&@YIA:8MN X;1F\:+?!# M2#BU&W?DV](V'UP$S>.]L2>YMRB(IASX9XFZO#$,VN5%3"V!E89V26'EZ0.23 MCD'TXO9W'0O7!\]@*9MT%D(\N;;[?&W]=D&]$D]J5J3S#0(K3>TI>'09G\OZ MX#HEC_>8SLR=7Q1#7=YF3LDS9@9?9I@FLJ6!KF.G5N3M6^AJ#KV+A)RX]0FM M[R18+ISCJ-[([PR#< RN8R!4=[8R\>^(PT5U7VUY"@^?IUF>C5](QC]$>2R/AM9]L,IAQCW3;?&Z7C>#6T ?\O//+B3^(>6-$<@[?]R9SNIM MP#??+%$*6P!50GCG>^WUY'N-H4Q!JY[+8S(N\HQ?/&2N YB62D>2M&EI]1*4 M$B2\QK=L%9:H>I.CBH1\"W+^V2!6H(D-R&YI3,)XSL_.WS"#N7_!R3/^EK*: MS7!*9TNTKOTM('CV(CCOG+$55_^+ WK_DO9D!2MLKIUXW\IOBH[>+A8,=%<^P/Q]H/-!4!O6!/"LIEY-<_2)J6>YV9X[I:-R[ LBB+[ M'"2\DID\89R?91G.L\^+;\&_4EHN]1IK0UL\3IOIK4F-EN1UG*W50[@.R)NI M3^J9:!:(=]&XP?4U9A1C,^_2F=%&'Y0.:][F!:YC=N_VT8.X_3MPJ^L5!8N& MTF$/?>\H%^%0<34>QI=\[5I]2=X+EH3H7CX=S\LYMFP2N3!&=NG@AIK/9E1? MJG/Y%E2_9G>'=\P2^(5K@N0@[J7]2PCWU0N\8_R,Y'$4)P6WPNICOZS^^/(: M)@5[#__JPWDZFQ?+B]GCZ9> DI@\9K>83OCBKE%0L'9K[4/U D%H31&J24+< M8R.!* Y4DX487:@D;(?RA;>B$*>< *48:93KUOW?VC-3!->TN=B5- VMXV ^ MV*Z5G!-?++7R@'$&:3?G!S^BG>N85?+X7JJ353RVK-<@!4>]34#Z? ]M8>?D M>(B2+_&HB&K >-K(5])2S?_UX M1=(.K07<1@9F05*^:=U0QL7!(Z@,!&M;_8TE+&7MQ,8)!_R_L3J+"2 :DSN> M,%#FWLO&,D9CDYL,60JO:83" Y[%E%26$ *=J":4[SRM2*V:X'AHA>("X!/? MO<^NB,#.+W'^=(V?<7(J:,@H\ZT[(+46"I=$H9@TI/S"Z$(E8>BTI9H=9H7- MOIFP"2UGS.T^FOHI6ZT"\!\/08;97_X?4$L#!!0 ( -"&TTR:2CUD#T, M +J;! 5 &UL[7WK<^.VLN?WK=K_03NW MMNXY'YP9>QZ9R3W96_(K\5F/Y6L[R>Y^4<$D)/&$(A0^_,A?OP ?$B6A 9 B MB>:$MVK/3BPTV-T_ -UH-!K_^,^7I3]ZHF'DL>#'-\??O7LSHH'#7"^8__CF ME_NC\?W9U=6;4123P"4^"^B/;P+VYC__UW__;R/^?__X'T='HTN/^NX/HW/F M'%T%,_8?HQNRI#^,?J(!#4G,PO\8_4K\1/R%77H^#4=G;+GR:4SY#]F'?QA] M^.[DQ!D='1GT^RL-7!;^U[G<1QZL?WKY]?G[^+F!/Y)F%OT??.?>+_<_SEX>3=#^\___#A_?\S_&A,XB1:?_3="__4\;MW[SYFY/_PO>#W M'\3_/)*(CCA$0?3#2^3]^*8DZO/[[U@X?WOR[MWQV__S]?K>6= E.?(" 95# MWQ14HA<9W?&7+U_>IK\63?=:OCR&?O&-]V\+=M8]\U_=>$U0;OSQ;?9CN:FG MZ+K$=.3]$*627#.'Q.F@U'(T EN(_SHJFAV)/QT=GQR]/_[N)7+?%#BER@Z9 M3^_H;"3^?SZVUE\-:2#&U((2/U[P0;5\*UJ\Y8 F2QK$X\"]"&(O?A7HALN4 M8RY%VN4BI+,?WX3!$SDJ!I/X[K^9T,:O*S[3(D],E#>CMX>P>DI\H=O[!:5Q MI.--VK@M9FX);Q4O:.PYQ*_$F92R03;%_*0"HV@RFZS$,L:QT2I/3=4&>Y/9 MV8($3Q+]Z&-.+?-IKAYCTTR/;8<5C"E7-''>H]D4?1H9I-F*)! MMFY#QJ="_"I6NS\2;R4 U#&FHFE68V%"W8N7%0TBJAU_0/,&&;IA,>5KVZL) M>+*V#;)R3A^YTI-0KY;]E@VR<4=]/NE=OM['KP\A"2+B&"W%.KH&63PC*R\F M_C7E+L;DT??F9L9"0]:H#EW*'2H^3O@*-*-A2-UTE=?K4$W7J#VH8;PZ,53) MBG M(_I'PK]T\20^IU\(Y.T[=6%OF>^93/[J/;7JTCZ(_S'QU)1T+;NW9DSJ*=MS M=8W5"!.UY/::<093M.("FS$%M6_?US3CSXBX7:?.C%$MH1T'SY#YNAVVZD,9 M\JZA:]TU,9QH!K16W!33=:)>?YWZ!^FS57S@2QR)N MXO,)N/]CSE%U;Z)*KRW[&E5QJM)'RZR7M*C@JHY U7INS\W:'B?E7\R'7JW^ M6G+.J@XV$]J66"VI2L)%%<;->K(B1J4#M .[[5; HU( US.>+@=WC$'(ID&M M\)56-D]5%PT]92MLEK2WQX$YRR:]M,T^QST]U TF29SF[7C!O!F1*O7:DE7NOX.#L^K#KEH_[<9@JG)?H8MV&2\- MA?37R2K=;/(I_.3%KX;#[-!^.Q/Q-Z'<(&Y4/'6?G8DV#F+/]?Q$#)U[ZB2A M)QR3BQ?'3USJ7H9L*3)$DRQL,)E=D##@AB:ZI>']@KLMC:BB61[L!"3+ [=$ M)6EIJK(.OMW-F79ENUJ]JU;CM947:>,>6F6[/"H@CJJ+4J77UD/4E;UA_9L1=7[I5S6^%.@CMA34.^?*9G ,;;36LLV5;L.O6ZQ/IO7KRXID_4 M?U^2LDU5UF6BQ32:RB;0D%[%,@F=@FM9XS(#P)V3XNJ+N&SR,>5KP;L(G>21 M'KD>AR!*\]/R#Y75LN[%"^*WO.G;O,U;:0?M\[W^V)'+EL2KR/0^=0<K<9@2M,]7P.)Q5=8*FD['))V1Q(]K#\J"?)MG_F'0T*JC*_R2!.\JZ&&WU MT2K[\LM@6_R><";7CAG_-]\YN>) TA7_BICON2+@.LI[&N5=Y4P7;/O,V>+5 M%U?_6"@=(RFV,Q(]I@ GT=&4C^.BK^DIN'HW7%^U^_?\C]/U[QR M!=$K_L^U7#YYI'[Z[6G>6-;V+0+6'\I7/A1LY^UV6=X,DG%8,)]/$,-5*)N5 M/PCGG0^KBVSOSV=VMCQJ@Y9*!^'V MOBYNDM.IFU_'4^B(ZFH2T*^Y4[P'C*#4$TYE8^PPE+:==0 !Q31@E?D'YT_= M!:TJ#@_/K!X.:\+IAU[BL,T_A,,'NX;EGH8>C7[:9AW$JU@B8*+I)ZQ8&?(. MX?0) TX_U\%)2C3]W N<8-XAG#YCP.FR#DY2(FY+>P&4@GEX$V07JCSR_AC% M(7%B&)WM=M-CF0?3 2#&FU 9OQ &=IWHC-.S)!09G:9 [#2WAH="S3(\I&PC MW6R2:*'8S?!?+2M=I4L&, OZP79GP-XEG!L:Y^(I)H*"JC?0Z(4 MY!6(;L* MQ"$="U\YNS!$Y5:]@62?:7#78A4"[FNLB%=<(1*I%O&"AEO2PL@8$/<&,&-9 M(!P_6IY*#EO2!_)")96\9'-*TKPW6"FX!_><"+RSGZGO7K+PGO#UF<7B D*: M_[1B$?%_"EFRTENK2OWT!L\Z8D% ?X\ :$,<^PF3$0J?+1NU[+[OK4^R<_?B MTJ_2SU!1X=\:Z;F'L/IB%:MSRB>X%V=RPN!L-<./AH1=.';3[.F!X6)ZPP)X MF1(=5>X',2H'R /"AB'BIK,PB"&1\ FJVFY@H90-R]?5\HTBL<;&K_IHFVD/ M^ .BU20! ;6[YRT)81PPA6FL@58+"Q#.:D%5NYO=(MZ5%SUP.APM+W#SF<$GW5Z:HGL!TF'H@EMAA(E=A'3Y#3\ ]"8S>ZD28>E(,[ MVN 41($!IKJA*;5,('1V(QX9TRR8/]!P*>SQ#0L*#+%0M)^)I)=D;"\-4+YN.E"(%>!:(^&__/ M6Q:F"H_CT'M,XO0=$"9&'0MBKE?.U?PJB&E((]5)6?/?ZO,(:4L;X$"S&[:I M#KGN75OH3:6/YJZ:[,UNM>TGS5W<86CUQK@ 0* *)C^?H#6RY9 M8 +-;LM^X2+G'@3%\D4)UTU52/Q;XKE701[04QS*R0GZ!9%2"! IN_'9L>,DRR0-G^^\=KH/FIZV7_B9R@-":3?>LB]S%0>C7U!!_(/0V(VW MZ)RG^GE=??8'S60#(2W%8?[Q=D?L:_Z?G94LD[]QLE6_['V=^F6COVWU_/>A MGME0SVRH9S;4,^M9^:RAGADR0(9Z9M],_2:T-<\,>0?G%X:Z0 W6;T);$\V0 M=P@G%/70&JS?U(]Z:##O$$Z6ZZ'MW"S8R<^L>+="2CW]@OQ:D[$0$(1-W^'< M?MC7%)+TFJ,!*5X\*DF TQ_?GOZ<[4F8RNVF)P/%VV&FAU00/5X(JXL!^AF( M<$RYC<9)O&"A]^N9[A)V0?]=W1X74514A6KC*:7.)58!WU"=!B5 MGA&N!E2)L)=H[?(/06;W=*1TM%W=EAD0HX?.5 ;0N\<"G[D)4Q#U":Y*QLMN M$NH>USK+!1#T#QX#FV4W%W6/8R.#I:+J'TBFIJJ4S-GYJ>]:NF@RVSPU*C_Q M_6!VXKOI5B?JPHII R_\K( M"T;E[_S[*/_2ENP(CB3WQO)PYCV<>3>)4IX(SY8K%HBEP/#<6T[6D[-OE'(D?BB#FD_%J1WC2\R\['J]ZKJA" M-!NV<:YZ)1==A\=>TQ;F4^-HR)D&L;!\@BJ_6Z #1DEF*WND"DAZ 4"K9!>P MW6LKNK0*3@'#0VEM-&#KLI82E)I,*>2,HR3BM3(>"U'RA"CX24 M8YR'T=DSF&FH]#P)Q0UL&GHL.X6XH<_I+\I=J0$Y?L",I/PC 5/?&7GBI[,LG_'WJ-/[ZG#6ZIKC!S4;5]1KR =SO-Q MY6AN?C08]MO7X5!%/)P'[F/W7TD4IY%6!NR/UL]77T*V!WZ MX5!?*IQI!LH%L3G4-?WU%783L0R2%O#@GH[CAY"2* E?TS9WU-/D!%7NJJ]H M:R12'3/C0SH;NLU K>BKKUCK1&K\2 "XDG-*@S0!AO@;[_22DC@)Z626W?R: M!/3AF6V?(TD@%-W5[ TOB(<*!<)H-^[&'<7,J;Q6&MNM9GA! KD%M5\*F%E- MZ!./SU_Z[!G(Y_M4)Y]/]#E*.^TPGV\2SDG@_9GN0L:!RW/3XB(LY7^ M52[A]URJ MY3 E&:UI6F7OG#YRH/AW ?6=[#)7)FB5L]*EUM>'D 01<>!TY>/WNWSFY*.4 M?K3=0:M\ X^_R-G^L,MV3CU*R4=;]"UKVZ5T*0:S:NW&/YE[+Q M'FUUV^[@9\NEET8@14D\[EG$?)=" \>#UI<]LU?J(34F.WVT"T^6R:A%8<_\ MY80=*EHX!4'LOV:[P=Q7X'JZ%P?U)'3EZC[9LX9%/Z.LH]&FIU&IJW9-$.00.SGKH(H#I-BY%\2+]PJY[PMAL2J M%AV.UCV.2EVF4T%T.LI[;7F9>HSH'XE(V7T27Y<+L6=R-V2C@L[R1N&6[VO MM>=DS_B:;1A&?RNZ;7LGM+]W2*\F .+L&67)#F+TMZR'MCF7;254O.]99_F& MHBOV=W86*L[W+/+N_J(KGLL;#17#>Q9W:[O1%;>;;82*USU#NR'KBE' G5=P M_7[/R().?5="2+QDE0![5A:XYM@1\^9.LTJH/9M;U77N3-X]+U0EUKX5WO=% M.YO44D].Q?V>"0;\N>Z6)5/'3B75GB6NZ-YU):W>@3H7N?%^=$/",&5?+N^> M]39UI/+N1^O^A_O2PWWIX;[T<%]ZN"\]W)<>[DM_P_>E6[D/>MR#6[L&$H"+ MHN4[O&;:TK/<0FVP-P;EN\IA1VS%;( *L MA@A(#5?[Z&$V:PTBW(YA [(:OY+7AX4GDA">V<.")1'?SXJPMC=?Q)0&(&R" MV(C65JV[2G.)U1$*@NA+PXFGG*,;+TV;K &0CG)Z;*G,Q 'XF,D$^AFU2T\8 MXU,3G%TI+#U+TAPR,H% 6"P_5O+ /S"9C<-05#\4TJI]0* Y;D=0*2.VR_(E M-D5H^H9O*C9_*6>\:7=553NRXR.JP6&'B8349[2%,69/LL5QT*EG.8XB&M\F MH;,@$1W/0YHRI32)*A)K3^G6G6NLBER@56RV%E,4QJ7)R?]K=V+R/TWOA'" M]>._EWY&:NVVF814VV@)$7/%@A.@X-J2%9(JC_+ M?K&KW)&ED*42' V09KI!9[-L88S9VK4X#CJU>O>4+)/HFLR)^NANK]WT^'L[ M%J[NK&):84"C]WW#QZ?GX?\F2^XBC?]%EIY2[9*64]Y;7Q4/B@.J_G/#JO\G M6P2GE#@+I=IW6DV/+65T-*!RJ2B@NIM.Y/B)A*_7I[XBH".:[;2:GKSKK;JE MHL!VO6%UGRU"+XK9:D'#Z(SP,$,S[NL-!ZWC[)BJ,7CT\L]*; 89/ M%V8[(4/ZZ8FE7!3%K&"UY0"GU4&Y)U$A;42=[^;LZ:U+O6Q.\7_L3B7^I^DU MG1,_,Z6 J>&M]AHA-2XR5B$]'U)VOK*6-;$IWL1J8%&A-P9PV(I5:%FO*!?] MRKKO='&_(0'[U7L,6>"]7 6.=)T< 0U59L0I.*X_(MD7M@53AS)1YI#N$)A%" M:3J:1+'CZX^ALY#<6)K,N+/L!7/-#2X3XNF)I;,A_3QA]60!9UG31T.GQ#VG MCZ)"9$3#)UGEG_35B>U6T_>6 N:&;V3(N(4TVO0&F?CBC:0G&B20,LM-D&MR MGU7P),=REEO*HC)K-&N!6.%23L&%P+*#NOO MN ZC&CZP_W*]Q2/*AH0XT?) M6 C0S-H-J++ED@4IKWOO"*G*LJC(\(-FP#X$E]W7D$N,WY)P$J829T^TW=(P M?;[+"#2(N%?0J86 +2;*%]B/WML;9S$"Q9Z?ZH>H%,0]0HP.?,04';S2[=C M^.98J>GPPV7"/X28WK[FS6]I<_SX*-AN^M #V-ED_@WQ1:)& M3/GPB/,"]< V!VR/6-D&?.,,4(K][J8<]"\!6;(P%C,W+8>=! IW7$N*&*]J M(H![UX9C .>B^ #_]I/GTL ]9\_!'6?"S1U-8+JHB1!C8,H\J/VFDYVW>#'2 M=J^TJ]%FW< H,W?6/B[%\SS(J,[#Z3M*%7:%KEN%3R#*K:[==^//%0)M2"& M0\,S"(?=K7GA).3/WYPEW(D.XJR*C9/]!XR/ 3%^P(R% !&TNS>_#9E#J1M= M<@V(1^Q(X-#)3/@4JNT>1(,?+QWO($QU=^90]2J'S^XH5R"W;K5RF)$"O?E'E0^W5WV8KM7)#0"Q(&U+UDX3T-GSQ'NG,N=D6RYL@U MKF8;U/4A^8(-! M)M$B'2LAYYG*7AHTB6 @3(<;(E'D0*;O;[M,DXI)%48G? M,Q;%DUDA3):<5BI/(7Y61*=J=H@?X8,$ P]![>8<%3*=L>6C%Z2WE>[IBH1< M)?[K'778/!!!B')QDLWC#9OGKG9UDH>;%,'FEC_)ADX .R&9[8'[5<1 !7IZ5PEIC.T3(,?1!WO($QVPS8[ M:PMQJBZC:XJ^0;3+.0B0W:B,G(N,UD^$V MY-MO?_&;Y*>M3NN\S3QVTJ/OB&^'J/9O]]]G[F@'VTZ$"^'Y_V+=YIE+8KGFH='FH='FK_91YJ+@7_#8AI= M,Q*DK[YG+ST%\\UL$'5JBW^+!TG4=SP/ZQ7W5= F-(;O1DJ94WWE95EK._=$ M&T%C]TH+K QT4=W#D<-\?[0C=#N]87I-'EDH6K_FQWO**Z5 ZZFM^MF*J<&, MN&YZ 02T_#.+U"]LBU;;C5J8"(TJ5<(MJ$R[YF3?7T\CH6>Z!",UW=36M6E3 M/]" ?0BPII]:\WWV++:!ERPLLHJA7 EI6[RZ5K.,T[W:XI M&-'CQ:RZ&*"WA6Q=NZ%QC55M0X4?,QWSH-MD,9AT&S*^Z8M?Q4/0?R3>2@B: M!W-NQ%N-XF*2/'3T>3=T5'0U(H$[6G>VC@V-UOT-4:(A2O3-1HF*67#KDS17 M>CT13E_UP2 C8MPQGPKR8_,]0-9-X@5&Q'8"/U4@,02S!^&>MM'$' QJ%?%. M0T#%3CY-JC>*4)1:V@I35)DVDJC%K@1(0Q=KAC-),"Y33NGJY ZGF;BE5NAAV./69R.1#HTKI8KXH5"JK,%">>J5%UY>_1H M*-CN2PBWE!&HB/#* [M?# .[VVF!FNCO$/,=8KY#S'>(^6)S)H:8[Q#S'6*^ MN&*^7ZGK.<1?LZ%^2$+:V%+27\W +RP#SD7S-/%\5_7"QSI84&[7HV@\S#_2 M6+Q^KN0M=\>8I9>!ZV,B$P"T1I9SV=)(RL_4=W_A>[HP+T5X34E$X<>TRWM0 M)>W4TCN:]:$SE DT,W;1O$Q"KEF^(T[SZE_2IP5T*,(TTP]]0T\C"X3:![NH MI:-+%)V\6JY"]I3Z4EK8%$2V@E?U<=,) P%G^:G$7^G"TR?J,R.X M0)+IY[X!IA8%@NPSTE"4IHZ4FFYZ8FG;5:4F@Y9_G$?(8\=)EHDO'BPJG^#Q M?_LTU6W@CK,7"]*_@X(JM@$-?0'_*&A64IQQ$Y#I&ZHN20U2X<=5S[W!6;>- M&BMA0MV\;F2T76"E_(OJ)/7#.TEU%4$\*JCW2ZML_[PY/=VHH@UQTTOC>9EW MH]L_'XYW14N[&.5]#)=^A@/@O](!L&GQA>CT]9K.B7^1UD2>S,X$%0U7A"^0 MS96*,?L*[B/E-C2*S1TH,2Y8W69>=UII1(R[T$PE[':#6L:J0W=(W3;LF ^I M<0P-S)GG5X$KW@-+%/58\J:[+6T=*529B[L/#$DD0'J0\"#<7_%T9,&RVE8# MS7$;7:6,V)*1]YC]S8L7=]1/PP/1PEL]L&Q0ZI;4RAW9L:IJ<#1 FND&G:FT MA3%F$]KB..@TR^ML$7I1S%8+&IY[9$DX'_!AGZ" "6Q9OKK3C!D+!1K#NFLO M ,;#,[L*GBCG)%1BL->.#YG>ZAX0!@X\V+[W5*[VKW8_9&UQ^QZP=,K;-M9Q MN"%+;68Q3&''E5#H6@7*OJCH'(;FL,'L AR,7Z>&_N%LS/G@WT]"=0'7_8:V MTGFTXYYIN8:T6SN)!]#N/5W%Z5>Y-7M8L"0B@7OOO<24!DIE:^FL6?8JRC>4 M C;IEB_4/I/0-0C\;S?#;HBPII7$318/MMU,=*0B-!/N/4( M@=C\HO8_JO2!VSFIK@W)Q0@T>.K?,-EO:\=KJ*%W&#CD#L%A"&$VQBV@V*V= M]1VN"Y=>7Y^IK>9NN^FQI6M?BF'/M/R"N][:5[N@"_OA-9D3M2>RU69Z8BFV M8*9/":_P6M.P+L_X?/)XUWEI/9$0L\GEW3T1D[6=GE@Z#3-[D$3!,Z3CAE>! MBRCVEF(4_$K\1/ID)J!N/2%RW9L* "X<#2_'[K^2*!9W M@F=P.;%>12)^_4KC!7.SDU'!_.0YH*$X4;WEOCC_;S)7Y*$;=X$8NWJB].&P M\H&&2].C,-$6/T@0SSC#SG=TE1=>!1>[M:.RW1(_$G*.<6ZBMT=-'CL2@\_@8:5=E!(JWFDO^>R>JMJLM'D/L('9AF#Y'M'DN0J<4%08R>\N M7HG,;VXJ3><10-X#V,S% "/#B&#DWHS'7,_)UP;C97";K&^P2=F'X/J""*Y+ M2L=+L7(=A@'MZ:8\LXNB5,5GC5%[_#9X1P$"%/R[!GC^SEN:!]] MFOTS2DM*> X]-D5,T47?(-2* F)J-UQQYI.(;S9^$R4&^,8\O//FB_@F$2J: MS.ZIDX2>\*7.B.]3]_3U@CB+[;8PU@=WC7\,-"0B.#;LQCVDTEV\T-#Q(IJ. M[?6/4?YKI)C[M;KKZ1@P$PO$W6Z$97ME^TIB,8Q?S[D^3!?V,@U^!'6\PV> MEFL)%G:&KS4Q;;77ON.RI ER3 M8P+S/O"C6546$-:Z81W@>&V;KXN\+-1Y0H'54! I:1!#8<@[J'J[H1AMJB.4 MZ3A9I?DW/Z4&^BK(PAF:E0K\&Q6N'W7'W#[Q M=6S+0SQ@I#7'Q#

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end